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Résumé Français 
Les mycotoxines sont des métabolites secondaires toxiques produits par certains champignons 
filamenteux. Selon leur toxicité et leur occurrence, certaines d'entre elles dont le déoxynivalénol 
(DON), l'une des toxines les plus répandues dans l'alimentation humaine et animale, sont été 
réglementées au sein de l'Union Européenne. D'autres métabolites secondaires découverts 
récemment ou encore peu étudiés sont appelées mycotoxines émergentes et ne sont ni détectés 
en routine ni réglementés. Les denrées alimentaires destinées à l'homme et à l'animal peuvent 
être naturellement contaminées par plusieurs mycotoxines et le risque lié à une exposition à des 
mélanges de mycotoxines est préoccupant. 
Parmi les animaux d'élevage, le porc est une espèce très sensible aux mycotoxines. De par son 
alimentation riche en céréales, il peut être exposé à de fortes concentrations de ces 
contaminants. 524 échantillons d'aliments complets pour porcs prélevés dans le monde entier 
ont été analysés par une technique de chromatographie en phase liquide couplée à la 
spectrométrie de masse en tandem (LC-MS/MS) pour plus de 800 métabolites. 88 % des 
échantillons étaient co-contaminés avec du DON et d'autres mycotoxines réglementées et 
émergentes. 
La toxicité du DON et des 10 mycotoxines émergentes les plus répandues a été évaluée en 
mesurant la viabilité de cellules épithéliales intestinales porcines (IPEC-1) après 48 h 
d'exposition. Trois mycotoxines émergentes (brevianamide F, cyclo-(L-Pro-L-Tyr) et 
tryptophol) n'ont pas eu d’impact sur la viabilité cellulaire. Les autres toxines ont été classées 
dans l'ordre de toxicité suivant: apicidine> enniatine A1> DON> beauvéricine> enniatine B> 
enniatine B1> émodine> aurofusarine. 
La toxicité combinée du DON et des 10 mycotoxines émergentes a été évaluée en fonction de 
leurs concentrations réelles dans les aliments analysés. Nous avons observé que malgré la très 
forte fréquence des co-contaminations, la corrélation entre les concentrations de DON et des 
mycotoxines émergentes étudiées était faible. Nous avons donc évalué les effets toxiques de 
trois mélanges correspondant à des situations auxquelles les animaux peuvent être exposés. Le 
ratio n°1 a été calculé en utilisant la concentration P25 (1er quartile) de la mycotoxine émergente 
et la concentration P75 (3ème quartile) du DON. Le ratio n°3 correspondait au scénario inverse 
du ratio n°1. Le ratio n°2 a été calculé en utilisant la concentration médiane (2ème quartile) du 
DON et de chaque mycotoxine émergente. 
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Pour la plupart des mélanges, la cytotoxicité combinée était similaire à celle du DON seul. Pour 
ce qui concerne la santé des animaux, ces résultats ont montré que lorsque ces mycotoxines 
émergentes sont présentes avec le DON, elles n'exacerbent pas la toxicité du DON. 
Outre l'intestin, le foie est le principal site de détoxification des xénobiotiques, y compris des 
mycotoxines, et représente un organe cible des contaminants alimentaires. Nous avons donc 
mis au point un nouvel outil, les Precision Cut Liver Slices (PCLS), des explants de foie 
d’épaisseur définie. Elles ont été utilisées pour évaluer la toxicité du DON (3 et 10 µM) à 
différents temps d'incubation (0 à 20 h), en étudiant l'expression génique, le contenu en ATP et 
en protéines totales. 
Le milieu d'incubation a permis d'évaluer la qualité des PCLS en mesurant les marqueurs de 
dommage hépatique (phosphatase alcaline, lactate déshydrogénase, alanine aminotransférase, 
aspartate aminotransférase et protéines totales). Nous avons montré que ces marqueurs n’étaient 
impactés ni par le temps d'incubation, ni par le traitement. Les PCLS traitées avec 10 µM de 
DON pendant 4 h ou plus, montrent une altération de l’expression de certains gènes.  
Ces expériences préliminaires ont montré que les PCLS représentent un modèle prometteur 
pour évaluer la toxicité hépatique des mycotoxines ou d'autres contaminants alimentaires. 
 
Mots-clés: Mycotoxines émergentes, DON, Toxicité, Aliments pour porcs, IPEC-1, Slice de 
foie, Expression de gènes 
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Summary 
Mycotoxins are toxic secondary metabolites, produced by several filamentous fungi. 
Depending on their toxicity and occurrence, some of them, including deoxynivalenol (DON), 
one of the most common toxin in food and feed, have been regulated in the European Union. 
Other secondary metabolites, which neither routinely determined nor regulated, are called 
emerging mycotoxins because they have been recently discovered or poorly investigated. Food 
and feed can be naturally contaminated by several mycotoxins and concern about the hazard of 
exposure to mycotoxin mixtures is increasing. 
Among farm animals, pig is one of the most sensitive farm animal to mycotoxins and it can be 
exposed, through its rich cereal diet, to high concentrations of mycotoxins. In total, 524 finished 
pig feeds samples from worldwide were analyzed for more than 800 metabolites using, LC-
MS/MS (liquid chromatography tandem-mass spectrometry) method. Eighty-eight percent of 
the samples were co-contaminated with DON and other regulated and emerging mycotoxins. 
The toxicity of DON and the 10 most common emerging mycotoxins was analyzed on the 
viability of porcine intestinal epithelial cells (IPEC-1) over a 48 h period. Among the emerging 
mycotoxins, 3 of them (brevianamide F, cyclo-(L-Pro-L-Tyr), and tryptophol) did not alter cells 
viability. The other mycotoxins were ranked in the following order of toxicity: apicidin> 
enniatin A1> DON> beauvericin> enniatin B> enniatin B1> emodin> aurofusarin. 
The combined toxicity of DON and the 10 emerging mycotoxins was assessed based on their 
actual ratios found in pig feed. We observed that, despite the very high frequency of co-
contamination, there was a poor correlation between the concentrations of DON and emerging 
mycotoxins. Thus, we assessed the toxic effects of three mixtures corresponding to situations 
to which animals may be exposed. Ratio #1 was calculated using the P25 (1st quartile) 
concentration of the emerging mycotoxin and P75 (3rd quartile) concentration of DON. Ratio 
#2 was calculated using the median (2nd quartile) concentration of DON and each emerging 
mycotoxin. Ratio #3 was the reverse scenario of ratio #1. 
Cytotoxicity analyses showed that, in most of the mixtures, the combined toxicity was similar 
to the one of DON alone. These results demonstrated that, when these emerging mycotoxins 
are present with DON, in terms of pig health, it does not exacerbate the problem of the toxicity 
of DON. 
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In addition to intestine, liver is the main site of detoxification for xenobiotics, including 
mycotoxins and represents a target organ for food contaminants. Hence, we developed a new 
tool the Precision Cut Liver Slices (PCLs) an ex vivo explants of liver with a well-defined 
thickness. This tool was used to assess the toxicity of DON (3 and 10 µM) at different 
incubation times (0 to 20 h), by studying gene expression, ATP and total protein contents. 
The incubation medium was used to assess the quality of PCLS by measuring liver damage 
markers (alkaline phosphatase, lactate dehydrogenase, alanine transaminase, aspartate 
transaminase and total proteins). We showed that these markers were not affected by either 
incubation time or treatment. 
PCLS treated with 10 µM DON for 4 h or more, showed an alteration in the expression of 
certain genes. These preliminary experiments demonstrated that PCLS represent a promising 
model for assessing the hepatic toxicity of mycotoxins or other food contaminants. 
 
Keywords: Emerging Mycotoxins, DON, Toxicity, Pig Feed, IPEC-1, Liver Slices, Gene 
Expression 
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1. Introduction 
1.1. Generalities on mycotoxins 
In today’s changing world, safety and security remains basic human needs. Ensuring food safety 
has been a major focus of national and international actions over the last years. Nowadays, 
international trade in agricultural commodities such as wheat, rice, barley, corn, sorghum, 
soybeans, groundnuts and oilseeds reaches hundreds of millions of tons each year (FAO 2019). 
In 2014, worldwide feed production was 964 million tons and among them 153 million tons 
were produced just in Europe (Kovalsky et al. 2016). As the occurrence of mycotoxins is 
widespread throughout the world, the global trade of agricultural commodities (e.g., animal 
feed) requires to monitor fungal toxins (Kovalsky et al. 2016). The worldwide contamination 
of food and feed with mycotoxins is a significant problem (Hussein and Brasel 2001). Recent 
surveys on the occurrence of mycotoxins have shown that 60 – 88% of the world's cereal grains 
are contaminated with mycotoxins (Gruber-Dorninger et al. 2019; Eskola et al. 2019). 
Mycotoxins can resist to high temperature and to chemicals like acids, both during 
storage/milling and cooking process and they are stable during food/feed processing like 
brewing, melting, hot drying or ensiling (Rodríguez-carrasco et al. 2016). Their presence in 
food and feed products is an important threat to human and animal health (Heshmati et al. 
2017). 
Origin of mycotoxins  
Mycotoxins are toxic secondary metabolites, produced by toxigenic moulds in the Aspergillus, 
Alternaria, Claviceps, Fusarium, Penicillium and Stachybotrys genera occurring in food and 
feed commodities both pre- and post-harvest (Milićević et al. 2010) under appropriate 
environmental conditions (Jestoi 2008). Mycotoxins represent a potential health risk for 
humans and/or livestock. (García & Jarque, 2014). The exact number of mycotoxins is not 
known, but the number of potential toxic fungal metabolites has been estimated to be in the 
thousands (Council for Agricultural Science and Technology 2003). Traditionally, toxigenic 
fungi contaminating agricultural grains have been conventionally divided into two groups: 
those invading seed crops have been described as “field” fungi (e.g., Cladosporium, Fusarium, 
Alternaria spp.), which reputedly gain access to seeds during plant development, and those 
proliferating during storage, “storage” fungi, (e.g., Aspergillus; Penicillium spp) (Ismaiel and 
Papenbrock 2015; Alshannaq and Yu 2017). Among the field occurring mycotoxins, Fusarium 
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mycotoxins are the most frequently identified in grain and animal feed and it is important for 
farmers to manage cereals contamination by Fusarium species (Steffen and Graham 2017). 
Occurrence and contamination 
Over the last years, mycotoxins have been regularly classified in the top ten and top one causes 
(European Union (EU) members and non-members countries, respectively) for the Rapid Alert 
System for Food and Feed (RASFF) notifications. RASFF is an European tool that ensures the 
inter-countries flow of information when risks to public health are detected in the food chain 
(RASFF 2018). The evidence suggests that mycotoxins are occurring increasingly in 
agricultural products including grains destined for human and animal consumption (Steffen and 
Graham 2017). Food can be contaminated with mycotoxins at various stages of the food chain, 
in field, during storage, milling or at later points (Bennett and Klich 2003). In fact, there is a 
notable length of time between the harvest of agricultural commodity at the exporting country 
and its arrival at the distribution center of the importing country. Furthermore, storage 
conditions at the farm level as well as during transport under adverse weather conditions may 
not always be satisfactory. Therefore, there is considerable opportunity for mycotoxin 
contamination of agricultural commodities to take place throughout the food system (FAO and 
Miller 1991). On the other hands, feeding animal with contaminated feeds can lead to 
contaminated animal products (eggs, meat, milk…). For example, aflatoxin B1 in cattle feed 
can be metabolized by cows into aflatoxin M1, which is then secreted in milk (Younis et al. 
2016). Furthermore, ochratoxin A in pig feed can accumulate in porcine tissues (Rutqvist 1978). 
Human exposure to mycotoxins also results from the consumption of several sources of food 
such as plant-derived foods, animal products (meat, eggs and milk) and/ or the exposure to 
contaminated air and dust (Council for Agricultural Science and Technology 2003). 
Regulations 
Regulations on mycotoxins have been established in many countries in order to protect the 
consumers from the harmful effects of mycotoxins. Two factors are mainly taken into account 
in the decision-making process of setting limits for mycotoxins: (i) the toxicity and (ii) the 
exposure (van Egmond et al. 2007). International survey on mycotoxins legislation in foodstuffs 
and feedstuffs have shown that approximately 100 countries (covering approximately 85% of 
the world’s inhabitants) had specific regulations or detailed guidelines for some mycotoxins 
(FAO 2004), whereas no data were available for about 50 countries, many of them were in 
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Africa (van Egmond 2002). In EU, mycotoxins regulation concern, ochratoxin A, patulin, 
deoxynivalenol (DON), zearalenone (ZEN), fumonisins (FUM) B1 & B2, T-2 & HT-2 toxin, 
aflatoxin B1 (AFB1), total aflatoxins (AFs) and patulin (Lerda 2011). In the following (Table 
1), the maximum level of each above mentioned mycotoxins for pig feed is stated based on the 
EU recommendations. 
Table 1: EU recommendation of mycotoxins in pig feed 
Mycotoxins Feedstuff 
Guidance value in mg/kg 
(ppm) relative to pig 
feedingstuff with a 
moisture content of 12 % 
DON Complementary and complete feedingstuffs for pigs 0.9 
ZEN 
Complementary and complete feedingstuffs for piglets and 
gilts (young sows) 
0.1 
Sows and fattening pigs 0.25 
The sum of 
FUMs (B1 + 
B2)  
Complementary and complete feedingstuffs for pig 5 
The  sum of T2 
& HT2  
Compound feed for pig 0.25 
Ochratoxin A Complementary and complete feedingstuffs for pigs 0.05 
(European-Commission 2016) 
Economical losses 
The economic consequences of mycotoxins contamination are important. Commodities over 
the regulation should be destroyed. In addition, contaminated feed can induce losses in animal 
production. Due to the insufficient information, the economic costs of mycotoxins are 
impossible to determine accurately. However, the U.S. Food and Drug Administration (FDA) 
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has utilized a computer model to estimate the losses due to selected mycotoxins such as AFs, 
FUM and DON. Only for United States, the mean economic annual costs of crop losses from 
the above mentioned mycotoxins are estimated to be $932 million (Council for Agricultural 
Science and Technology 2003), whereas in UK they represent approximately £200/hectare and 
€450/hectare in Germany (Steffen and Graham 2017). 
Toxicity 
Acute and chronic dietary exposure to mycotoxins can induce a variety of adverse health effects 
in humans and animals, making these chemically diverse substances highly relevant agricultural 
contaminants (Eskola et al. 2019). Mycotoxins can exhibit acute toxicity as well as 
carcinogenic, mutagenic, teratogenic, immunotoxic, hepatotoxic, nephrotoxic, neurotoxic or 
estrogenic effects in human and animals (van Egmond et al. 2007). The European Food Safety 
Authority (EFSA), Panel on Contaminants in the Food Chain (CONTAM) calculated the acute 
and chronic exposure across the 22 European countries, using the highest reliable percentile of 
concentrations and individual consumption data for different age groups. Toddlers were in 
general the age group with the highest dietary chronic and acute exposure to the mycotoxins 
(EFSA 2014, 2018). 
Unlike bacterial toxins, fungal toxins are not proteins and are usually barely detectable by the 
immune system of humans and animals. Most illnesses caused by mycotoxins are not reported 
to the doctors, whereas low levels can be dangerous to humans health (Steffen and Graham 
2017). On the other hands, diagnosis of mycotoxicoses in human and animals is difficult as they 
may be similar to diseases with other causations. This is even more difficult in cases where 
more than one mycotoxin is involved (Alassane-Kpembi et al. 2017b). 
Mycotoxins are more thoroughly studied in animals. Studies on animals have demonstrated that 
among farm animals, pig is one of the most sensitive species to the deleterious effects of 
mycotoxins. It can be exposed to high concentration of mycotoxins due to its rich cereal diets 
(Pinton et al. 2010). Previous studies on pig species have shown that, mycotoxins affect 
intestinal function. The gastrointestinal tract is the first physiological barrier against food 
contaminants, as well as the first target for these toxicants (Pinton and Oswald 2014). Indeed, 
after oral intake, the gastrointestinal tract is the first possible site of interaction (Fraeyman et 
al. 2018). In pigs, mycotoxins can decrease the feed consumption, reduce weight gain and alter 
reproduction and immunity (Korosteleva et al. 2007). Ruminants are less susceptible to 
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mycotoxins than monogastrics, because of the rumen microbiota. Ruminant’s digestive system 
and especially resident bacteria and protozoa, are able to detoxify mycotoxins. Nevertheless, 
there is some evidence that ruminants can be poisoned by mycotoxins, causing lower animal 
production or even death of animals. Recent in vitro research showed that at conditions of 
rumen acidosis and lower microbial activity, a reduced detoxification in the rumen can take 
place (Debevere et al. 2020).  Recent insights have generated an entirely new perspective where 
a bi-directional relationship exists between mycotoxins and gut microbiota, thus suggesting that 
gut microbiota might be involved in the development of mycotoxicosis (Jouany et al. 2009; 
Liew and Mohd-Redzwan 2018). Moreover, most of the toxicant can be detoxified in the liver, 
which is the main site of metabolism and detoxification of toxins and also a target organ of 
mycotoxins (Zain 2011; Pongratz and Bergander 2011). Nevertheless, the contamination of 
animal feed can have a major impact on dairy farming. Mycotoxins can be found in dairy 
products from two origins, indirect contamination, which results when dairy cows ingest feed 
that contains mycotoxins which pass into the milk such as aflatoxin M1 and direct 
contamination, which results from accidental growth of moulds secreting aflatoxins (Younis et 
al. 2016). 
Mitigation strategies 
Mycotoxins are still considered unavoidable contaminants in foods and feeds, because 
agronomic technology has not yet advanced to the stage at which pre-harvest contamination of 
susceptible crops by fungi can be eliminated (Wood 1992). In order to avoid harmful effects of 
contamination of food and feed caused by mycotoxins, three principles could be implemented; 
(i) prevention of contamination; (ii) decontamination of mycotoxin containing food and feed; 
and (iii) inhibition of absorption of mycotoxin from the digestive tract (Karlovsky 1999). There 
are three common strategies to mitigate toxicity of mycotoxins (Figure 1). One of the 
methodologies employed for mycotoxins detoxification is the physical strategy. Even though 
mycotoxins are stable compounds, some food processes including sorting, trimming, cleaning, 
milling, brewing, cooking, baking, frying, roasting, canning, flaking, nixtamalization and 
extrusion may affect their chemical structure (Bretz et al. 2006). Another common mitigation 
strategy is biotransformation. It consists in the use of enzymes that have been found to be 
effective in transforming mycotoxins into less toxic metabolites or completely inactivating 
them (Varga et al. 2010). For example, a mixed culture of two soil bacteria Pseudomonas sp 
and Lysobacter sp through formation of 3-keto-DON an enzymatic epimerization was capable 
of transforming DON into the non-toxic 3-epi-DON (Zhai et al. 2019). Likewise, a de-
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epoxidase first isolated from Eubacterium isolated from bovine rumen fluid, is capable of 
converting DON into the nontoxic compound DOM-1 (Pierron et al. 2016c; Loi et al. 2017). 
Patulin was converted by Saccharomyces cerevisiae into two isomers of ascladiol, E-ascladiol 
and Z-ascladiol which are nontoxic to human cell lines (Tannous et al. 2017; Wang et al. 2019). 
Detoxification of fumonisin B1 was carried out in two steps. Initial step was de-esterification 
reaction followed by deamination of the resulting hydrolyzed fumonisin B1 (Heinl et al. 2010; 
Grenier et al. 2012). Furthermore, isothiocyanates are natural reactive compounds that were 
found to reduce the toxicity of some mycotoxins (Varga et al. 2010). In addition, yeast cell 
wall, probiotics, prebiotics, fibers and protein ingredients have been used to reduce mycotoxins 
bioaccessibility in the gastrointestinal tract (Mallebrera et al. 2013) (Figure 1). 
Control should begin as early as possible, starting at the farm level with primary agricultural 
production. Good agricultural practices (GAP) is the first line against contamination of cereals 
with mycotoxins (Awad et al. 2010). Furthermore, preventive strategies in storage level such 
as; storage at low moisture levels and prevention of grain damage during processing and 
prevention of the formation of mycotoxins in feed help to reduce mycotoxins content (Dawson, 
2001). 
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Figure 1: General schematization of physical, chemical and microbial strategies used for mycotoxin reduction in 
food and feed chains (Luz et al. 2017). 
Co-contamination 
Another issue that pays attention of researchers is the co-contamination of food and feed by 
several mycotoxins. Food commodities are commonly contaminated with various fungal 
species at a time. In addition, most fungi are able to simultaneously produce number of 
mycotoxins. Therefore feed commodities can be contaminated by several mycotoxins, and 
completed feed is made from various commodities (Streit et al. 2012). The simultaneous 
presence of mycotoxins in products intended for human consumption is of high importance, 
because mycotoxins could interact with each other, potentially enhancing their toxic effects 
(Ruiz et al. 2011). Maize is an example where several mycotoxins have been reported to occur 
simultaneously (Gonçalves and Cubero-leon 2017). 
There are reports of a combination of many mycotoxins, such as DON, AF (B1, B2 and M1), 
FUM (A, B1, B2 and B3), ZEN and other fungal secondary metabolites in maize seeds and 
Washing
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grains, as well as in animal feed formulated (Streit et al. 2013; Anjorin et al. 2016; Abdallah et 
al. 2017). DON co-occurs with other regulated mycotoxins as well as with emerging 
mycotoxins (Borutova et al. 2012; FVaclavikova et al. 2013; Streit et al. 2013). Multi-
mycotoxin studies have reported that 75%–100% animal feed was co-contaminated by DON 
and other mycotoxins (Streit et al. 2012; Kovalsky et al. 2016; Novak et al. 2019). In food and 
feed ingredients sourced in Southern Europe, DON was found in 94% of the samples at 
maximum 365 µg/kg concentration (total number of samples ‘n’ = 416) (Griessler et al. 2010). 
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1.2. Deoxynivalenol (DON) 
Origin  
Deoxynivalenol (DON) is a regulated mycotoxin belonging to the group of type B 
trichothecenes (Knutsen et al. 2017), mainly produced by the fungi of the Fusarium genus, 
(Lewczuk et al. 2016). DON is one of the most common contaminants of wheat, corn, and 
barley worldwide. Second, DON is a very stable compound, during both storage and the 
processing/cooking of food, and does not degrade at high temperatures. On the other hands, 
DON is chemically also stable and to some extent resistant to food and feed processing (Table 
2) (Wood 1992; Kabak 2009). DON occurs in cereal grains alone or in combination with its 
most relevant acetylated derivatives, such as 3-acetyl-DON, 15-acetyl-DON and DON-3-
glucoside (10–20% of the DON-levels) and either with other fungal secondary metabolites so 
called emerging mycotoxins (Eskola et al. 2019; Schatzmayr and Streit 2013). It is produced in 
fields prior to harvest and its occurrence in food cannot be completely avoided due to the major 
impact of weather conditions as well as the high chemical and thermal resistance, both during 
storage/milling and processing/cooking of food (Lewczuk et al. 2016). DON is an undesirable 
substance in animal feed; in particular pigs were identified as the most sensitive animal species 
(EFSA 2013). In addition, DON can affect all animal species, with the following rank order of 
sensitivity: pigs > mice > rats > poultry ≈ ruminants (Rotter 1996). 
Table 2: Characteristics of DON 
Property Information 
Name Deoxynivalenol (DON) vomitoxin 
Chemical structure 
 
IUPAC name 12,13-epoxy-3α,7α,15-trihydroxytrichothec-9-en-8on 
Molecular formula  H15O20O6 
Molar mass  296.32 g/mol 
CAS number 51481-10-8 
Physical state  Colourless fine needles 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform, 
acetonitrile, and ethyl acetate) and water 
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Occurrence 
DON is one of the most widely distributed trichothecene (Sprando et al. 2005). It contaminates 
grains and cereal-based food and feed such as wheat, barley, oats, rye and maize, and less often 
in rice, sorghum and triticale (Kabak 2009). A worldwide ten years survey on more than 70,000 
different commodities reported that DON was found in finished feed (70%), maize (67%), 
maize dried distillers grains with soluble (DDGS) (83%), maize silage (62%), soybean grains 
(29%), soybean meal (31%), wheat (65%) barley (61%), and rice (27%) samples with maximum 
concentrations of 32,890 μg/kg, 51,370 μg/kg, 84,860 μg/kg, 34,860 μg/kg, 5,500 μg/kg, 5,600 
μg/kg, 49,300 μg/kg, 35,000 μg/kg and 3,860 μg/kg respectively (Gruber-Dorninger et al. 
2019). As well, in more than 25,000 samples collected from 28 European countries between 
2007 and 2014, DON was found in food (52%, n= 21,916), feed (47%, n=4,000) and in 
unprocessed grains of undefined end-use (45%, n= 15,943) samples, with mean concentrations 
of 95.5 µg/kg, 1,815 µg/kg and 357 µg/kg respectively (Knutsen et al. 2017). A global survey 
performed in 2004 covering 19,000 of food and feed samples showed that DON was found in 
Central Europe (56%), North Asia (78%) and North America (68%) in mean concentration of 
1,009 μg/kg, 1,060 μg/kg and 1,418 μg/kg respectively (Schatzmayr and Streit 2013). DON 
was found simultaneously with 16-35 other metabolites in 79% of 1113 finished feed, maize 
and maize silage samples collected between 2012 to 2015 from worldwide (Kovalsky et al. 
2016). 
Toxicity 
DON is one of the least lethal trichothecenes, but at high dose, acute exposure to DON elicits 
abdominal distress, increased salivation, malaise, diarrhea, necrosis of bone marrow, lymphoid 
tissue and both kidney and heart lesion (Pestka 2010; Ruiz et al. 2011). Based on adverse 
gastrointestinal effects of DON on Chinese people, the CONTAM identified that vomiting 
occurred within 30 minutes after an eating occasion and a non-observed adverse effect level 
(NOAEL) for acute effect was calculated, 26 µg DON/kg b.w for a single eating occasion. The 
highest acute dietary exposure to DON was identified in the young children and infants. Human 
outbreaks from acute exposure to DON have been repeatedly reported in Asia. Indeed, vomiting 
is a critical acute effect of DON in humans (Knutsen et al. 2017). The evidence of adverse 
health effects in humans due to chronic exposure to DON is lacking, but the CONTAM panel 
has identified reduced body weight gain in experimental animals as the critical chronic effect 
for human risk assessment. 
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Furthermore, the CONTAM Panel calculated a lowest observed adverse effect level (LOAEL) 
and NOAEL of DON for pig. It is noted that naturally contaminated feed had a stronger effect 
on the feed intake and weight gain than pure DON, and this lead to the assumption that other 
toxic compound are present (EFSA 2004). Overall, NOAELs for reduced feed intake and 
reduced body weight gain (0.7–5.0 mg DON/kg feed) was observed overlapping with even a 
wider range of LOAELs (0.35–13 mg DON/kg feed) (Knutsen et al. 2017). Impaired immune 
response, reproductive, neurological, hematological, and molecular effects are also reported 
from in vivo or in vitro studies (Sobrova et al. 2010). Previous findings have shown that, if the 
concentration of DON increases over than 12.5 mg/kg feed, it causes feed refusal and vomiting 
in animals (Fink‐Gremmels 1999). However, the oral bioavailability and absorption of DON in 
animals depends on several parameters including species, age and gender. For example after 
oral ingestion, within 15–30 min, 7 % of DON was detected in ruminants (sheep and cow), 25 
% in rat’s, and up to 89 % in pig’s blood (Goyarts and Dänicke 2006; Payros et al. 2016). A 
major part of the ingested DON in pigs was absorbed quickly from the proximal segments of 
the small intestine (Eriksen and Pettersson 2004; Dänicke et al. 2004). In mice, DON was 
rapidly distributed to the tissues, e.g. liver, kidney, spleen and heart, following oral exposure to 
a 25 mg/kg b.w dose, reaching the maximum concentrations at about the same time as in plasma. 
Concentration of DON in liver was (12.1 - 19.6 µg/g,), in kidney (7.6 - 9.0 µg/g,) and in spleen 
was observed (7.9 µg/g) respectively (Pestka et al. 2008). Since nutrients are absorbed in the 
small intestine, the gastrointestinal tract is the first barrier against food contaminants and it may 
be exposed to high concentration of mycotoxins (Pinton and Oswald 2014; Alassane-Kpembi 
et al. 2015; Fraeyman et al. 2018). 
Effects of DON were assessed on human intestinal epithelium using in vitro approach and on 
porcine intestinal epithelium using in vitro and in vivo approaches. DON decreased the 
transepithelial electrical resistance (TEER) in a time and dose-dependent manner in Caco-2 and 
IPEC-1 cells in vitro. Exposure of Caco-2 to DON 5 or 20 μM decreased only 7% of TEER, 
but the decrease reached 58% after treatment with DON 100 μM. In longer treatment, during 
14 days of exposure TEER was decreased by 19, 29, 77 and 79% for cells treated with DON 5, 
10, 50 and 100 μM respectively. DON also decreased TEER in a time and dose dependent 
manner in IPEC-1 in vitro. In short time of exposure (one day), the TEER was decreased only 
by 25% and 60% due to DON 10 μM and 50 μM, whereas following a longer incubation it was 
significantly decreased by 58, 69, 75 and 97% for cells treated with DON 5, 10, 20 and 50 μM 
respectively. Furthermore, a significant decrease in cell viability was observed when cells were 
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exposed to highest concentration of DON (200 μM in IPEC-1 cells and 500 μM in Caco-2 cells). 
DON decreased by 40% the amount of the tight junction protein claudin-4 (CLDN-4), when 
pigs received DON contaminated feed (2.85 mg/kg DON/kg feed) during 5 weeks compared to 
the control diet. Overall, the porcine intestinal epithelial cells IPEC-1 showed more sensitivity 
than human cells Caco-2 (Pinton et al. 2009). 
Mode and mechanism of action 
Concerning the mode of action, DON binds to ribosomes, leading to a ribotoxic stress and the 
inhibition of protein synthesis and subsequently also RNA and DNA synthesis (Sobrova et al. 
2010). This ribotoxic stress also activates different mitogen-activated protein kinases 
(MAPKs). Activation of MAPKs explains several effects of DON, such as apoptosis or survival 
of cells, inflammatory effect and oxidative stress. Two major mediators of DON-induced 
anorexia/emesis have been described, pro-inflammatory cytokines and secretion of satiety 
hormones, which activate receptors in the abdominal vagus afferent (Knutsen et al. 2017). 
Furthermore, DON regulates tight junction proteins such as CLDN through signaling molecules 
as activation of MAPKs (Ghareeb et al. 2015). 
Regulation 
Exposure to DON usually originates from the consumption of contaminated plant commodities, 
but might occur also via a secondary route following the consumption of meat, milk and eggs, 
containing residual amounts of mycotoxins ingested by food-producing animal (Fink‐
Gremmels 1999). The highest exposure of DON comes from grain-based products, especially 
‘bread and rolls’, ‘fine bakery wares’ and ‘pasta (raw) (Knutsen et al. 2017). In order to protect 
public health, to keep contaminants at levels that are toxicologically acceptable, many countries 
have established the maximum level for DON in food and feed. According to the EU 
commission regulation a tolerable daily intake (TDI) of 1 µg/kg b.w per day was established 
for DON. Although, young children were chronically exposed to DON at levels close to or even 
higher than the TDI (EFSA 2013). For example; the assessment of chronic dietary exposure of 
the German population resulted that young children 4-6 year-old received 2.7 fold higher DON 
than the TDI. Chronic exposure level of the Norwegian population was estimated on average 
2.0 μg/kg b.w (2 year-old children) per day, which is twofold higher than the TDI. Toddlers 
and other children are the most exposed groups considering chronic exposure. Chronic dietary 
exposure of children to DON is estimated between 0.54 and 1.02 μg/kg b.w per day. Chronic 
25 
dietary exposure of adolescents, adults, elderly and very elderly to DON is estimated between 
0.22 and 0.58 μg/kg b.w. per day. The acute effects of DON in humans are similar to those in 
animals (EFSA 2013). EU commission established maximum level for food and feedstuff as 
stated following (Table 3 and Table 4). 
Table 3: EU regulation for DON in foodstuff 
 Foodstuff 
Maximum recommendation 
level (mg/kg) 
1 Unprocessed cereals other than durum wheat, oats and maize 1.25 
2 Unprocessed durum wheat and oats  1.75 
3 
Unprocessed maize with the exception of unprocessed maize 
intended to be processed by wet milling  
1.75 
4 
Cereals intended for direct human consumption, cereal flour, bran 
and germ as end product marketed for direct human consumption, 
with the exception of foodstuffs  
0.75 
5 Pasta (dry)  0.75 
6 
Bread (including small bakery wares), pastries, biscuits, cereal snacks 
and breakfast cereals 
0.5 
7 
Processed cereal-based foods and baby foods for infants and young 
children 
0.2 
8 
Milling fractions of maize with particle size > 500 micron falling 
within and other maize milling products with particle size > 500 
micron not used for direct human consumption  
0.75 
9 
Milling fractions of maize with particle size ≤ 500 and other maize 
milling products with particle size ≤ 500 micron not used for direct 
human consumption  
1.25 
(European-Commission 2007) 
Table 4: EU regulation for DON in feedstuff 
 
Feedstuff 
Guidance value in mg/kg 
(ppm) relative to a 
feedingstuff with a moisture 
content of 12 % 
1 Feed Materials : 
 Cereals and cereal products  with the exception of maize by-
products 
 Maize by-products 
 
8 
 
12 
2 Complementary and complete feedingstuffs with the exception of: 
 complementary and complete feedingstuffs for pig 
 complementary and complete feedingstuffs for calves (< 4 
months), lambs and kids 
5 
0.9 
2 
(European-Commission 2006)   
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1.3. Fungal toxic secondary metabolites (Emerging Mycotoxins) 
Emerging mycotoxins are fungal secondary metabolites that are neither routinely determined, 
nor legislatively regulated (Vaclavikova et al. 2013). Emerging Mycotoxins are usually co-
produced with other well-known mycotoxins (Hussein and Brasel 2001). The most relevant and 
frequently occurring emerging mycotoxins are Fusarium toxins including Enniatins (ENNs), 
Beauvericin (BEA), Apicidin (API), Aurofusarin (AFN), Moniliformin and Fusaproliferin 
(Gruber-Dorninger et al. 2016; Jajić et al. 2019). ENNs and BEA belong to a group of cyclic 
hexadepsipeptides, AFN is a dimeric naphthoquinone, and API is a cyclic tetra peptide 
(Frandsen et al. 2006; Niehaus et al. 2014; Rodríguez-Carrasco et al. 2016). Furthermore, other 
fungal species such as Alternaria, Aspergillus and Penicillium produce some emerging 
mycotoxins such as Brevianamid-F (BRV-F), Emodin (EMO) and Cyclo-Pro-L-Tyr (Cyclo) 
(Streit et al. 2013). In addition, Acremonium which is perceived to be a heterogeneous taxon, 
also produce some emerging mycotoxins such as Tryptophol (TRPT) (Glenn et al. 1996). 
As these mycotoxins have only been discovered over the last few decades, they are to date 
poorly investigated (Springler et al. 2016b). Although recent sensitive analytical methods via 
LC-MS/MS has assisted the discovery of new fungal secondary metabolites (Malachová et al. 
2014), but still the toxicology, toxicokinetics and toxicodynamics data of these metabolites are 
fragmentary (Taevernier et al. 2015). 
Emerging mycotoxins can occur in high frequency and sometimes also in high concentrations 
in cereals and in other grain-based products (Rodríguez-Carrasco et al. 2016; Gruber-Dorninger 
et al. 2016). In addition, their presence was reported in mold of water-damaged houses in milder 
climate regions such as North America and Western Europe (Taevernier et al. 2016). Thus, 
emerging mycotoxins gain growing interest due to their rapidly increasing presence across the 
food chain (Lucioli et al. 2013; Fraeyman et al. 2018). Although emerging mycotoxins are 
concerned, maximum permitted levels may not be proposed in the immediate future. This is 
primarily due to the lack of data related to their occurrence, contamination level, and toxicity. 
In order to better assess the risk of these mycotoxins, regular surveillance is a prerequisite to 
understand their significance as natural contaminants in human and animal nutrition (Jestoi 
2008). Among them, the ten most prevalent emerging mycotoxins in feed are presented. 
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1.3.1. Enniatins (ENNs) 
Origin 
ENNs (A, A-1, B and B-1) are cyclic hexadepsipeptides (Table 5) secondary metabolites that 
have been known since few decades (Ivanova et al. 2006), and produced by several Fusarium 
species, such as F. avenaceum, F. oxysporum, F. poae, or F. tricinctum (Gruber-Dorninger et 
al. 2016). So far 29 species of ENNs have been isolated and characterized, either as a single 
compound or mixtures of inseparable homologs (Sy-Cordero et al. 2012). The most frequently 
detected ENNs in food and feed are ENN A, A-1, B and B-1 (Kamyar et al. 2004; Fraeyman et 
al. 2017). Naturally occurring ENNs commonly consist of three d-2-hydroxycarboxylic acid 
residues linked alternatively to three l-N-methyl-amino acid residues (Table 5) (Uhlig et al. 
2006). 
Table 5: Characteristics of ENNs 
Property Information 
Chemical structures 
 
Molar mass g/mol ENN-A 681.9  ENN-A1 667.9  ENN-B 639.8 ENN-B1 653.9  
CAS number 2503-13-1 4530-21-6 917-13-5 19914-20-6 
Physical state  Colourless fine needles 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform) DMP, DMSO and 
poor solubility in water 
Chemical structure and characteristics of ENNs (ENN-A, A1, B and B1) (Uhlig et al. 2006; Escrivá et al. 2015). 
Occurrence 
ENNs were detected in food (63%, n= 4,251), feed (32%, n = 3,640) and unprocessed grains 
(76%, n = 2,647) samples collected between 2010 and 2013 in 12 EU countries (EFSA 2014). 
ENNs (A, A-1, B and B-1) were also detected in more than 90% of feed and feed raw materials 
(n=83) with maximum concentrations of 1,745 μg/kg, 2,216 μg/kg, 780 μg/kg and 2,690 μg/kg 
respectively (Streit et al. 2013). In pig feed (n=1,141, worldwide) samples, ENNs (A, A-1, B 
and B-1) were found in 50%, 77%, 82% and 82% with maximum concentration of 307 μg/kg, 
549 μg/kg, 1,514 μg/kg and 1,846 μg/kg respectively. ENN-B and ENN-B1 were the most 
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prevalent than of ENN-A and ENN-A1 as well the concentrations of ENN-B and ENN-B1 were 
higher than of ENN-A and ENN-A1 (Novak et al. 2019). ENNs (A, A-1, B and B-1) were also 
found in Egyptian feed (87%, 91%, 93% and 91%) samples (n=77) and maize (32%, 35%, 44% 
and 28%) samples (n=79) respectively. Concentration of ENNs was higher in feed (1.9 – 25 
µg/kg) rather than maize (<1 µg/kg). Since feeds are composed of several raw materials, 
therefore compound feeds might be higher contaminated than maize (Abdallah et al. 2017). 
ENNs (A, A-1, B and B-1) were also found in Finland’s grain samples (wheat, barley, rye and 
oats, n=38) collected in 2001 and 2002. The incidence of positive samples and the 
concentrations of ENNs were quite high in both years, especially for ENN-B and B1 that were 
detected in all samples (maximum concentrations of 18,300 μg/kg and 5,720 μg/kg 
respectively). ENN-A and A1 were detected in 68 % of the samples with the highest levels of 
950 μg/kg and 2,000 μg/kg respectively (Jestoi et al. 2004). ENN-B was also found in 70 % of 
the baby food samples at levels up to 1,100 µg/ kg and in 44 % of pasta samples at levels of up 
to 106 µg/kg while other authors reported contamination rates of between 50 – 90 % of wheat, 
maize and barley samples with total concentrations of ENNs of up to 500 mg/kg (Juan et al. 
2013). 
Toxicity 
ENNs possess a wide range of biological properties, such as; cytotoxicity, hemolysis, 
permeability and skin damage and decrease of TEER. ENNs have ionophoric properties and 
can form complexes with cations (Kolf-Clauw et al. 2013; Taevernier 2016; Fraeyman et al. 
2016; Springler et al. 2016b; Olleik et al. 2019). Cytotoxicity of ENNs (A, A1, B and B1) was 
assessed during 24 h incubation in both proliferating and differentiated IPEC-J2 cells. ENNs 
were ranked in the following order of decreasing toxicity ENN-A > > ENN-A1 > ENN-B1> > 
>ENN-B respectively (Fraeyman et al. 2018). In similar cell line, after 48 h incubation all ENNs 
(A, A1, B and B1) showed almost similar absolute IC50 values of 3.40 µM, 4.15 µM, 3.25 µM 
and 3.67 µM respectively (Novak et al. 2019). In a similar time of exposure, cytotoxic effect of 
ENNs (0 to 100 µM) were studied in different cell types of human origin such as Caco-2, human 
normal lung epithelial cells (BEAS-2B), human normal epidermal keratinocytes (HEK), human 
liver cell line HepG2, human normal endothelial cells (HUVEC) and human gastric cell line 
(N87). Effect of ENNs in different cell types was dissimilar (Table 6). Among them, N87 cells 
were more sensitive than other cell lines (Olleik et al. 2019). 
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Table 6: Cytotoxicity of ENNs in different cell lines 
Organ Cell Type Toxicity Range of IC50 
Human intestinal 
cells 
Caco-2 
ENN-A > ENN-A1 > ENN-B1 >ENN- B 
1.1 µM to 4.6 µM 
Human lung 
epithelial cells 
BEAS-2B 5.7 µM to 43.7 µM 
Human epidermal 
keratinocytes 
HEK 2 µM to 54 µM 
Human endothelial 
cells 
HUVEC 2.8 µM to 17.3 µM 
Human liver cells HepG2 ENN-A > ENN-B > ENN-A1 ≈ENN- B1 3 µM to 5.6 µM 
Human gastric 
carcinoma cell line 
N87 ENN-A1 > ENN-B1 > ENN-A >ENN- B 0.003 µM to 1.7 µM 
Furthermore, hemolytic activity of ENNs was assessed on human erythrocytes. According to 
their hemolytic activity, ENNs were ranked in the following order of toxicity; ENN-A> ENN-
A1> ENN-B1> ENN-B respectively (Olleik et al. 2019).  
In another study performed on Caco-2 cells, ENN-B decreased cell viability from 2.5 to 10 µM 
up to 30% 24 h whereas at 48 and 72 h it decreased the viability from 1.25 to 10 µM up to 50% 
and over 90% respectively. The obtained IC50 were of 9.2 µM, 6.9 µM and 5.09 µM after 24 h, 
48 h and 72 h respectively (Fernández-Blanco et al. 2016). For tumor cells (neuronal origin), 
ENN-B was highly toxic. In a short term treatment (8 h) and at a very low concentration, ENN-
B (0.1-1 µM) had tumor promoting functions based on growth stimulation (Dornetshuber et al. 
2007). 
Taking into account the above results, ENNs are toxic in vitro, whereas the in vivo studies that 
have been carried out in rodent and mice, have shown very low or no toxicity. Oral doses of 
0.5–1 g/kg body weight (b.w) per day over 6 days to mice and single oral doses of up to 50 
mg/kg b.w/day in rats did not produce toxic effects (Kolf-Clauw et al. 2013). In a study of 
(Rodríguez-carrasco et al. 2016), 5 mg/kg b.w ENN-B administrated to the mice for 9 days did 
not affect body weight, food intake and behavior of animals. In another study, 20.91 mg/kg 
b.w/day of ENN-A was administrated in the feed to a 2-month-old female Wistar rats, during 
the 28 day experiment and no adverse effect were seen in organ weight and histology of 
duodenum (Manyes et al. 2014). In similar treatment period 465 mg/kg feed, ENN-A was 
assessed in rats, no significant difference in feed intake and no gross illness was observed (Juan 
et al. 2014). 
Concerning the metabolism of ENNs, it depends on the species or compound. A toxicokinetic 
study was performed in one piglet, in order to investigate the simultaneous detection and 
quantification of ENN-A, A1, hB and B1 in animal plasma. The pig received a single oral intra-
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gastric bolus of 0.05 mg/kg b.w of all these mycotoxins including BEA. Blood samples were 
collected before (0 min) and at 10, 20, 30 and 40 min, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h post-
administration. The authors claimed that despite of their similar chemical structure, there was 
a big difference in oral absorption between the different ENNs. ENN-B seemed to have the 
highest oral absorption, followed by ENN-B1, A1 and finally ENN-A. The maximal plasma 
concentrations (Cmax) for ENN-B, B1, A1 and A, were 73.4, 35.2, 11.6 and 6.8 ng/mL 
respectively. The time to maximal plasma concentration (Tmax) was 20 min after bolus 
administration for ENN-B1, B and A1, whereas the Tmax for ENN-A was 30 min post-
administration. The authors claimed that the elimination rate of all ENNs was fast and 
comparable to DON (Devreese et al. 2013). Furthermore, toxicokinetic properties and absolute 
oral bioavailability of ENN-B1 was evaluated in pig. Pigs were administered ENN-B1 (0.05 
mg/kg b.w), either by oral gavage or by intravenous (IV) injection in the ear vein. ENN-B1 was 
rapidly absorbed after oral administration. The absolute oral bioavailability was 91% after 2 h. 
After IV administration, ENN-B1 was distributed and eliminated in accordance with oral 
administration (Devreese et al. 2014). 
1.3.2. Beauvericin (BEA) 
Origin 
BEA is a cyclic hexadepsipeptide (Table 7) synthesized by several Fusarium species, including 
F. subglutinans, F. proliferatum, F. oxysporum, F. moniliforme, F. anthophilum and F. 
beauvrecin (Fotso and Smith 2003). BEA was firstly isolated from Beauveria bassiana (Hamill 
et al. 1969) and reported for its insecticidal properties and its toxicity to Artemia salina 
(Randazzo et al. 1993). BEA is known to exert a broad spectrum of biological effects such as, 
antibiotic, anti-inflammatory activities, as well as anticancer effects in various cancer cell lines 
(Heilos et al. 2017). 
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Table 7: Characteristics of BEA 
Property Information 
Chemical structures 
 
C45H57N3O9 
Molar mass  784.0 g/mol 
Physical state  Colourless fine needles 
CAS number 26048-05-5 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform) DMP, 
DMSO and poor solubility in water 
Chemical structure and characteristics of BEA (Logrieco et al. 1998; Liuzzi et al. 2017). 
Occurrence  
BEA was reported in food (80%, n=732), feed (79%, n=861) and unprocessed grains (46%, 
n=554) samples collected between 2010 and 2013 in 12 EU countries. For food, the highest 
mean concentrations were measured in dried fruits (29.5 µg/kg), followed by oilseeds (8.86 
µg/kg) and cereal-based food for infants and young children (8 µg/kg). For feed and 
unprocessed grains, BEA was present in maize gluten (EFSA 2014). In a worldwide survey of 
pig feed, BEA was reported in 68% of total samples (n=1,141) with maximum concentration of 
413 µg/kg (Novak et al. 2019). BEA was found in high prevalence (98%, n=83) with maximum 
concentration of 2,326 µg/kg in feed and feed raw materials collected in EU (Streit et al. 2013). 
Furthermore, occurrence of BEA was reported from different countries in various commodities. 
BEA was found 33-95% in several food commodities, such as wheat based products, rice, maize 
based products and barley based products, collected in Italy, Spain, Morocco and Tunisia 
(n=265), with maximum concentrations 844 µg/kg, 57.4 µg/kg, 73.9 µg/kg and 82 µg/kg 
respectively (Serrano et al. 2012). In Italian corn (n=94) and oat (n=7) samples BEA was found 
27-57% in maximum concentrations 41 µg/kg (Ritieni et al. 1997; Juan et al. 2013). All the 
wheat samples (n=13), from Finland and all the rice samples (n=70) from morocco were 
contaminated by BEA with maximum concentration 3,500 µg/kg and 12,810 µg/kg 
respectively. Even, 33% of baby food (n=68) were contaminated by BEA with maximum 
concentration of 10,600 µg/kg in Morocco (Logrieco et al. 2002b; Meca et al. 2010; Sifou et 
al. 2011). In addition, BEA was reported in Egyptian maize (63%, n=79) and feed (88%, n=77). 
Concentration of BEA in feed (88 µg/kg) was higher than maize (63 µg/kg) (Abdallah et al. 
2017). 
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Toxicity 
Acute exposure to BEA is not a concern to human health (EFSA 2014). However, in human 
and mammalian cell lines, BEA demonstrated toxic effects as it induces apoptosis, increases 
cytoplasmic calcium concentration and leads to DNA fragmentation (Logrieco et al. 2002a; 
Luz et al. 2017). The toxicity of BEA is primarily regarded to its ionophoric properties that 
alters the normal physiological concentrations of cations in and out of cells, acting as an ion 
carrier through the plasma membrane (Hilgenfeld and Saenger 1982; Fotso and Smith 2003). It 
also induces lipid peroxidation and alters kinetics in heart metabolism (Ruiz et al. 2011). 
Cytotoxic effect of BEA was assessed on different human cell lines: Caco-2, BEAS-2B, HEK, 
HepG2, HUVEC and N87 for 48 h. They were ranked based on the following order of 
decreasing sensitivity: HUVEC> HepG2> Caco-2> HEK> BEAS-2B>N87, with IC50 of 2.4 
µM> 3.4 µM> 3.9 µM> 5.4 µM> 6.3 µM> 27.5 µM respectively (Olleik et al. 2019). In 
addition, BEA revealed toxic effect on human fibroblast-like cell line (MRC-5) After 24 h, the 
IC50 was of 5.0 µM and 1.1 µM via Alamar Blue
TM and BrdU assay respectively (Ivanova et 
al. 2006). Furthermore, a toxicogenomic study was performed to investigate gene expression 
changes triggered by BEA exposure (1.5, 3 and 5 μM) during 24 h in Jurkat cells, a human 
lymphoblastic T cell line, through RNA-sequencing and differential gene expression analysis. 
The results demonstrated BEA-induced mitochondrial damage affecting the respiratory chain 
and pointing to apoptosis through the caspase cascade. The most significantly altered pathways 
genes, involved in the respiratory chain, were significantly down-regulated. These results bring 
greater relevance to mitochondria as a target site for BEA induced cytotoxicity in cellular 
models (Escrivá et al. 2018). 
Nevertheless, BEA is identified toxic in vitro, but is reported to be not toxic in vivo. Toxicity 
and pharmacological behavior of BEA was investigated in mice during 9 days, no effect on 
body weight, food intake and behavior was observed at 5 mg/kg b.w (Rodríguez-carrasco et al. 
2016). However, in a brain influx study performed in mice, BEA crossed the blood-brain barrier 
(Taevernier et al. 2016). Therefore, no conclusion could be drawn with respect to chronic 
exposure due to the lack of relevant in vivo toxicity data. 
Metabolization of BEA was studied in pig. A toxicokinetic study was performed in one piglet, 
in order to investigate detection and quantification of BEA in plasma. The pig received a single 
oral intra-gastric bolus of 0.05 mg/kg b.w of BEA along with ENNs (ENN-A, A1, B and B1). 
Blood samples were drawn before (0 min) and at 10, 20, 30 and 40 min, 1, 1.5, 2, 3, 4, 6, 8, 10 
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and 12 h post-administration. The authors claimed that for BEA, no plasma concentration-time 
profile was designed as the plasma concentrations were above the limit of quantification (LOQ) 
level at only 2 time points, i.e. 0.51 ng/mL at 30 min and 0.82 ng/mL at 40 min post-
administration. Thus, BEA revealed a lower oral bioavailability compared to ENNs (Devreese 
et al. 2013). 
1.3.3. Aurofusarin (AFN) 
Origin 
AFN is a dimeric naphthoquinone belonging to the naphthoquinone group of polyketides (Table 
8) (Frandsen et al. 2006). AFN is a yellow-red pigment produced by Fusarium head-blight 
disease caused by several species of Fusarium, such as F. graminearum, F. culmorum, and F. 
crookwellense (Kim et al. 2006). 
Table 8: Characteristics of AFN 
Property Information 
Chemical structures 
C30H18O12 
Molar mass  570.4 g/mol 
Physical state Black and brown fine needles 
CAS number 88360-87-6 
Physical state  Dependent on the pH value of the solvent, ranging from golden yellow in 
acidic solvents to red/purple in alkaline solvents 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform) DMP, 
DMSO and poor solubility in water 
Chemical structure and characteristics of AFN (Tanaka and Tamura 1961). 
Occurrence 
AFN has been identified in feed ingredients in particular in contaminated grains and known as 
a new crop pollutant (Dvorska et al. 2003). AFN was found in feed raw materials 84% (n=83, 
Europe), finished feed 80.7% (n=1,141, worldwide), 73% (n=77, Egypt) and maize 9% (n=79, 
Egypt) with maximum concentration of 17,659 µg/kg, 85,360 µg/kg, 3,005 µg/kg and 1,858 
µg/kg respectively (Streit et al. 2013; Abdallah et al. 2017; Novak et al. 2019). In addition, 
AFN was found in settled dust of Polish poultry farms (n=13), among 27 other detected 
chemicals, with the highest concentration of 281.44 µg/kg (Skóra et al. 2016). 
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Toxicity 
AFN was investigated on several endpoints of toxicological importance such as cytotoxicity, 
genotoxicity and oxidative stress. AFN at 10 µM significantly decreased the cellular 
proliferation of colon adenocarcinoma cell line (HT29) and non-tumorigenic colon cells 
(HCEC-1CT) after 72 h of exposure at 12% and 7% respectively. Exposure to AFN 5 μM for 
24 h significantly reduced mitochondrial activities of HT29 and HCEC-1CT (24 % and 23 %), 
whereas AFN 10 μM reduced up to 30 % and 40% respectively. Furthermore, the genotoxic 
impact of AFN (5 μM and 10 μΜ) after 1 h was investigated in the comet assay. AFN 
significantly increased a tail intensity of DNA damage. The authors claimed significant DNA 
damage indicating the potential involvement of other mechanisms in the genotoxic impact of 
AFN. Overall, AFN was found to be cytotoxic in both tumorigenic and non-tumorigenic colon 
cells (Jarolim et al. 2018). Likewise, AFN 10 µM reduced the mitochondrial activity of Caco-
2 cells (Dvorska et al. 2001). AFN showed similar potential toxicity as DON, in terms of 
mitochondrial activity determined by the WST-1 assay. Although the results obtained with 1 
and 5 µM has indicated that AFN may show a steeper dose response curve compared to DON 
(Vejdovszky et al. 2016). 
AFN was either toxic in vivo to poultry and reduced the nutritional quality of quail meat and 
eggs. A dose 26.4 mg AFN /kg feed administrated to 45 days old quails caused a significant 
decrease of vitamins A and E, total carotenoid, lutein and zeaxanthin concentrations in the meat 
and significantly increased egg yolk susceptibility to lipid peroxidation. AFN also 
compromised immune function of laying chickens and quail and decreased fertility and 
hatchability (Dvorska and Surai 2004). Accumulation of AFN in egg yolk stimulated lipid 
peroxidation directly, causing a decrease in antioxidant concentration (Dvorska 2014) and also 
caused a significant decrease in vitamins A and E and fatty acids in egg yolk (Kim et al. 2008). 
Another possibility proposed to explain the detrimental effect of AFN on antioxidants is a 
disruption of nutrients absorption in intestine (Dvorska 2014). 
In spite of a great variety of toxic effects, the molecular mechanisms of action are poorly 
understood and information about AFN is still limited (Dvorska et al. 2001). 
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1.3.4. Apicidin (API) 
Origin 
API is a cyclic tetrapeptide built up of four amino acids; N-methoxy-L-tryptophan, L-
isoleucine, D-pipecolic acid, and L-2-amino-8-oxodecanoic acid (Table 9) produced by some 
Fusarium species (Niehaus et al. 2014). It was firstly isolated in 1996 from F. pallidoroseum 
(later known as F. semitectum) as a new agent showing histone deacetylase inhibiting activity 
in apicomplexan parasites such as Plasmodium berghei (Singh et al. 1996; von Bargen et al. 
2013). Derivatives of API have been identified, but their structure, mode of action and 
biological activities are almost similar. The most frequent derivatives of APIs are API-E, API-
D2 and API-B (Jin et al. 2010). 
Table 9: Characteristics of API 
Property Information 
Chemical structures 
C34H49N5O6 
Molar mass  623.8 g/mol 
CAS number 183506-66-3 
Physical state  Colourless fine needles 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform) DMP, 
DMSO and poor solubility in water 
Chemical structure and characteristics of API (Singh et al. 1996). 
Occurrence 
API was found in feed raw materials 66% (n=83 Europe), finished feed 52% (n=1,141 
worldwide) and 17% (n=77 Egypt) with maximum concentrations of 160 µg/kg, 1,568 µg/kg 
and 5.4 µg/kg respectively (Streit et al. 2013; Abdallah et al. 2017; Novak et al. 2019).  
Toxicity 
API is known as a potential toxic agent (Zhang et al. 2017). API revealed strongest cytotoxic 
effect on IPEC-J2 with an absolute IC50 value of 0.52 μM during 48 h (Novak et al. 2019). In 
the same cell line, API 2.5 µM decreased the TEER over 93%, after 24 h of exposure (Springler 
et al. 2016b). API inhibited proliferation of different human cancer cell lines (MCF-7, a human 
breast cancer cell; HBL-100, a human breast cancer cell line, HeLa, a human cervix cancer cell 
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line; and AGS, a human gastric adenocarcinoma cell line) dose dependently. The half maximal 
effect (IC50) were calculated; 1.17, 0.57, 0.51 and 0.13 µM after 48 h respectively. In the same 
study, API showed toxicity in mouse cancer cell lines (v-ras-transformed NIH3T3, a mouse 
fibroblast cell line and Colon 3.1-M26, a mouse colon carcinoma cell line). The IC50 were 
obtained 0.18 and 0.17 µM respectively (Han et al. 2000). Human pancreatic cancer cell lines 
(Capan-1 and Panc-1) were exposed to API for 48 h. For concentrations above 100 nM, the 
cytotoxicity and a sustained loss of cell viability were significantly increased (Bauden et al. 
2015). API showed potent inhibitory activity against lung carcinoma (GLC-82) cells with the 
IC50 value of 6.94 μM after 48 h. API 14.0 μM induced apoptosis via mitochondrial pathway in 
GLC-82 cells by 7.2 %, 16.6 %, 26.4 % and 37.8 %, after 12 h, 24 h, 36 h, and 48 h respectively 
(Zhang et al. 2017). API was incorporated into complete rat diets during 14 days at 
concentrations of 0.5 and 1 g/kg feed and fed to 21 day-old female rats. API induced toxic 
effects including body weight loss, hemorrhage in the stomach, intestine and bladder and finally 
death. API at 0.5 g/kg caused death after 10 to 14 days of exposure and at 1 g/kg animal died 
within 7 days (Park et al. 1999). 
1.3.5. Emodin (EMO)  
Origin 
EMO, an orange-red crystalline compound, is a 1,3,8-trihydroxy-6-methylanthraquinone, 
extracted from Aspergillus wentii isolated from weevil-damaged Chinese chestnuts (Table 10) 
(Wells et al. 1975). It belongs to the anthraquinones group, mainly produced by several 
Aspergillus species, including A. wentii, A. flavus and A. ochraceus (Nandani et al. 2013; Streit 
et al. 2013).  
Table 10: Characteristics of EMO 
Property Information 
Chemical structures 
                    C15H10O5 
Molar mass  270.24 g/mol 
CAS number 518-82-1 
Physical state  The orange-red, crystalline 
Soluble in: Polar organic solvents DMP, DMSO and in water 
Chemical structure and characteristics of EMO (Wells et al. 1975). 
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Occurrence 
EMO was originally reported as being more common in bark and roots, but it is clear now that 
EMO occurs in vegetative organs (stem, foliage) as well in reproductive organs (flower, fruit, 
seeds and pods). EMO is occurring in tropical and subtropical plant families as well in the plant 
families from temperate regions (Izhaki 2002). EMO was found in 89% sample of feed and feed 
raw material (n=83, Europe), finished feed 69% (n=1141, worldwide) and 92% (n=79, Egypt) 
and maize 57% (n=77, Egypt) with maximum concentrations of 1,570 µg/kg, 1,170 µg/kg, 76 
µg/kg and 66.6 µg/kg respectively (Streit et al. 2013; Abdallah et al. 2017; Novak et al. 2019). 
Toxicity 
The toxicity of EMO has been very poorly investigated either in vitro or in vivo. Cytotoxic 
effect of EMO was assessed on the viability of IPEC-J2 over 48 h. The maximum toxicity of 
EMO was reached  up to 50 µM and IC50 was obtained 13.09 µM (Novak et al. 2019). The 
cytotoxic effect of EMO was assessed on mouse embryos at the blastocyst stage, subsequent 
embryonic attachment and outgrowth in vitro, and in vivo implantation by embryo transfer. 
Blastocysts treated with EMO 25–75 µM exhibited significantly increased apoptosis and a 
corresponding decrease in total cells number. Furthermore, EMO in drinking water of mouse 
led to apoptosis and decreased cell proliferation in embryo and inhibited early embryonic 
development to the blastocyst stage (Chang et al. 2012). EMO was also toxic, when it was given 
orally to redwing blackbirds (Agelaius phoeniceusin) and starlings (Sternus vulgaris). The oral 
administration of EMO to cockerels caused moderate diarrhea and mortality within 5 days of 
ingestion (LD50 = 3.7 mg/ kg) (Wells et al. 1975). 
1.3.6. Brevianamide-F (BRV-F) 
Origin 
BRV-F is a precursor of the biosynthetic pathway of fumitremorgins and the tryprostatins, 
produced by Penicillium brevicompactum, Aspergillus versicolor and A. fumigatus (Table 11) 
(Frisvad et al. 2009). 
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Table 11: Characteristics of BRV-F 
Property Information 
Chemical structures 
 C16H17N3O2 
Molar mass  283.3 g/mol 
CAS number 38136-70-8 
Physical state  White solid fine needless 
Soluble in: Polar organic solvents (e.g., aqueous methanol, ethanol, chloroform) DMP, 
DMSO  
Chemical structure and characteristics of BRV-F (Wilson et al. 1973). 
Occurrence 
BRV-F was found in feed and as well in feed raw materials. The proportion of the contaminated 
samples were 65.2% (n= 1,141, worldwide), 69% (n=83, Europe), 86% (n= 77, Egypt), maize 
6% (n= 79, Egypt) and processed cassava 79.6% (n=373, Nigeria) with maximum concentration 
of 1,170 µg/kg, 2,043 µg/kg, 353 µg/kg , 5 µg/kg and 44 µg/kg respectively (Novak et al. 2019; 
Streit et al. 2013; Abdallah et al. 2017; Abass et al. 2017). 
Toxicity 
The toxic effect of BRV-F is poorly investigated. In a recent study, effect of BRV-F was 
examined on the viability of IPEC-J2 cells over 48 h, but did not show negative effect up to 
150 µM (Novak et al. 2019). Likewise, a preliminary toxicity study of BRV (BRV-A3) showed 
no acute toxicity in mice upon oral or intraperitoneal administration. However, the molecule 
induced cytotoxicity and inflammatory lung response in intratracheally exposed mice (Wauters 
2015). 
1.3.7. Cyclo-(L-Pro-L-Tyr) (Cyclo) 
Origin 
Cyclic dipeptide Cyclo-(L-Pro-L-Tyr) is a diketopiperazine formed by the fusion of tyrosine 
and proline (Table 12), reported as a secondary metabolite of fungi (Capon et al. 2007). Cyclo 
was firstly isolated from Alternaria alternata decades ago (Stierle et al. 1988). 
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Table 12: Characteristics of Cyclo-Pro-L-Tyr 
Property Information 
Chemical structures 
C14H16N2O3 
Molar mass  260.3 g/mol 
CAS number 357-67-5 
Physical state  White solid fine needless 
Soluble in: Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility. 
Chemical structure and characteristics of Cyclo (Holden et al. 1999). 
Occurrence 
Occurrence of Cyclo is reported in finished feed 87.6% (n=1,141 worldwide), 100% (n=77, 
Egypt) and maize 43% (n=79, Egypt) with a maximum concentration of 34,910 µg/kg, 4,244 
µg/kg and 21 µg/kg respectively (Abdallah et al. 2017; Novak et al. 2019). 
Toxicity 
Toxicity of Cyclo is not reported yet. In a recent study, effect of Cyclo was assessed up to 150 
µM on the viability of IPEC-J2 over 48 h, but was not toxic (Novak et al. 2019). 
1.3.8. Tryptophol (TRPT) 
Origin 
TRPT (indole-3-ethanol) is an aromatic alcohol (Table 13) produced by Acremonium species 
and formed as the end product of tryptophan catabolism (Kosalec et al. 2008; Streit et al. 2013). 
TRPT was firstly isolated from cucumber seed as a plant growth regulator (Rayle and Purves 
1967). However, it is an endogenous plant constituent and growth regulator, but is also 
produced as a secondary metabolite by certain bacteria, yeast and fungi (Kosalec et al. 2011). 
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Table 13: Characteristics of TRPT 
Property Information 
Chemical structures 
C10H11NO 
Molar mass  161.2 g/mol 
CAS number 526-55-6 
Physical state  White solid fine needless 
Soluble in: Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility. 
Chemical structure and characteristics of TRPT (Kosalec et al. 2008) 
Occurrence 
The occurrence of TRPT is reported in feed and feed raw materials. TRPT was found in 75% 
(n=1,141) of animal feed collected worldwide, with maximum concentration of 10,270 µg/kg 
(Novak et al. 2019). Another study, carried out on Egyptian animal feed and maize, reported 
the presence of TRPT in 90% (n=77) and 16% (n=79) of the samples at concentrations of 10,878 
µg/kg and 101 µg/kg respectively (Abdallah et al. 2017). In addition, occurrence of TRPT was 
reported in 71% (n=83, Europe) of feed and feed raw materials samples in mean concentration 
of 267 µg/kg (Streit et al. 2013). 
Toxicity 
TRPT was not cytotoxic in vitro for IPEC-J2 exposed to 150 µM for 48 h (Novak et al. 2019). 
Whereas, in vivo studies have reported that TRPT is a highly lipophilic compound that freely 
penetrates cell membranes. TRPT was injected into laboratory mammals and chicken and 
induced a sleep-like state and lethargy accompanied with alteration of body temperature. 
(Kosalec et al. 2011). When administered to laboratory animals, it was rapidly distributed to 
the brain and other tissues. TRPT also readily penetrates into lymphoid tissues and its 
immunosuppressive effects have been observed in mice (Ackerman and Seed 1976). TRPT 
induces apoptosis in human lung (lymphoblast) U937 cell line via activation of caspase-8 
followed by caspase-3 (Inagaki et al. 2007). Despite interesting biological functions, the overall 
toxicity profile of TRPT has not yet been adequately explained. Only a few studies have dealt 
with mutagenicity and genotoxicity of TRPT (Kosalec et al. 2011).  
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1.4. Structure and function of the small intestine 
The intestine constitutes the largest and most important barrier to prevent the passage of harmful 
intraluminal substances from the external environment into the organism, including foreign 
antigens, microorganisms, and their toxins (Pierron et al. 2016a). It is the first barrier to food 
contaminants. Following the ingestion of mycotoxin contaminated food or feed, intestinal 
epithelial cells can be exposed to high concentrations of toxicants, potentially affecting 
intestinal functions (Pinton and Oswald 2014; Bouhet and Oswald 2005). Indeed, the intestine 
is a privileged immune site, where immunoregulatory mechanisms simultaneously defend the 
body against pathogens, but also preserve tissue homeostasis to avoid immune mediated 
pathology in response to environmental challenges (Pinton and Oswald 2014). 
The small intestine is a specialized abdominal tubular structure in length of 4 to 7 m (Thomson 
and Shaffer 1992) and its epithelium is a single-cell layer that constitutes the largest and most 
important barrier against the external environment. The intestinal epithelium has two critical 
functions: (i) it acts as a selective filter, allowing the translocation of essential dietary nutrients, 
electrolytes, and water from the intestinal lumen into the circulation; (ii) it acts as a barrier to 
prevent the passage of harmful intraluminal entities, including foreign antigens, 
microorganisms, and their toxins (Groschwitz and Hogan 2009). These functions are supported 
by the unique structure of layers of the gastrointestinal tract (GT). The GT is divided into several 
layers: the mucosa, the submucosa, the muscularis propria, and the serosa (Figure 2) (Rao and 
Wang 2010). The mucosa consists of an epithelial lining, a laminal propria of loose connective 
tissue, and the muscularis mucosae, which is composed of two layers of smooth muscle fibers, 
separating the mucosa from the submucosa. The submucosa is a layer of irregular loose 
connective tissue, containing large blood and lymphatic vessels, glands, lymphatic tissue, and 
a submucous (Meissner's) nerve plexus. The muscularis externa is formed of thick bundles of 
smooth muscle fibers arranged into two sublayers: circular in the internal sub layer and 
longitudinal in the external sublayer. Serosa is a thin layer of loose connective tissue. It is 
continuous with adjacent tissue in the esophagus. Serosa replace the adventitia in the 
gastrointestinal tract, which is composed of a layer of mesothelium and the underlying loose 
connective tissue, rich in blood and lymphatic vessels and adipose cells (Zhang 1999).  
Mucosa is also referred to as a mucous membrane, as mucus production is a characteristic 
feature of gut epithelium. The membrane consists of epithelium, which is in direct contact with 
ingested food, and the lamina propria, a layer of connective tissue analogous to the dermis 
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(Betts et al. 2017). The small intestinal mucosa is constructed to act first as an absorptive 
surface and second as a barrier to potentially pathogenic substances and microorganisms. The 
intestinal epithelium is composed of absorptive cells such as enterocytes and protective cells, 
such as goblet cells, paneth cells and endocrine cells(Table 14) (Greaves 2011). 
Table 14: The roles of the cells in the small intestinal mucosa (Betts et al. 2017). 
Cell type Location in the mucosa Function 
Absorptive Epithelium/intestinal glands Digestion and absorption of nutrients in chime 
Goblet Epithelium/intestinal glands Secretion of mucus 
Paneth cells Intestinal glands Secretion of the bactericidal enzyme lysozyme; 
phagocytosis 
G cells Intestinal glands of 
duodenum 
Secretion of the hormone intestinal gastrin 
I cells Intestinal glands of 
duodenum 
Secretion of the hormone glucoses-dependent 
insulinotropic peptide, which stimulate the release 
of insulin 
K cells Intestinal glands Secretion of the hormone glucose-dependent 
insulinotropic peptide, which stimulates the release 
of insulin 
M cells Intestinal glands of 
duodenum and jejunum 
Secretion of the hormone motilin, which accelerates 
gastric emptying, stimulates intestinal peristalsis, 
and stimulates the production of pepsin 
S cells Intestinal glands Secretion of the hormone secretin 
 
Figure 2: Layers of the alimentary canal. The wall of the alimentary canal has four basic tissue layers The 
mucosa, submucosa, muscularis, and serosa (Betts et al. 2017): 
The normal gastrointestinal tract is a finely integrated system geared to carry out the 
assimilation of ingested foodstuffs. Assimilation (the process by which ingested foods reach 
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body fluids and cells) takes place in the small intestine (Thomson and Shaffer 1992). Thus, the 
intestine is potentially highly exposed to the food contaminants (Pinton and Oswald 2014). 
In order to investigate the effect of food contaminants such as mycotoxins in the intestine, 
several in vivo, in vitro and ex vivo model are generally used so far. In vitro models of intestinal 
mucosa have been developed for studying enteritic diseases. Ex vivo tissue cultures represent a 
model between in vitro and in vivo, where whole tissue slices are cultured, such as organotypical 
slice cultures. In the ex vivo models, the cytoarchitecture is retained as well as many of the 
intercellular connections and interplays. Thus, metabolic processes more closely represent the 
in vivo situation. In the context of reducing the number of experimental animals, intestinal 
explants represent a powerful model (Kolf-Clauw et al. 2009; Fadeel et al. 2012; Pearce et al. 
2018). Although, the in vitro studies can be criticized for being very different from the natural 
environment they have several advantages. First, they do not demand the technical skills in 
animal handling and have typically lower costs. Secondly, in vitro assays are more rapid and 
can be more easily performed. Furthermore, in vitro assays allow identification of direct effects 
on target cells. Finally, in vitro studies have the advantage of allowing genetic manipulation of 
cells as well as the utilization of cells and tissues from transgenic species (Goodwin 2007). 
The toxic effect of DON and emerging mycotoxins on intestinal cells using in vitro model are 
summarized in Tables 15 and 16. This part is mainly focusing on in vitro studies, thus in vivo 
and ex vivo has not been included. 
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Table 15: Effect of DON on the intestine in vitro 
Cells 
Type 
Dose and time 
of exposure 
Range or 
time point of 
toxicity 
Endpoint References 
IP
E
C
-1
 
10-50 µM 
(48 h) 
TEER 2-16 days 
Toxicity >5 
µM 
TEER >2 
days 
Decrease in claudin-3 & 4 
tight junction protein 
Increase in 4 kDa dextran 
permeability 
Increase in E coli 28C 
translation 
Decrease in TEER 
(Pinton et al. 2009) 
10-30 µM 
(24 – 48 h) 
>10 µM 
Decrease in TEER 
Decrease in claudin-3 & 4 
tight junction protein 
Increase in 4 Dka dextran 
permeability 
(Pinton et al. 2012) 
0. -13.5 µM 
(72 h) 
>3 µM 
Decrease in protein expression 
of ZO-1 
(Diesing et al. 2011b) 
IP
E
C
-J
2
 
0. -13.5 µM 
(72 h) 
>6 µM 
Affect the distribution pattern 
of ZO-1 
(Diesing et al. 2011b) 
6.74 µM 
(1 - 48 h) 
>1 h 
Decrease in TEER values 
Decrease in protein expression 
of claudin-3, occludin and 
ZO-1 Affect the distribution 
pattern of ZO-1 
(Gu et al. 2014) 
2.5-10 µM 
(24 – 48 h) 
>2.5 µM 
24 – 48 h 
Inhibit proliferation 
Increase LDH release 
Decrease ATP contents 
(Awad et al. 2012) 
20 µM 
(48 h) 
- Decreased proliferation (Novak et al. 2019) 
20 µM 
(0 – 72 h) 
TEER (30 days) 
>1 h 
TEER >7 
days 
Decrease in TEER 
Decrease in protein 
expression, claudin-3 & 4 
(Springler et al. 2016a) 
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through p44/42 
phosphorylation 
1.5-3 µM 
(24 – 72 h) 
>1.5 µM 
Inhibit proliferation 
Decrease in TEER 
(Springler et al. 2016b) 
0.67–13 µM 
(24–72 h) 
>0.67 µM 
>24 h 
Decrease in TEER value 
Decrease in protein expression 
of claudin-3, occludin and 
ZO-1 
Affect the distribution pattern 
of ZO-1 
(Diesing et al. 2011a) 
0.03-3 µM 
(72 h) 
>0.03 µM 
Decrease in TEER values 
Increase in permeability of 
doxycycline and 
paromomycin 
(Goossens et al. 2012) 
4 µM 
(12 h) 
- 
Decrease in TEER values 
Increase in permeability of 4 
kDa FITC-dextran 
Increase in translocation of 
commensal E coli 
Increase in transcript level of 
claudin-1, claudin-4, occludin 
and ZO-1 
Decrease in protein expression 
of claudin-3 and claudin-4 
(Ling et al. 2016) 
0.001-100 µM 
(48 h) 
>10 µM Decrease in TEER (Maresca et al. 2002) 
0.1–1 µg/mL 
(24 h) 
>0.75 µg/mL 
Increase in translocation of 
pathogenic Salmonella 
typhimurium 
(Vandenbroucke et al. 
2011) 
H
T
-2
9
 
2-50 μM 
(24 h) 
>5 µM 
Inhibit proliferation 
Increase in total DNA damage 
Increase in p53 protein level 
and caspase-3 activity 
(Bensassi et al. 2009) 
0.13-0.7 μM 
(6 -20 days) 
>0.13 µM 
>15 days 
Decrease in protein content 
Decrease in TEER 
(Kasuga et al. 1998a) 
46 
Increase in lucifer yellow 
permeability 
C
a
co
-2
 
 
30 μM 
(48 h) 
- 
Decrease in TEER 
Decrease in claudin-4 tight 
junction proteins 
Increase in 4 kDa dextran 
permeability 
(Pinton et al. 2009) 
10 μM 
(12 h) 
- 
Decrease in TEER values 
Increase in permeability of 
HRP and 4 kDa FITC dextran 
Increase in E coli K12 
translocation 
(Maresca et al. 2008) 
1.7-17 μM 
(24 h) 
>1.7 µM 
Decrease in TEER values 
Increase in permeability of 
mannitol Increase in transcript 
level of claudin-4 and 
occludin Decrease in protein 
expression of claudin-4 
(De Walle et al. 2010) 
0.37-1.5 μM 
(6 – 120 h) 
>0.75 µM 
>35 h 
Decrease in horizontal 
impedance value of 
undifferentiated cells 
(Manda et al. 2015) 
50–200 ng/mL 
(14 days) 
>100 ng/mL Decrease in TEER values (Kasuga et al. 1998b) 
1.39 - 21.5 μM 
(24 h) 
>1.39 µM 
Decrease in TEER values 
Decrease in horizontal 
impedance value 
Increase in permeability of LY 
and 4 kDa FITC dextran 
Increase in transcript level of 
claudin-3, claudin-4, occludin 
and ZO-1 
Decrease in tight junctional 
protein expression of claudin-
1, claudin-3 and claudin-4 
Affect the distribution pattern 
of claudin-1, claudin-3, 
claudin-4, occludin and ZO-1 
(Akbari et al. 2014) 
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Table 16: Effect of emerging mycotoxins on the intestine in vitro 
Cells 
Type 
Toxins 
Dose and 
time of 
exposure 
Range or time 
point of 
toxicity 
Endpoint References 
IP
E
C
-J
2
 
ENN-A 
0 – 5  µM 
(72 h) 
>2.5 µM 
Decrease in TEER value 
Inhibit proliferation 
(S
p
ri
n
g
le
r 
et
 a
l.
 2
0
1
6
b
; 
F
ra
ey
m
an
 e
t 
a
l.
 2
0
1
8
; 
N
o
v
ak
 e
t 
a
l.
 2
0
1
9
) 
0 – 20 µM 
(48 h) 
>5 µM Inhibit proliferation 
0 – 10 µM 
(24 h) 
>5 µM 
Early and late apoptosis 
Necrotic proliferation 
ENN-
A1 
0 – 10 µM 
(72 h) 
>5 µM 
Decrease in TEER value 
Inhibit proliferation 
0 – 20 µM 
(48 h) 
>5 µM Inhibit proliferation 
0 – 10 µM 
(24 h) 
>5 µM 
Early and late apoptosis 
Necrotic proliferation 
ENN-B 
0 – 5 µM 
(72 h) 
>1.5 µM 
Decrease in TEER value 
Inhibit proliferation 
0 – 20 µM 
(48 h) 
>5 µM Inhibit proliferation 
0 – 100 µM 
(24 h) 
>10 µM 
Early and late apoptosis 
Necrotic proliferation 
ENN-
B1 
0 – 5 µM 
(72 h) 
>2.5 µM 
Decrease in TEER value 
Inhibit proliferation 
0 – 20 µM 
(48 h) 
>5 µM Inhibit proliferation 
0 – 25 µM 
(24 h) 
>10 µM 
Early and late apoptosis 
Necrotic proliferation 
BEA 0 – 10 µM >3 µM Decrease in TEER value 
48 
(72 h) Inhibit proliferation 
0 – 20 µM 
(48 h) 
>2.5 µM Inhibit proliferation 
0 – 10 µM 
(24 h) 
>5 µM 
Early and late apoptosis 
Necrotic proliferation 
API 
0 - 2.5 µM 
(72 h) 
>0.43 µM 
Decrease in TEER value 
Inhibit proliferation 
0 – 5 µM 
(48 h) 
>0.2 µM Inhibit proliferation 
AFN 
0 – 10 µM 
(72 h) 
>1 µM 
Decrease in TEER value 
Inhibit proliferation 
0 – 20 µM 
(48 h) 
>5 µM Inhibit proliferation 
EMO 
0 – 150 µM 
(48 h) 
>6.25 µM Inhibit proliferation 
 
H
T
2
9
 
ENN-A 
0.6 – 30  
µM 
(24 – 48 h) 
>6 µM 
Decrease viability 
(M
ec
a 
et
 a
l.
 2
0
1
1
) 
ENN-
A1 
>6 µM 
ENN-B >15 µM 
ENN-
B1 
>15 µM 
 
C
a
co
-2
 
ENN-A 
0.6 – 30  
µM 
(24 – 48 h) 
>3 µM 
Decrease viability 
ENN-
A1 
>6 µM 
ENN-B >6 µM 
ENN-
B1 
>6 µM 
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1.5. Structure and function of the liver 
The porcine liver consists of five lobes, the left lateral and medial, right lateral and medial, and 
caudate lobes (Figure 3) (Mulaikal and Emond 2018). The external anatomy is described from 
gross landmarks including the gallbladder, the vena cava and the hepatic ligaments. The internal 
anatomy is defined by the vascular structures and eight functionally independent segments, each 
segment with its individual blood supply and biliary drainage (Mulaikal and Emond, 2018; 
Sibulesky, 2013). Moreover, the liver is composed of a rich population of specialized cells that 
allow it to carry out complex functions. They can be grossly characterized as “parenchymal” 
cells (hepatocytes) and “nonparenchymal cells” (Mulaikal and Emond 2018). The parenchymal 
cells, make up 60 – 80% of liver cells and carry out the metabolic, detoxification, and synthetic 
functions of the liver, such as metabolism of amino acids, fats, carbohydrates, vitamins, 
byproduct wastes, and toxins (Table 17). Whereas the nonparenchymal cells makes 20 – 40% 
of the liver (Sheth and Bankey 2001; Racanelli and Rehermann 2006). 
 
Figure 3: Anatomy and different lob of pig liver (Kim and Lee 2013). 
The liver is a unique anatomical and immunological site in which antigen-rich blood from the 
gastrointestinal tract is pressed through a network of sinusoids and scanned by antigen 
presenting cells and lymphocytes (Racanelli and Rehermann 2006). Of the total hepatic blood 
flow (100–130 ml/min per 100 g of liver, 30 ml/min/kg/b.w), only one fifth to one third is 
supplied by the hepatic artery. The rest of blood about two thirds is supplied by portal vein. 
This blood contains oxygen and many nutrients brought to the liver from the intestines for 
processing (Lautt 2010). Any blood antigen or contaminant can target the liver (Sheth and 
Bankey 2001). Liver is also the main site of detoxification for xenobiotics, including 
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mycotoxins and represents a target organ for food contaminants. Liver detoxifies mycotoxins 
via biotransformation before reaching any tissue through the general bloodstream. The 
biotransformation process comprises a series of biochemical reactions leading to changes in the 
structure of contaminants facilitating their excretion from the body. A typical xenobiotic 
metabolism pathway contains a variety of enzymes that are involved in both phase I and phase 
II xenobiotics metabolism. The examples of phase I reactions are oxidation, reduction, 
dehalogenation, or hydrolysis and are catalyzed by several enzymes including cytochrome P450 
(CYP1, CYP2 and CYP3). Phase II reactions are conjugation reactions, for example with 
glucuronic acid, sulfate, glutathione and/or amino acids (Slobodchikova et al. 2019). The 
majority of mycotoxin biomonitoring is performed using urine since it is non-invasive and 
accessible in relatively large volumes. These methods of analysis can be performed with and 
without B-glucuronidase treatment. B-glucuronidase catalyzes hydrolysis of conjugated 
mycotoxins, such as sulfate and glucuronide conjugates. Thus, the use of enzymatic hydrolysis 
can provide an appropriate alternative to direct metabolite monitoring for at least those 
mycotoxins which are predominately metabolized to phase II conjugated forms such as DON 
(Vidal et al. 2018). 
The liver’s lymphocyte population is selectively enriched in natural killer T cells which play 
critical roles in first line immune defense against invading pathogens, modulation of liver injury 
and recruitment of circulating lymphocytes (Racanelli and Rehermann 2006). The high local 
blood flow results in a high rate of interaction with foreign antigens, and confers immunologic 
responsibility on the liver. Because the liver acts as a detoxification center for the body, it can 
be regenerated if injured (Sheth and Bankey 2001). Lastly, the liver is the site of cholesterol 
synthesis and therefore crucial in the genesis of endogenous steroid hormones such as cortisol, 
aldosterone, and testosterone. While these hormones are synthesized in the adrenal gland, their 
precursors have an hepatic origin (Shen and Shi 2015). 
Despite the similarity of digestive physiology between human and pig, their liver are different 
from the morphological point of view. Human liver consists of four lobes, the left, right, 
quadrate, and caudate lobes. Whereas, porcine liver consists of five lobes (Figure 3). Another 
difference is that inferior vena cava is divided into supra-and infra-hepatic in humans, whereas 
in porcine dissection between the liver and vena cava is very difficult (Kim and Lee 2013). 
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Table 17: Cellular microanatomy and their function 
Cells type Function 
Hepatocytes 
Hepatic regeneration 
Protein and lipids synthesis and metabolism 
Xenobiotic metabolisms 
Stellate/Ito cells 
Vitamin A and fat storage 
Scar tissue and wound healing 
Liver Sinusoidal 
Endothelial cells 
Regulate vascular resistance 
Kupffer cells 
Innate immunity 
Ischemia reperfusion injury 
Dendritic cells Innate immunity 
Cholangiocyte Bile duct cells 
Lymphocytes 
NK Nonspecific targeting of tumor and viruses 
Innate immunity 
Target lipid antigens 
Innate and adaptive immunity 
Cell mediated, adaptive immunity 
Humoral mediated, adaptive immunity 
NKT 
T cells 
B cells 
(Mulaikal and Emond 2018) 
We have reviewed the effects of DON and emerging mycotoxins on liver and hepatic cells 
extensively in vitro and in vivo (Tables 18, 19 and 20). 
Table 18: Effect of DON on liver cells 
In vitro 
Cells Type 
Dose and 
time of 
exposure 
Range or time 
point of 
toxicity 
Endpoint References 
Rat’s Clone9 
0.1 – 25 
μg/mL 
(24 h) 
 
>0.1 μg/mL 
Oxidative stress 
Decrease in the 
mitochondrial function 
(Sahu et al. 2010) 
0 - 100 
μg/mL 
(48 h) 
 
>10 μg/mL 
Cytotoxicity 
Double-stranded DNA 
(ds-DNA)content 
Oxidative stress 
(Sahu et al. 2008) 
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Decrease mitochondrial 
function 
Rat’s 
MH1C1 
0 – 25 μg/mL 
(24 h) 
>0.1 μg/mL 
Oxidative stress 
Decrease in the 
mitochondrial function 
(Sahu et al. 2010) 
Rat’s NBL 
CL2 
>0.1 μg/mL 
Rat’s 
WRL68 
>0.1 μg/mL 
HepG2 
0 – 25 μg/mL 
(24 h) 
>0.1 μg/mL 
Oxidative stress 
Decrease in the 
mitochondrial function 
(Sahu et al. 2010) 
1-10 μM 
(48 h) 
>1 μM 
Alteration of ATF3 
expression 
(Nielsen et al. 
2009) 
Human 
primary 
hepatocytes 
0.1-100 μM 
(8 – 48 h) 
>1 μM 
Obvious cytotoxicity 
LDH release 
Activation of caspase-3 
(Königs et al. 2008) 
Rat’s 
primary 
hepatocytes 
0.01 – 100 
μg/mL 
(3 h) 
>10 μg/mL 
Cytotoxicity 
Increases of the 
micronucleus (MN) 
frequencies 
(Knasmüller et al. 
1997) 
0.1-100 
μg/mL 
(24 h) 
>5 μg/mL 
An increased percentage 
of large-sized nuclei 
(Bradlaw et al. 
1985) 
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Table 19: Effect of DON on the liver 
In vivo 
M
o
d
el
 
Dose and time of 
exposure 
Range or 
time point 
of toxicity 
Endpoint References 
P
ig
s 
3 mg/kg feed 
(4 – 16 days) 
>4 days 
Histopathological lesions in the liver 
Disorganization of hepatic cords 
Hepatic cell vacuolization 
Apoptosis, megalocytosis, nuclear 
vacuolation 
(Grenier et al. 
2011) 
1.5 – 3 mg/kg feed 
(4 weeks) 
1.5 μg/kg 
Significant increase on histological 
changes in the liver 
(Gerez et al. 
2015) 
4 mg/kg feed 
(2 – 5 weeks) 
2 – 5 
weeks 
Oxidative stress and lipid 
peroxidation 
(Wu et al. 
2014a) 
4 mg/kg feed 
(15 – 30 days) 
15 – 30 
days 
Increased serum concentrations of 
ALP, ALT and AST 
(Xiao et al. 
2013) 
6 mg/kg feed 
(3 weeks) 
- 
Relative liver weights 
Increase of ALP, ALT and AST 
(Wu et al. 2013) 
1100 µg/kg feed 
(6 weeks) 
- 
Damage in liver tissue 
Decrease of average daily gain 
(ADG) 
Alteration of immune system through 
a tendency to increase monocytes 
and immunoglobulins. 
(Weaver et al. 
2013) 
300–900 µg/kg 
feed 
(5 weeks) 
>300 
µg/kg 
Fibrosis in liver tissues 
(Chaytor et al. 
2011) 
1 mg/kg b.w 
injection 
(6 – 24 h) 
>6 h 
Cleaving of caspase-3 
Dilation of sinusoids 
Apoptotic hepatocytes, Apoptotic 
bodies of hepatocytes, (acidophilic 
bodies) 
(Mikami et al. 
2010) 
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0.2–0.4 mg/kg 
feed 
(12 days) 
0.2–0.4 
mg/kg 
Regressive lesions in liver 
Hyperaemia of the blood vessels 
Hepatocytes and necrosis of the 
individual hepatic cells 
(Zielonka et al. 
2009) 
1 mg/kg feed 
(6 weeks) 
- 
Decrease in total protein, albumin, 
and globulin 
Increase of ALT, AST and  γ-
glutamyltransferase 
Increase of mRNA expression levels 
of IFN-γ, TNF-α, IL-2 
(Chen et al. 
2008) 
0.2 – 9.57 mg/kg 
feed 
(5 weeks) 
>0.2 
mg/kg 
Glycogen reduction 
Increase of hemosiderin particles 
Thickness of interlobular connective 
tissue septum 
High contents of smooth 
endoplasmic reticulum (ER) 
Loss of ribosomes 
Increased number of fatty and 
autophagic vacuoles 
(Tiemann et al. 
2006) 
8.6 mg/kg feed 
(16 h) 
- 
Decrease of serum activity of the 
liver enzyme glutamate 
dehydrogenase 
(Döll et al. 
2003) 
5.5 g/kg feed 
(3 weeks) 
- Decrease in liver weight 
(Swamy et al. 
2002) 
R
a
ts
 
5 mg/kg feed 
(3 weeks) 
- 
Lipid peroxidation 
DNA fragmentation 
Decreased hepatic glutathione 
content 
Upregulating mRNA Fas and TNF-α 
gene expression 
(Abdel-Wahhab 
et al. 2015) 
8 µg/g feed 
(2 – 4 weeks) 
>2 weeks Increase of ALP and ALT 
(Qiang et al. 
2011) 
0.5 – 5 mg/kg feed 
>2.5 
mg/kg 
Increase in maternal liver weight/ 
body weight ratios 
(Collins et al. 
2006) 
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(3 weeks) Cytoplasmic alterations of 
hepatocytes 
M
ic
e 
1000 mg/kg feed 
(2 weeks) 
- 
Cellular apoptosis 
DNA damage 
Positive MN1 
(Singh et al. 
2015) 
1- 25 μg/kg.b.w 
(10 – 30 days) 
25 μg/kg 
in 10 days 
>2.5 
μg/kg in 
30 days 
IL-1β increase and a modulation of 
proinflammatory gene expression in 
liver 
(Tardivel et al. 
2015) 
5 mg/kg feed 
(2 weeks) 
- 
Activities of ALT and/or AST 
Decreased albumin and/or total 
protein concentration in the serum 
Oxidative stress 
Upregulation of the apoptotic genes 
caspase-3 
(Sun et al. 2014) 
3 mg/kg feed 
(7 weeks) 
- 
Changes in liver morphology 
Oxidative stress 
(Hou et al. 
2013) 
12 mg/kg feed 
(1 – 5 h) 
>1h 
Hepatic suppressors of cytokine 
signaling mRNA 
(Amuzie et al. 
2009) 
1.78 mg/kg feed 
(4 weeks) 
- 
Increase of liver microsomal 
pentoxyresorufin depentylase 
Increase of cytosolic glutathione 
transferase activities 
(Gouze et al. 
2006) 
3 mg/kg.b.w 
(8 weeks) 
- 
Fibrosis of liver portal and periportal 
veins 
(Bilgrami 1991) 
10 g/kg feed 
(6 weeks) 
- 
Decrease of manganese and 
molybdenum in liver 
(Hunder et al. 
1991) 
25 mg /kg b.w 
(2- 4 h) 
2 -4h 
Elevation of TNF-α and TGF-β in 
liver 
(Azconaolivera 
et al. 1995) 
                                                 
1 Micronucleus 
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Table 20: Effect of emerging mycotoxins on liver cells 
Cells 
Type 
Toxins 
Dose and time 
of exposure 
Range or time 
point of toxicity 
Endpoint References 
HepG2 
ENN-A 
0- 100 µM 
(48h) 
>3 µM Inhibit proliferation 
(M
ec
a 
et
 a
l.
 2
0
1
1
; 
Ju
an
-G
ar
cí
a 
et
 a
l.
 2
0
1
3
, 
2
0
1
5
; 
Jo
n
ss
o
n
 e
t 
a
l.
 2
0
1
6
; 
S
v
in
g
en
 e
t 
a
l.
 2
0
1
7
; 
O
ll
ei
k
 e
t 
a
l.
 2
0
1
9
) 
1.5 - 3 µM 
(24 – 72h) 
≥ 1.5 µM 
≥ 24h 
Inhibit proliferation 
Apoptosis 
Necrosis 
0.6 - 30 µM 
(24 – 48h) 
>6 µM 
> 24h 
Decrease viability 
ENN-A1 
0- 100 µM 
(48h) 
>5 µM Inhibit proliferation 
1.5 - 3 µM 
(24 – 72h) 
≥ 1.5 µM 
≥ 24h 
Apoptosis 
Necrosis 
0.6 - 30 µM 
(24 – 48h) 
>6 µM 
> 24h 
Decrease viability 
ENN-B 
0- 100 µM 
(48h) 
>5 µM Inhibit proliferation 
1.5 - 3 µM 
(24 – 72h) 
≥ 1.5 µM 
≥ 24h 
Inhibit proliferation 
Apoptosis 
Necrosis 
0.6 - 30 µM 
(24 – 48h) 
>6 µM 
> 24h 
Decrease viability 
10 45 µM 
(24h) 
≥ 1.5 µM 
≥  24h 
Decrease viability 
Apoptosis 
Gene modulation 
0.009-100 µM 
(24 – 72h) 
>0.9 µM 
≥  24h 
Decrease lysosome 
activity 
Decrease plasma 
membrane integrity 
Concomitant effects on 
mitochondrial area 
Decrease nuclear count 
ENN-B1 
0- 100 µM 
(48h) 
>5 µM Inhibit proliferation 
57 
1.5 - 3 µM 
(24 – 72h) 
≥ 1.5 µM 
≥ 24h 
Apoptosis 
Necrosis 
0.6 - 30 µM 
(24 – 48h) 
>6 µM 
> 24h 
Decrease viability 
BEA 
0- 100 µM 
(48h) 
>3 µM Inhibit proliferation 
1.5 - 3 µM 
(24 – 72h) 
≥ 1.5 µM 
≥ 24h 
Apoptosis 
Necrosis 
0.009-100 µM 
(24 – 72h) 
>0.9 µM 
≥  24h 
Decrease lysosome 
activity 
Decrease plasma 
membrane integrity 
Concomitant effects on 
mitochondrial area 
Decrease nuclear count 
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2. Objectives of the study 
Mycotoxins are common natural contaminants present in food and feed samples (FAO 2004), 
and they occur throughout the world. More than 50% of the world's cereal grains are 
contaminated with mycotoxins. Despite of many years of research and the introduction of good 
agricultural and manufacturing practices, mycotoxins occurrence remains a global problem. 
Their acute and chronic dietary exposures can induce a variety of adverse health effects in 
humans and animals (Eskola et al. 2019). International enquiry’s on existing mycotoxins 
legislation in foodstuffs and animal feedstuffs have been carried out several times (FAO 2004). 
Nevertheless, so far, only few mycotoxins are regulated worldwide. In European Union, only 
DON, ZEN, ochratoxin A, patulin, FUM, T-2 and HT-2 toxins are regulated (Lerda 2011). In 
addition to those regulated mycotoxins, other fungal secondary metabolites have been 
discovered which are neither routinely determined, nor legislatively regulated and have been 
defined as emerging mycotoxins (Vaclavikova et al. 2013). They are usually co-produced with 
other well-known toxins (Eskola et al. 2019; Hussein and Brasel 2001).  
The toxicity of mycotoxins when present together, cannot always be predicted based upon their 
individual toxicities. Multi-exposure may lead to additive, synergistic or antagonistic toxic 
effects (Alassane-Kpembi et al. 2015). Therefore, analysis of the combined toxicity of 
mycotoxins is highly important. However, at the present very little is known about the health 
risk from combined exposure to mycotoxins.  
In this study, we aimed to provide additional information about the occurrence of emerging 
mycotoxins and their combined effects when present in mixture with DON. DON is one of the 
most widely distributed type B trichothecene contaminants found in food and animal feed 
(Sprando et al. 2005), whereas emerging mycotoxins have been identified but less investigated 
so far (Vaclavikova et al. 2013). In order to do so, pig finished feed samples were collected 
worldwide market. Then combined toxicity of DON and the 10 most prevalent emerging 
mycotoxins was assessed on porcine intestinal cell line (IPEC-1), using their concentration 
observed in the feed. 
The second objective of this thesis is driven by the fact that the intestine is not the only target 
for food contaminants. Indeed, liver which is the main site of metabolism and detoxification of 
xenobiotics is also a target organ for mycotoxins (Zain 2011). Therefore, we developed a tool, 
called precision cut liver slices (PCLS), in order to assess the toxicity of mycotoxins on this ex 
vivo model and the tests performed during this thesis were focused on DON.  
59 
2.1. Contribution of this doctoral thesis 
Among food/feed contaminants, mycotoxins have been regularly classified in the top ten and 
top one causes of alert notification for RASFF in EU members and non-members countries 
respectively (RASFF 2018). So far, numerous studies have been carried out on the toxicity of 
well-known mycotoxins such as DON, ZEN, FUM, AFs whereas, emerging mycotoxins are 
still poorly investigated. 
So far, most of the studies on the occurrence of mycotoxins are performed in cereal grains and 
raw materials. However, presence and concentration of mycotoxins in compound feed is not 
always similar as in raw materials (Streit et al. 2012). It is important to investigate mycotoxins 
in compound and finished feed. Furthermore, most of the studies and surveys on the occurrence 
of mycotoxins are limited to one region or one country (Streit et al. 2013; Abdallah et al. 2017). 
Occurrence of mycotoxins and contamination levels across the globe is different and it is 
important to have a global view on the worldwide occurrence of mycotoxins in feed samples. 
The aim of this study is to investigate the occurrence of emerging and regulated mycotoxins in 
finished pig feed worldwide. 
Among farm animals, pig is one of the most sensitive species to the deleterious effects of 
mycotoxins. It can be exposed to high concentration of mycotoxins due to its rich cereal diets 
(Pinton et al. 2010). Following ingestion of contaminated feed, the gastrointestinal tract is the 
first physiological barrier against food contaminants, as well as the first target for these 
toxicants (Pinton and Oswald 2014). 
The toxicity of known mycotoxins are quite well investigated, the knowledge on the potential 
toxicity of emerging mycotoxins is still scarce. Therefore, this study aimed at investigating and 
characterizing the potential toxicity of the 10 most prevalent and DON co-occurring emerging 
mycotoxins using a model of porcine intestinal epithelial cells. The risk for human and animal 
health related to the presence of combinations of mycotoxins should not be neglected. In this 
context, most of the published studies on mixtures have focused on iso-toxicity or combination 
of identical ratios (1:1), regardless of their ratios in food or feed (Ficheux et al. 2012; Prosperini 
et al. 2014b; Fernández-Blanco et al. 2016) . To the best of our knowledge, there is no study 
investigating the combined toxicity based on the ratios concerning the occurrence in the food 
or feed. Herein, this study will investigate combined toxicity of emerging mycotoxins and DON 
based on the actual ratios determined in pig finished feed worldwide. 
60 
Some of the mycotoxins such as DON can cross the intestinal barrier, reach into the blood 
circulation and finally reach to the liver. Of the total hepatic blood flow (100–130 ml/min per 
100 g of liver, 30 ml/min/kg/b.w), only one fifth to one third is supplied by the hepatic artery. 
The rest of blood (about two thirds) is supplied by portal vein. This blood contains oxygen and 
many nutrients brought to the liver from the intestines for processing (Lautt 2010). Therefore, 
not only the intestine can be a target of mycotoxins, the liver can be also a target organ to 
mycotoxins. Most of the published studies on the effect of DON on liver are performed either 
in vivo or in vitro (Nielsen et al. 2009; Sahu et al. 2010; Wu et al. 2014a; Gerez et al. 2015). 
Although, both models are used in experimentation, but none of them are considered an ideal 
model. Since in vitro assays do not allow assessing more than one cell at a time and in vivo 
assays require large number of animals and is quite costly. In the context of reducing the number 
of experimental animals, ex vivo models represent a powerful tool as many samples can be 
obtained from one animal (Kolf-Clauw et al. 2013). In the ex vivo models, the cytoarchitecture 
should be retained as well as many of the intercellular connections and interplays. 
In order to investigate the toxicity of mycotoxins in liver, the precision cut liver slices (PCLS), 
ex vivo explants with well-defined thickness represent a promising model (Graaf et al. 2010). 
They contain all cell types of the tissue in their natural environment and natural architecture, 
with intercellular and cell-matrix intact interactions (Zimmermann et al. 2009). To the best of 
our knowledge, PCLS have never been used to investigate the toxicity of mycotoxins (Graaf et 
al. 2010). This study will aim developing this new tool in order to assess the toxicity of 
mycotoxins using an ex vivo model of liver explants. 
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Abstract: Food and feed can be naturally contaminated by several mycotoxins, and concern about
the hazard of exposure to mycotoxin mixtures is increasing. In this study, more than 800 metabolites
were analyzed in 524 finished pig feed samples collected worldwide. Eighty-eight percent of the
samples were co-contaminated with deoxynivalenol (DON) and other regulated/emerging mycotoxins.
The Top 60 emerging/regulated mycotoxins co-occurring with DON in pig feed shows that 48%, 13%,
8% and 12% are produced by Fusarium, Aspergillus, Penicillium and Alternaria species, respectively.
Then, the individual and combined toxicity of DON and the 10 most prevalent emerging mycotoxins
(brevianamide F, cyclo-(L-Pro-L-Tyr), tryptophol, enniatins A1, B, B1, emodin, aurofusarin, beauvericin
and apicidin) was measured at three ratios corresponding to pig feed contamination. Toxicity was
assessed by measuring the viability of intestinal porcine epithelial cells, IPEC-1, at 48-h. BRV-F, Cyclo
and TRPT did not alter cell viability. The other metabolites were ranked in the following order
of toxicity: apicidin > enniatin A1 > DON > beauvericin > enniatin B > enniatin B1 > emodin >
aurofusarin. In most of the mixtures, combined toxicity was similar to the toxicity of DON alone.
In terms of pig health, these results demonstrate that the co-occurrence of emerging mycotoxins that
we tested with DON does not exacerbate toxicity.
Keywords: global survey; finished pig feed; co-occurrence; emerging mycotoxins; DON; toxicity;
combined toxicity; IPEC-1
Key Contribution: A worldwide survey of finished pig feed demonstrates the co-occurrence of
DON and emerging mycotoxins. Assessment of their combined toxicity with DON at realistic ratios
revealed that their toxicity was similar to that of DON alone.
1. Introduction
Mycotoxins are low molecular weight fungal secondary metabolites that trigger a detrimental
response when ingested by humans and animals. They are mainly produced by filamentous fungi
belonging to Aspergillus, Fusarium and Penicillium species [1]. Mycotoxin contamination can occur
all along the food chain from field to storage, including the food process. This depends upon the
requirements of fungi, and Fusarium mostly occurs in the field, whereas Aspergillus and Penicillium
mostly occurs during storage.
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Because of their toxicity and occurrence, deoxynivalenol (DON), zearalenone, aflatoxins, ochratoxin
A, patulin, fumonisins and T-2/HT-2 toxins are regulated in Europe. For example, the maximum
recommendations limits that are set up for complete piglet feed are 0.9, 0.1, 0.05, 5 and 0.25 mg/kg
feed for DON, zearalenone, ochratoxin, fumonisins and T2 + HT2, respectively [2,3]. However, in
addition to regulated mycotoxins, many other fungal secondary metabolites are being identified in
food and feed [4,5]. Metabolites that are neither routinely determined, nor legislatively regulated,
have been defined as ‘emerging mycotoxins’ [6], while the derivatives of regulated mycotoxins that are
undetectable using conventional analytical techniques due to their modified structure, are defined as
‘modified/masked mycotoxins’ [4,7]. Recent findings showed that more than 70% of the world’s cereal
grains are contaminated by mycotoxins [8,9], often in a mixture [10].
Among regulated mycotoxins, DON very frequently contaminates cereals (wheat, barley, oats, rye
and maize, and less frequently rice, sorghum and triticale) and cereal-based food and feed. DON belongs
to the group of B-trichothecenes, and is one of the most widely distributed contaminants in human food
and animal feed. In a total of more than 25,000 samples collected from 28 European countries between
2007 and 2014, DON was found in 47% of 4000 feed samples and 45% of 1621 unprocessed grains
with no defined end use, respectively [11]. Even though DON is considered as a non-carcinogenic
compound [12], the maximum level of this toxin in food and feed have been set up in different countries.
For example, in complete piglet feed, the maximum limits are 0.9, 1 and 5 mg/kg feed in Europe,
Canada and the USA, respectively [2,13]. Exposure to high concentrations of DON is associated with
diarrhea, vomiting (emesis), leukocytosis and gastrointestinal bleeding. Chronic exposure affects
growth, immunity and intestinal barrier function in animals [14–16]. This toxin interacts with the
peptidyl transferase region of the 60S ribosomal subunit, inducing ‘ribotoxic stress’, resulting in the
activation of mitogen-activated protein kinases (MAPKs) and their downstream pathways [14,17].
Among emerging mycotoxins, those that occur most frequently are enniatins (ENNs), beauvericin
(BEA), apicidin (API), aurofusarin (AFN), culmorin, butenolide, fusaric acid, moniliformin,
fusaproliferin and emodin (EMO). They are produced by Fusarium species except EMO, which
is produced by Aspergillus species [6,18]. ENNs and BEA were detected in food (63% and 80%), feed
(32% and 79%), and unprocessed grains (24% and 46%) collected between 2010 and 2014 in 12 European
countries [19]. AFN, API, brevianamide-F (BRV-F), EMO and tryptophol (TRPT) were also found in
pig feed (80%, 52%, 65%, 63% and 75%) [20], Egyptian animal feed (73%, 17%, 86%, 98% and 90%) [21]
and feed raw materials (84%, 55%, 5%, 74%, 59%) [22].
Multiple mycotoxins are frequently present in food and feed [10]. The co-occurrence of DON,
aflatoxins, fumonisins, zearalenone and other fungal secondary metabolites in maize seeds and
grains, as well as in animal feed, has been reported [21–23]. The presence of different fungi on the
same raw material, the ability of fungal species to produce several toxins, as well as the various
commodities present in completed feed, can explain this multiple contamination [24,25]. Compound
feed is particularly prone to multiple contaminations, as it typically contains a mixture of several
raw materials.
The co-occurrence of mycotoxins is challenging for at least two reasons: (i) The toxicity of
mycotoxins when present together cannot always be predicted based upon their individual toxicity and
(ii) the risk assessment is performed on a chemical-by-chemical basis [24,25]. Scientific interest in the
toxicity of these mixtures of mycotoxins is currently increasing rapidly [26–29]. Several studies have
investigated the combined toxicity of regulated mycotoxins on the intestine [30–33], but the combined
effect of regulated and other mycotoxins is poorly documented [34,35].
Among farm animals, pig is one of the most sensitive species to mycotoxins [36]. As feed raw
materials are potentially contaminated by several fungi at a time, and completed feed is made from
various commodities, pig can be exposed, through its rich cereal diet, to high concentrations of mixtures
of mycotoxins [10,37]. The sanitary and economic losses due to mycotoxin contamination are important
in the pig industry, even if they are hard to estimate precisely [38].
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The aims of this study were thus to (i) determine the prevalence and concentration of mycotoxins
present in finished pig feed and (ii) assess the intestinal combined toxicity of DON in mixture with the
10 most prevalent emerging mycotoxins present in pig feed using realistic ratios.
2. Results
2.1. Occcurrence and Abundance of Emerging Mycotoxins and DON in Finished Pig Feed
A total of 524 finished pig feed samples collected worldwide were analyzed, and more than
235 different metabolites were detected, including regulated mycotoxins, emerging mycotoxins and
modified/masked mycotoxins. Table 1 lists the 60 most prevalent fungal metabolites that contaminated
more than 20% of the finished pig feed samples. Among regulated mycotoxins, DON was detected
in 463 samples (88%), mostly in the Northern Hemisphere and in relatively similar concentrations in
samples from all countries (median concentration 206 µg/kg) (Figure 1A,B).
Figure 1. (A) Worldwide contamination of deoxynivalenol (DON). Concentration of DON is highlighted
by colors, where yellow indicates > 100 µg/kg, green > 200 µg/kg, dark green > 300 and dark blue
indicates > 400 µg/kg. (B) Abundance of DON in pig finished feed (P25, median, mean, P75). X axis
represents the distribution of the concentration, Y axis describes the number of contaminated samples.
All DON-contaminated samples were co-contaminated by other mycotoxins. The distribution
of the samples was checked. Table 1 gives the descriptive statistics for DON and the most abundant
metabolites that co-occur with DON.
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Table 1. Top 60 emerging and regulated mycotoxins co-occurring with DON in finished pig feed.
Metabolites
Occurrence
n (%)
Co-occurrence
with DON n
(%)
Contamination Level (µg/kg
Feed)
Correlation (DON
and Other
Mycotoxins)
P25 P50 P75 Coefficient p-Value
1 Deoxynivalenol 463 (88%) 463 (100%) 111 206 389 1.00 NA
2 Culmorin 492 (94%) 458 (99%) 38 107 247 0.50 0.00
3 Zearalenone 502 (96%) 449 (97%) 9 18 46 0.64 0.00
4 Brevianamide F 500 (95%) 446 (96%) 17 28 45 0.17 0.00
5 Cyclo-(L-Pro-L-Tyr) 494 (94%) 434 (94%) 117 196 371 0.14 0.00
6 Enniatin B 479 (91%) 430 (93%) 9 32 83 0.02 0.61
7 Enniatin B1 481 (92%) 430 (93%) 10 37 87 0.04 0.39
8 Asperglaucide 470 (90%) 419 (90%) 18 38 94 -0.11 0.02
9 Emodin 472 (90%) 418 (90%) 3 5 10 -0.01 0.91
10 Aurofusarin 464 (89%) 417 (90%) 87 211 548 0.59 0.00
11 Moniliformin 469 (90%) 416 (90%) 7 17 45 0.11 0.03
12 Beauvericin 464 (89%) 411 (89%) 4 7 13 0.32 0.00
13 Enniatin A1 459 (88%) 411 (89%) 5 16 33 0.09 0.08
14 3-Nitropropion acid 455 (87%) 407 (88%) 3 6 10 -0.03 0.57
15 Tryptophol 454 (87%) 407 (88%) 119 197 319 0.10 0.04
16 15-Hydroxyculmorin 429 (82%) 391 (84%) 76 142 277 0.79 0.00
17 Equisetin 424 (81%) 386 (83%) 5 10 23 0.01 0.80
18 Infectopyron 409 (78%) 366 (79%) 108 263 449 -0.16 0.00
19 DON-3 Glucoside 380 (73%) 362 (78%) 10 21 47 0.79 0.00
20 Neoechinulin A 407 (78%) 357 (77%) 10 19 42 0.06 0.22
21 Tenuazonic-acid 384 (73%) 347 (75%) 53 90 182 0.04 0.49
22 Alternariol 366 (70%) 333 (72%) 2 4 9 0.01 0.79
23 Rugulusovin 373 (71%) 332 (72%) 4 7 14 0.15 0.01
24 Tentoxin 342 (65%) 319 (69%) 2 3 6 -0.03 0.56
25 Apicidin 341 (65%) 310 (67%) 3 7 11 -0.13 0.02
26 Fumonisin B1 332 (63%) 304 (66%) 26 70 254 0.14 0.02
27 Nivalenol 315 (60%) 296 (64%) 10 24 57 0.14 0.02
28 Cyclo-(L-Pro-L-Val) 337 (64%) 286 (62%) 85 137 246 0.15 0.01
29 Epiequisetin 307 (59%) 285 (62%) 2 4 7 0.05 0.42
30 Citreorosein 317 (60%) 283 (61%) 3 5 8 0.12 0.05
31 Enniatin A 306 (58%) 282 (61%) 2 3 5 -0.01 0.81
32 Alternariolmethylether 307 (59%) 275 (59%) 2 3 5 0.09 0.14
33 Altersetin 301 (57%) 275 (59%) 13 29 76 0.18 0.00
34 Asperphenamate 311 (59%) 269 (58%) 5 11 27 -0.02 0.75
35 Lotaustralin 288 (55%) 257 (56%) 15 30 85 -0.10 0.13
36 Butenolid 253 (48%) 242 (52%) 22 37 70 0.32 0.00
37 Kojic acid 262 (50%) 241 (52%) 43 74 148 -0.06 0.39
38 Enniatin B2 258 (49%) 238 (51%) 2 3 5 -0.01 0.84
39 Fumonisin B2 258 (49%) 237 (51%) 19 50 143 0.16 0.01
40 Zearalenone Sulfate 236 (45%) 222 (48%) 10 25 53 0.25 0.00
41 Antibiotic Y 233 (44%) 215 (46%) 40 111 402 -0.02 0.75
42 T2 Toxin 235 (45%) 209 (45%) 2 4 9 0.12 0.07
43 Macrosporin 219 (42%) 202 (44%) 2 3 8 0.02 0.76
44 N-Benzoyl-Phenylalanine 220 (42%) 191 (41%) 3 5 11 -0.02 0.82
45 Flavoglaucin 206 (39%) 175 (38%) 7 16 34 0.05 0.51
46 Curvularin 196 (37%) 171 (37%) 2 4 8 -0.09 0.27
47 Questiomycin A 178 (34%) 162 (35%) 4 10 20 0.22 0.01
48 Rubellin D 179 (34%) 161 (35%) 4 8 18 0.10 0.21
50 Bikaverin 171 (33%) 153 (33%) 10 25 56 0.27 0.00
50 Fusarinolic-acid 157 (30%) 153 (33%) 47 130 320 0.3 0.00
51 Fumonisin B4 165 (31%) 149 (32%) 11 23 68 0.2 0.03
52 Cytochalasin J 170 (32%) 146 (32%) 13 29 63 0.1 0.46
53 Ergometrine 152 (29%) 145 (31%) 6 11 24 0.0 0.57
54 Ergocristine 151 (29%) 143 (31%) 2 5 13 0.2 0.02
55 Fumonisin B3 154 (29%) 136 (29%) 24 48 103 0.1 0.15
56 HT2-toxin 149 (28%) 134 (29%) 13 20 30 0.2 0.01
57 Monocerin 144 (27%) 133 (29%) 1 2 3 0.2 0.02
58 Chrysogin 136 (26%) 126 (27%) 7 12 17 0.4 0.00
59 Ergosin 128 (24%) 123 (27%) 3 6 13 -0.1 0.39
60 5-Hydroxyculmorin 121 (23%) 117 (25%) 107 170 304 0.7 0.00
The 60 mycotoxins found in more than 20% of the 524 samples of finished pig feed. Their concentrations in the three
quartiles (P25, P50 and P75) are expressed in µg/kg of feed. The correlation of their concentration with DON and the
associated P-value was calculated using Spearman’s rank correlation coefficient.
From this list, the most prevalent emerging mycotoxins co-occurring with DON and which were
commercially available were selected for the toxicological studies. Because of its high toxicity [39],
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apicidin (API) was included in the list. The worldwide distributions of these compounds are presented
in Supplementary Figure S1. Except for API, which was detected in only 67% of DON-contaminated
samples, the selected emerging mycotoxins were present in more than 87% of them (Table 1).
Three compounds API, emodin (EMO) and beauvericin (BEA) were detected in a median concentration
range of 5 to 10 µg/kg feed. The median concentration of four metabolites, enniatins A1, B, B1 (ENN-A1,
B, B1) and brevianamide F (BRV-F), was in the range of 15-40 µg/kg feed, and the last three compounds
aurofusarin (AFN), cyclo-(L-Pro-L-Tyr) (Cyclo) and tryptophol (TRPT) had median concentrations
close to 200 µg/kg feed, like DON (Supplementary Figure S2). Despite their high co-occurrence with
DON, with the exception of AFN, and to a lesser extent BEA, the concentration of these mycotoxins
showed limited correlation with DON concentration (Table 1 and Supplementary Figure S3).
2.2. Intestinal Toxicity of Emerging Mycotoxins Found in Pig Feed, alone or Combined with DON
2.2.1. Individual Toxicity of DON and Emerging Mycotoxins
The individual intestinal toxicity of 10 selected emerging mycotoxins, as well as that of DON,
was first analyzed at a wide range of concentrations (Supplementary Figure S4). As shown in
Supplementary Figure S4, all tested metabolites exhibited dose-dependent toxicity toward intestinal
epithelial cells, except BRV-F, Cyclo and TRPT, that were not toxic for this porcine cell line. AFN, EMO
and ENN-B1 reduced the viability of IPEC-1, but their toxicity was less than that of DON. The toxicity
of BEA and ENN-B was close to that of DON, whereas API and ENN-A1 were more toxic than DON.
As shown in Figure 2, low doses of API (0.01–0.3 µM) significantly stimulated the proliferation of
IPEC-1. When the doses leading to a 50% reduction in the cell viability (IC50) of these emerging
mycotoxins were compared with the dose of DON, then BRV-F, Cyclo and TRPT were classified as
non-toxic metabolites, while EMO, AFN and ENN-B1 were given as moderately toxic metabolites, and
finally API, ENN-A1, ENN-B and BEA as highly toxic metabolites (Table 2).
Figure 2. Dose effect curve of individual toxicity of apicidin (API). Data are mean ± SEM of three
biological replicates. Bonferroni multiple comparison test. Significant difference between control and
different doses of API *** p < 0.001.
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Table 2. IC50 values of the selected emerging mycotoxins on IPEC-1 cells.
Metabolites Abbreviation IC50 (µM) Toxicity
Brevianamide F BRV-F Non-Toxic
Non-toxicCyclo-(L-Pro-L-Tyr) Cyclo Non-Toxic
Tryptophol TRPT Non-Toxic
Aurofusarin AFN 19.1 ± 3.4
Moderately toxicEmodin EMO 19.0 ± 0.7
Enniatin B1 ENN-B1 13.5 ± 2.5
Enniatin B ENN-B 4.4 ± 0.9
Highly toxic
Beauvericin BEA 4.3 ± 1.8
Deoxynivalenol DON 3.2 ± 0.7
Enniatin A1 ENN-A1 1.6 ± 0.3
Apicidin API 1.5 ± 0.5
Data are the mean ± the standard error of the mean (SEM) of three biological replicates.
2.2.2. Combined Toxicity of DON and Emerging Mycotoxins
Next, the combined toxicity of DON and the selected emerging mycotoxins was assessed.
As mentioned above, the concentration of these secondary metabolites was not correlated with the
concentration of DON (Table 1 and Supplementary Figure S3). Thus, to account for the different
situations to which pigs can be exposed, three ratios were tested (Supplementary Table S1). Ratio 1
was calculated using the P25 (1st quartile) concentration of the emerging mycotoxin and P75 (3rd
quartile) concentration of DON. Ratio 2 was calculated using the median (2nd quartile) concentration
of DON and each emerging mycotoxin. Ratio 3 was calculated using the P75 concentration of the
emerging mycotoxin and P25 concentration of DON. For each ratio, serial dilutions were tested to
obtain a dose-effect curve that encompassed the realistic concentrations of the mixture of DON and the
tested metabolites.
2.2.3. Combined Toxicity of DON and the Non-Toxic Secondary Metabolites (BRV-F, Cyclo and TRPT)
First, the combined toxicity of DON and the ‘non-toxic’ secondary metabolites BRV-B, Cyclo and
TRPT were analyzed. As shown in Figure 3, whatever the ratios tested, the toxicity of the combination
of DON and the compound being tested was similar to the toxicity of DON alone.
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Figure 3. Dose-effect curves of deoxynivalenol (DON) (blue lines and symbols), emerging mycotoxins
(brevianamide-F (BRV-F), cyclo-(L-Pro-L-Tyr) (Cyclo) and tryptophol (TRPT)) alone (red lines and
symbols), or in combination with DON (black lines and symbols) at different ratios: ratio 1 was
calculated from the P25 concentration of emerging mycotoxin and P75 concentration of DON; ratio 2
was calculated from the median concentration of emerging mycotoxin and DON; ratio 3 was calculated
from the P75 concentration of emerging mycotoxin and the P25 concentration of DON. Six serial
dilutions of each ratio were tested (Emerging mycotoxin alone, DON alone, mixture). Data are mean ±
SEM of three biological replicates. Bonferroni multiple comparison test. Significant difference between
emerging mycotoxins alone and the mixtures *** p < 0.001. Significant difference between DON alone
and the mixtures # # # p < 0.001.
2.2.4. Combined Toxicity of DON and the Moderately Toxic Secondary Metabolites (AFN, EMO and
ENN-B1)
Next, the combined toxicity of DON and the moderately toxic metabolites AFN, EMO and ENN-B1
was assessed (Figure 4). The toxicity of AFN, EMO and ENN-B1 was minimal when used at ratio 1.
In these conditions, the toxicity of the combination of DON and emerging toxins was similar to the
toxicity of DON alone. Ratio 2 reached toxic concentrations of AFN and ENN-B1, but the toxicity of the
mixture was similar to the toxicity of DON alone, except at the highest concentration of ENN-B1 (4.1
µM), where the toxicity of the mixture (ENN-B1 4.1 µM + DON 50 µM) was higher than the toxicity of
ENN-B1 alone, but lower than the toxicity of DON alone.
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Figure 4. Dose-effect curves of DON (blue lines and symbols), emerging mycotoxins (AFN, EMO and
ENN-B1) alone (red lines and symbols) or in combination with DON (black lines and symbols) at
different ratios: ratio 1 was calculated from the P25 concentration of emerging mycotoxin and P75
concentration of DON; ratio 2 was calculated from the median concentration of emerging mycotoxin and
DON; ratio 3 was calculated from the P75 concentration of emerging mycotoxin and P25 concentration
of DON. Six serial dilutions of each ratio were tested (Emerging mycotoxin alone, DON alone, mixture).
Data are mean ± SEM of three biological replicates. Bonferroni multiple comparison test. Significant
difference between emerging mycotoxins alone and the mixtures *** p < 0.001. Significant difference
between DON alone and the mixtures # # # p < 0.001.
When cytotoxicity was tested at ratio 3, the toxicity of AFN + DON was identical to the one of
DON alone except at the concentrations DON 0.6 µM + AFN 1.6 µM and DON 1.9 µM + AFN 4.7 µM,
when the toxicity of the mixture was slightly lower than the toxicity of DON alone. At this ratio, EMO
alone was still not toxic, and even induced proliferation (up to 130% of treated cells).
The combined toxicity of DON and EMO was similar to the toxicity of DON alone except at the
highest concentration of EMO, when the mixture of DON (50 µM) and EMO (5 µM) was still less toxic
than DON alone. The combined toxicity of ENN-B1 + DON was the same as the toxicity of DON alone,
except at the highest concentrations of ENN-B1 (6 and 18 µM), when the toxicity of the mixture was
the same as the toxicity of ENN-B1 alone, but lower than the toxicity of DON alone.
In conclusion, our data showed that the toxicity of the combination of DON and emerging
mycotoxins such as AFN, EMO and ENN-B1 was similar to or lower than the toxicity of DON alone,
whatever the ratio used.
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2.2.5. Combined Toxicity of DON and The Highly Toxic Secondary Metabolites (ENN-B, BEA,
ENN-A1and API)
The combined toxicity of DON and highly toxic compounds (ENN-B, BEA, ENN-A1 and API)
was also analyzed at different ratios (Figure 5). At the first tested ratio (ratio 1), ENN-B, BEA, ENN-A1
and API were not toxic, and their combined toxicity in the presence of DON was similar to the toxicity
of DON alone. Ratio 2 reached toxic concentrations of ENN-B, ENN-A1 and API.
Figure 5. Dose-effect curves of DON (blue lines and symbols), emerging mycotoxins (ENN-B, BEA,
ENN-A1 and API) alone (red lines and symbols) or in combination with DON (black lines and symbols)
at different ratios: ratio 1 was calculated from the P25 concentration of the emerging mycotoxin and
the P75 concentration of DON; ratio 2 was calculated from the median concentration of emerging
mycotoxin and DON; ratio 3 was calculated from the P75 concentration of emerging mycotoxin and
the P25 concentration of DON. Six serial dilutions of each ratio were tested (Emerging mycotoxin
alone, DON alone, mixture). Data are mean ± SEM of three biological replicates. Bonferroni multiple
comparison test. Significant difference between emerging mycotoxins alone and the mixtures *** p <
0.001. Significant difference between DON alone and the mixtures # # # p < 0.001.
For ENN-B and ENN-A1, the toxicity of the mixture was similar to the toxicity of DON alone,
except at the highest concentrations of ENN-B (3.6 µM) and ENN-A1 (1.7 µM). The combined toxicity
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of DON (50 µM) + ENN-B (3.6 µM) was similar to the toxicity of ENN-B alone, but lower than the
toxicity of DON alone, whereas the combined toxicity of DON (50 µM) + ENN-A1 (1.7 µM) was higher
than the toxicity of ENN-A1 alone, but still lower than the toxicity of DON alone. The combined
toxicity of API and DON was similar to the toxicity of DON only for the higher doses. For the doses
lower than DON (5.6 µM) + API (0.09 µM) the combined toxicity was lower than the toxicity of DON
alone, but higher than API alone.
At ratio 3, the combined toxicity of DON and ENN-B displayed a different characteristic. At a
high concentration, the combined toxicity of DON (50 µM) + ENN-B (17.2 µM) was lower than the
toxicity of either DON alone or ENN-B alone. At this ratio, the toxicity of the mixture of DON and
BEA was similar to the toxicity of DON alone, except at the highest concentration of BEA (2.3 µM)
when mixed with DON (50 µM), where the toxicity was higher than that of BEA alone, but lower
than that of DON alone. The combined toxicity of DON (16.7µM) + ENN-A1 (2.2 µM) at ratio 3 was
similar to the toxicity of ENN-A1 alone, but lower than the toxicity of DON alone; the toxicity of DON
(50 µM) + ENN-A1 (6.5 µM) was higher than the toxicity of ENN-A1 alone, but lower than the toxicity
of DON alone. Finally, the combined toxicity of DON and API, at concentrations lower than DON
(5.6 µM) + API (0.3 µM), was always similar to API alone, but lower than DON alone, whereas at
higher concentrations, it was similar to the one of DON alone and higher than the one of API alone.
As mentioned above, a proliferation of IPEC-1 cells was observed at low concentrations of API.
In conclusion, our data showed that the toxicity of the combination of DON and highly toxic
emerging mycotoxins such as ENN-B, BEA, ENN-A1 and API, whatever the ratio used, was similar to
or lower than the toxicity of DON alone.
3. Discussion
Progress in analytical methods enabled the discovery of numerous fungal secondary metabolites
that are the subject of increasing attention today due to their prevalence in human food and animal
feed [19,20]. In the present study, 524 samples of finished pig feed were analyzed. In addition to
regulated mycotoxins such as DON, zearalenone and fumonisin B1, less known secondary metabolites
were detected.
As already described in other surveys [20–22], BRV-F, Cyclo, TRPT, ENNs, EMO, BEA and AFN,
culmorin, and moniliformin were highly prevalent emerging mycotoxins detected in more than 85% of
pig feed samples. The diversity of the metabolites detected is very likely related to the wide range of
fungal species that contaminate the raw materials used to make pig feed. Indeed, Fusarium species
produce ENNs (A1, B and B1), BEA, AFN, API, culmorin and moniliformin, while Penicillium species
produce BRV-F and Cyclo, Aspergillus EMO and Acremonium TRPT [22,40].
The toxicity of these new poorly documented metabolites was also investigated in the present
study. The results of our analyses showed that, even at high concentrations of up to 300 µM, BRV,
Cyclo and TRPT are not toxic to intestinal cells. Similar results were recently obtained using another
porcine intestinal cell line, IPEC-J2, and a different readout, cellular protein content [20]. Interestingly,
at a much higher concentration (2 mM), TRPT induced DNA damage in HepG2, A549 and THP-1
cells [41]. AFN and EMO were identified as moderately toxic compounds at relative IC50 values of 19.1
µM and 19 µM, respectively. These emerging mycotoxins were found to be more toxic for IPEC-J2 with
relative IC50 of 9.3 µM and 13.1 µM, respectively [20]. On the other hand, human multiple myeloma
blood cells were less sensitive to EMO (IC50 38 µM) [42]. According to their IC50, ENNs were ranked
in the following order of toxic potency ENN-A1 > ENN-B > ENN-B1. Similar ranking was reported
for HT-29 [43] and IPEC-J2 [44]. ENN-A1 is also more toxic than ENN-B1 for Caco-2 and HepG2,
but ENN-B displayed no toxicity at all [43]. The mechanism of toxicity of ENNs is related to their
ionophoric properties [19] that facilitate the transport of mono- or divalent cations such as K+ or Ca2+
across membranes, but the relative sensitivity of the different cell lines to the different ENNs is still
not understood. The high toxicity of BEA has already been reported in other cell lines of human
and porcine origin, including Caco-2, HT-29 and IPEC-J2 [20,43]. BEA also has ionophoric properties
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and increase ions permeability (Na+ K+ and Ca2+) in biological membrane, this mechanism of action
participates to the toxicity of this mycotoxin [6,19,44].
Data on the toxicity of API are very limited. We confirmed the toxicity of this metabolite when used
at high concentration (> 0.5 µM) [20,39]; we also observed that low concentrations of API (<0.1 µM)
stimulate the proliferation of porcine intestinal cells. The proliferative effect of low doses of some
mycotoxins has already been described. For example, up to 200% proliferation has been observed
in lymphocytes and splenocytes exposed to low doses (> 0.1µM) of DON, nivalenol, aflatoxin B1 or
fumonisin B1 [45]. Because of its high prevalence and its low IC50, it would be of great interest to
deepen our knowledge of API. The toxicity of other very prevalent metabolites, such as culmorin and
moniliformin, could not be evaluated in this study because they were not commercially available in
the quantities required for cellular experiments.
Different studies have described the co-occurrence of mycotoxins in cereals and other raw materials
used for animal feed in several regions of the globe [21,46,47]. In the present study, we investigated the
co-occurrence of mycotoxins in pig feed. We identified 60 metabolites that co-occur with DON in more
than 20% of samples, confirming the prevalence of co-contamination, and as a result, the exposure of
animals to a mixture of mycotoxins. Our results are in accordance with those of previous surveys of
raw materials and finished feed [20,46]. Although the exact composition of the analyzed pig feed is
not known, the main component of the majority of the samples is maize. The extraction efficiencies
are between 85%-95% determined in seven different matrices [48]. However, the focus of our study is
to provide a general picture of the worldwide contamination of pig feed and to test realistic ratios of
fungal compounds in vitro.
Despite the very high frequency of co-contamination by DON and emerging mycotoxins, the
correlation between the concentrations of DON and emerging mycotoxins was very low. The correlation
between DON and emerging mycotoxins is poorly documented. In winter wheat, Blandino and
co-workers [49] addressed the correlation between DON and other mycotoxins produced by Fusarium
graminearum and F. culmorum, and showed that correlations between DON and either culmorin or
moniliformin were significant (0.94 and 0.42, respectively). By contrast, the correlations between
DON and AFN or BEA were not significant (0.2 and -0.14, respectively). Correlations between the
concentration of DON and its modified forms enabled EFSA to calculate ratios between these different
toxins [11].
In the present study, the absence of correlation between the concentrations of the emerging
mycotoxins and DON could be explained by the diversity of fungi that produce the various metabolites
via different biosynthetic pathways. Furthermore, pigs feed is made of different raw materials, which
also explains the lack of correlation between the amounts of the different fungal metabolites involved.
The main objective of the present study was to assess the combined toxicity of DON and emerging
mycotoxins. As no correlation was found, to encompass the situations to which animals may be
exposed, different plausible ratios were tested. These ratios were based on the P25, the median and the
P75 concentrations of DON and emerging mycotoxins observed in pig feed, because these summary
statistics are robust to extreme outlier values. In most cases, we observed that when the non-toxic
metabolites (BRV, Cyclo and TRPT) were present in mixture with DON, whatever the doses or the ratio,
the effect was driven by DON. We observed a similar trend for the combined toxicity of DON with
moderate and highly toxic metabolites ENNs, BEA, API, AFN and EMO. The effect of the mixtures
was mostly similar to the effect of DON alone. The only exception was when very high concentrations
of DON were used, in which cases surprisingly, the toxicity of the mixture was lower than the toxicity
of DON alone.
To the best of our knowledge, this is the first study to investigate the interactions of different
mycotoxins using plausible ratios. Most published studies used toxins of equal toxicity, regardless of
their concentration in food or feed. For example, exposure of Caco-2 or IPEC-1 cells to low doses of
DON, combined with isotoxic concentrations of nivalenol and/or their acetylated derivatives, led to a
synergistic effect [31,32]. Similarly, mixtures of ENNs as well as mixtures of DON, ENNs and alternariol
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managed to induce synergistic cytotoxicity in Caco-2 cells [50,51]. A synergistic inflammatory effect
was also observed in porcine intestinal explants co-exposed to DON and nivalenol [33].
In the future, these original data on the intestinal toxicity of realistic mixtures of DON and
emerging mycotoxins should be completed by toxicity studies on other types of cells to account for all
target organs. In vivo experiments are also needed to confirm the in vitro data. More widely, the effects
of other mixtures of mycotoxins or of mycotoxins with other food contaminants should be investigated
at realistic doses. As the pig is a good model for human toxicity studies of food contaminants [52],
the results would be useful to estimate the effects of similar mixtures of toxins on human health.
Better knowledge of the occurrence and toxicity of the real mixtures present in food is a precondition
for the assessment of health risk [29].
4. Conclusions
This global survey of finished pig feed confirmed that such feed is co-contaminated by DON and
emerging mycotoxins. However, despite the high percentages of co-occurrence, no correlation was
found between the concentration of DON and most of these emerging mycotoxins. Using ratios based
on the concentration of DON and emerging mycotoxins in feed, we observed that the toxicity of most
of the mixtures was similar to the toxicity of DON alone. This demonstrates that, when these emerging
mycotoxins are present together with DON, the toxicity of the mixture is not exacerbated.
5. Materials and Methods
5.1. Extraction and Analysis of Metabolites
A total of 524 finished pig feed samples were collected from 2014 to 2018 on the world market,
but most in Europe (76.5%) and North America (15.8%) and fewer in Asia (3.2%), South Africa (1.5%),
Australia (2 samples) and some of unknown origin (2.5%) (Figure 1 and Supplementary Figure S1),
and more than 800 analytes, including fungal and bacterial secondary metabolites, were sought.
Samples were provided by the BIOMIN Mycotoxin Survey, and the analyses were performed using the
Liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) multi-mycotoxin method
described by Malachova [5].
A QTrap5500 LC-MS/MS System (Applied Biosystems, Foster City, CA, USA) equipped with a
TurboIonSpray electrospray ionization (ESI) source and a 1290 Series ultra high performance liquid
chromatography (UHPLC) System (Agilent Technologies, Waldbronn, Germany) was used for detection
and quantification of the analytes (Supplementary Figures S5 and S6). Chromatographic separation
was performed on a Gemini® C18-column (150 × 4.6 mm i.d., 5 µm particle size) equipped with a
C18 security guard cartridge (4 × 3 mm i.d.) (all from Phenomenex, Torrance, CA, USA) at 25 ◦C.
Elution was carried out in binary gradient mode. Both mobile phases contained 5 mm ammonium
acetate (NH4CH3CO2) and were composed of methanol/water/acetic acid in a ratio of 10:89:1 (v/v/v;
eluent A) or 97:2:1 (v/v/v; eluent B). After an initial time of 2 min at 100% A, the proportion of B was
increased linearly to 50% within 3 min. Further linear increase of B to 100% within 9 min was followed
by a hold-time of 4 min at 100% B and 2.5 min column re-equilibration at 100% A. The flow rate
was 1000 µL/min. ESI-MS/MS was performed in the scheduled multiple reaction monitoring (sMRM)
mode both in positive and negative polarities in two separate chromatographic runs. The sMRM
detection window of each analyte was set to the respective retention time ± 27 s and ± 42 s in positive
and in negative mode, respectively. The target scan time was set to 1 s. Confirmation of positive
analyte identification is obtained by the acquisition of two sMRMs per analyte (with the exception of
moniliformin and 3-nitropropionic acid, that each exhibit only one fragment ion), which yields 4.0
identification points according to commission decision 2002/657/EC (EU, 2002).
A total of 235 mycotoxins and other fungal secondary metabolites were detected and quantified
in the samples of finished pig feed analyzed. The threshold of relevant concentrations was set at > 1.0
µg/kg or the limit of detection, whichever was higher. Samples were collected only by trained staff,
Toxins 2019, 11, 727 13 of 17
or after the instruction of untrained staff according to a protocol. A minimum of 500 g homogenized
sample was sent to the laboratory of the Institute of Bioanalytics and Agro-Metabolomics at the
University of Natural Resources and Life Sciences Vienna (BOKU) in Tulln, Austria. Samples were
milled and extracted with a mixture of acetonitrile, water and acetic acid (79:20:1, per volume) on
a shaker for 90 min. The solution was centrifuged, after which the supernatant was diluted and
injected into an LC-MS/MS system (electrospray ionization and mass spectrometric detection using
a quadrupole mass filter). Quantification was done by comparing an external calibration using a
multi-analyte stock solution. During the period 2014 to 2018, the number of substances measured
using this method increased each year, and more substances were included in the survey. Nevertheless,
the list of compounds investigated in this manuscript were those measured in 2014. All concentration
data were collected in a single file, and sample information such as sampling year and month, country
and region of origin and sample matrix were added for subsetting. Data were imported and analyzed
in R v 3.5.1 mainly using tidy-verse packages (www.tidyverse.org). Spearman correlation coefficients
and associated p-values were calculated with the corr.test function from the psych R package. Data
were plotted (including maps) using ggplot2.
5.2. Toxins
For the cytotoxicity test, toxins were purchased from Sigma (St Quentin Fallavier, France):
deoxynivalenol (DON) (purity > 98%), tryptophol (TRPT) (purity > 97%), apicidin (API) (purity > 98%)
and emodin (EMO) (purity > 90%). Enniatins (ENNs) (A1, B, B1, purity > 99%), cyclo-(L-Pro-L-Tyr)
(Cyclo) (purity > 98%), and brevianamide-F (BRV-F) (purity > 95%) were purchased from BioAustralis
(Smithfield, Australia), beauvericin (BEA) (purity > 95%) and aurofusarin (AFN), (purity > 97%)
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). All mycotoxins were dissolved in
dimethyl sulfoxide (DMSO) (Sigma) to prepare stock solutions stored at −20 ◦C. Working dilutions
were freshly prepared in cell culture medium for each experiment.
To convert the concentration in the pig feed into the concentration to which intestinal cells might
be exposed, we assumed, as already done in previous studies [53], that mycotoxins were ingested
in one meal, diluted in 1 L of gastrointestinal fluid and were entirely bioaccessible. Next, the ratio
of DON to emerging mycotoxins was calculated based on three plausible scenarios according to the
concentration of DON and emerging mycotoxins in the feed (Supplementary Table S1).
Several 3-fold dilutions of each individual toxin and mixtures at different ratios were performed
to account for the concentrations present in feed.
5.3. Cell Culture and Cytotxicity Assay
IPEC-1, derived from the small intestine of a newborn unsuckled piglet were maintained in
complete medium (Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F12 medium (Sigma) plus
1% Penicillin Streptomycin (Eurobio, Courtaboeuf, France), 5% fetal bovine serum (FBS) (Eurobio), 1%
L-glutamine (Eurobio), 5 µg/L epidermal growth factor (EGF) (Becton–Dickinson, Le Pont de Claix,
France), and 1% ITS solution (insulin (5 µg/mL), transferrin (5 µg/mL), selenium (5 ng/mL), (Sigma
Aldrich)) at 39 ◦C under 5% CO2, as previously described [54].
For the cytotoxicity experiments, cells were seeded in 96-white-well flat-bottom cell culture
plates (Costar, Cambridge, MA, USA) at a rate of 104 cells per well in 100 µL culture medium.
After 24 h, the medium was replaced by complete medium without FBS containing the mycotoxins
and incubated for a further 48 h. Toxicity was then assessed using the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, Charbonnières-les-Bains, France) that determine the number of viable cells
based on the quantitation of adenosine triphosphate (ATP). The luminescent signal produced by the
luciferase reaction, reflecting the presence of metabolically active cells, was read using a multiplate
reader (TECAN, Lyon, France). The results were obtained by calculating the percentage of viability
obtained by calculating the ratio of the luminescence in treated samples and the luminescence in
non-treated samples.
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5.4. Statistical Analysis
The reported values on viability are expressed as the means ± the standard error of the mean
(SEM) of at least three biological replicates, with duplicate wells for each dose. The IC50 value, the
dose of each toxin leading to 50% viability, was determined using CompuSyn statistical software
(CompuSyn Version-1 Inc. Paramus, NJ, USA). Significant differences between groups were analyzed
using the Bonferroni multiple comparison test in GraphPad (GraphPad Prism 4 La Jolla, CA, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/12/727/s1,
Figure S1: Worldwide contamination of emerging mycotoxins. Figure S2: Abundance of emerging mycotoxins in
finished pig feed. Figure S3: Scatter plot of the correlation between DON and 10 selected emerging mycotoxins.
Figure S4: Dose-effect curves of the individual toxicity of DON and 9 selected fungal emerging mycotoxins Table
S1: Concentration of the metabolites in 3 quartiles (P25, P50 and P75) and ratios between the concentration of
DON and 10 selected emerging mycotoxins. Figure S5: LC-ESI(+)-MRM chromatograms of one pig feed sample.
Figure S6: Overlay of the extracted ion chromatograms of both quantifier as well as qualifier of the 11 investigated
compounds in one pig feed sample.
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4. Supplementary Data of Article 
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Supplementary Figure S1. Worldwide contamination of BRV-F, Cyclo, TRPT, EMO, ENN-B1, AFN, ENN-A1, 
ENN-B, BEA and API. 
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Supplementary Figure S2. Abundance of emerging mycotoxins in pig feed (P25, median, mean, P75). X axis 
represents the distribution of the concentrations of fungal secondary metabolites (ppb). Y-axis describes the 
number of co-contaminated samples by DON and other emerging mycotoxins. Median concentrations of AFN, 
TRPT and Cyclo were ≈ 200 ppb, median concentrations of ENN-B1, ENN-B, BRV-F and ENN-A1 were 15 -40 
ppb, and median concentrations of API, BEA and EMO were 5-10 ppb 
84 
  
 
 
 
 
85 
  
  
Supplementary Figure S3. Scatter plot showing the correlation between the concentrations of BRV-F, Cyclo, 
TRPT, AFN, EMO, ENN-B1, ENN-B, BEA, DON, ENN-A1 and API in pig feed samples. 
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Supplementary Figure S4. Dose effect curve of individual toxicity of 9 selected emerging mycotoxins 
(BRV-F, Cyclo, TRPT, AFN, EMO, ENN-B1, ENN-B, BEA, ENN-A1) and DON. Data are mean ± SEM of 
three biological replicates. 
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Figure S5a. LC-ESI(+)-MRM chromatogram (overlay of all acquired MRMs) of AT5-4153-009 (only compounds for 
toxicity tests are annotated). 
 
Figure S5b. LC-ESI(-)-MRM chromatogram (overlay of all acquired MRMs) of AT5-4153-009 (only compounds for 
toxicity tests are annotated). 
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Figure S6. Overlay of the Extracted Ion Chromatograms of both quantifier (pink) as well as qualifier (blue; filled) 
of the 11 investigated compounds in sample AT5-4152-9; the horizontal lines denote the target height of the qualifier 
(± 30% tolerance) calculated from the height of the quantifier and the target ion ratio calculated from the standards. 
 
Supplementary Table S1. Concentrations of DON and emerging mycotoxins converted in µM and the 
corresponding different ratios. 
Metabolites 
Concentrations at selected 
quartiles (µM) 
Ratio DON/emerging mycotoxin 
P25 P50 P75 Ratio 1 Ratio 2 Ratio 3 
DON 0.38 0.70 1.31    
BRV-F 0.06 0.10 0.16 21.7 7.1 2.4 
Cyclo 0.45 0.75 1.42 2.9 0.9 0.3 
TRPT 0.74 1.22 1.98 1.8 0.6 0.2 
AFN 0.15 0.37 0.96 8.7 1.9 0.4 
EMO 0.01 0.02 0.04 122.7 36.5 9.9 
ENN-B1 0.02 0.06 0.13 87.4 12.2 2.8 
ENN-B 0.01 0.05 0.13 95.3 13.9 2.9 
BEA 0.005 0.01 0.02 258.3 70.0 21.9 
ENN-A1 0.01 0.02 0.05 184.0 29.4 7.7 
API 0.006 0.01 0.02 236.2 63.4 20.5 
The concentrations corresponding to the quartiles P25, median, P75 of emerging mycotoxins in µg/kg in pig feed 
were converted in µM assuming their dilution in 1 L of gastrointestinal fluid. Ratio 1 was calculated using the P25 
(1st quartile) concentration of emerging mycotoxin and P75 (3rd quartile) concentration of DON. Ratio 2 was 
calculated using the median (2nd quartile) concentration of DON and each emerging mycotoxin. Ratio 3 was 
calculated using the P75 concentration of emerging mycotoxin and P25 concentration of DON. 
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5. Development of an ex vivo model for studying the effects of 
mycotoxins on liver: the Precision Cut Liver Slices 
Liver is an important organ for the uptake, biliary excretion and metabolism of xenobiotics and 
food contaminants. The main target organ for toxicity and carcinogenicity is the liver (Peraica 
et al. 1999). In most of the cases, toxicity of liver go unnoticed due to the absence of good 
predictive models and specific toxicity biomarkers. In vivo methods imply the use of a large 
number of animals. Therefore, more attention has been given to design and validate alternative 
models for toxicity testing that lead to reduction and eventually replacement of animal use. 
Thus, there is interest in developing reliable liver models for early detection of toxic effects of 
toxins (Starokozhko et al. 2015). In order to explore liver toxicity of mycotoxins, we developed 
precision-cut liver slices (PCLS). PCLS are viable ex vivo explants of tissue with well-defined 
thickness. PCLS technique is easily transferable to mouse, mini-pig, monkey or pig liver, and 
human liver. Slices can be remained viable up to 96 h when incubated under carbogen (95% 
O2/5% CO2) and appropriate conditions (Graaf et al. 2010). 
PCLS contain all cell types of the tissue in their natural environment and natural architecture, 
with intercellular and cell-matrix interactions remaining intact (Zimmermann et al. 2009). In 
addition, PCLS has already been proven to be functional and efficient in numerous metabolism 
and toxicity studies (Elferink et al. 2008). They are mainly used to study the metabolism and 
toxicity of xenobiotics, but they are suitable for many other purposes, such as endogenous 
metabolism, biotransformation and its induction and transport of drugs, as well as for 
toxicological studies, and for assessing the efficacy of drugs in diseased tissues. 
The main objective of the development of this model was first to determine whether liver slices 
could be incubated and maintained viable during a reasonably long time of incubation and then, 
to expose pig liver slices to DON and assess its toxic effect through different markers. 
We measured at different time points, the total protein and ATP contents in the liver slices. We 
have also collected the incubation medium in order to measure different liver damage markers. 
Ultimately, we assessed the effect of DON on the expression of selected genes. 
5.1. Materials and Methods 
Liver slices experiments were performed on pig and the first aimed to optimize the conditions 
of cutting and incubation of slices. Three piglets (5 weeks -old) were slaughtered in consecutive 
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days. Liver was sampled and a piece of the right lateral lobe (Figure 4) was perfused with cold 
sodium chloride (NaCl 0.9%) (Sigma St Quentin Fallavier, France) using a 50 mL syringe. 
Perfused liver was placed under the cylinder-shaped coring tool and liver cores were prepared 
using a drill and a tissue coring tool (Ø 10 mm) (Figure 5a). Then, cores were transferred to the 
cylindrical core holder of the Krumdieck slicer (Figure 5b–d). Slices were in thickness of 250-
350 μm and average weight was 50-70 mg (Figure 5e) (Krumdieck et al. 1980). Coring and 
slicing was carried out into “Krebs-Henseleit” buffer supplemented with NaHCO3 (Sigma). 
Krebs was bubbled in advance with carbogen. Good quality slices were round, equally thick at 
all sides and had smooth edges (Figure 5f). Slices were transferred to 12-well plates using a 
spatula to avoid damages (Figure 5g-h) (Graaf et al. 2010). 
 
Figure 4: Four steps (an overview) of PCLS preparation (Olinga and Schuppan 2013). 
In parallel, William medium E (WME) (Sigma) supplemented with 0.5% Gentamycin (10 
mg/ml) and 1% Glutamine (200 mM) (Eurobio, Courtaboeuf, France) was also bubbled in 
carbogen, 1 h in advance. 
Slices were maintained in Krebs buffer under carbogen bubbling for 1 h of regeneration phase, 
to maintain the quality and remove the debris. Surface and edges of the slices were smoother 
after regeneration. Then slices were immersed individually in 12 wells plate containing 2 mL 
WME containing or not DON (Sigma) dissolved in DMSO (1%) (Sigma). Control slice were 
incubated with same concentrations of vehicle in each incubation time. Plates were incubated 
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at 39°C for 2, 4, 6, 8 and 20 h in presence of DON or without DON (control) under orbital 
shaking. In the space between wells, few mL of medium were added and bubbled with carbogen 
in order to maintain high humidity and oxygen concentration. Incubation medium was refreshed 
after 8 h in order to maintain quality of medium. At each incubation time, incubation medium 
was collected to assess liver damage markers such as: alkaline phosphatase (ALP), 
aminotransferases such as aspartate transaminase (AST), and alanine transaminase (ALT), 
lactate dehydrogenase (LDH) and total protein over the incubation. PCLS were also collected 
in microtubes, snap frozen in liquid nitrogen and stored at – 80 °C for assessment of gene 
expression, total protein and ATP contents. 
 
Figure 5: Preparation and incubation of liver slices. Liver cores are prepared using a drill and a tissue coring 
tool and transferred to the cylindrical core holder of the Krumdieck slicer (Graaf et al. 2010). 
5.2. Statistical Analysis 
One-Way Analysis of Variance (ANOVA) non-parametric test was used to find significant 
difference between the mean group across the incubation time or treatment and significant 
differences between the control and treated samples were analyzed via Bonferroni's multiple 
comparison tests, using statistical software GraphPad (La Jolla, CA, USA). 
5.3. Analysis of Liver damage markers in culture medium 
The main goal of this experiment was to assess quality of PCLS through several sensitive liver 
damage markers such as ALP, AST, ALT, LDH and total proteins, in order to know whether 
incubation (time) or treatment (DON 10 µM) influence the quality of PCLS. 
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5.3.1. Methods 
Incubation medium was collected in different time (2, 4, 6, 8 and 20 h). Medium was renewed 
after 8 h of incubation. Samples were analyzed by GenoToul-Anexplo platform (Toulouse, 
France) using a Pentra 400 Clinical Chemistry benchtop analyzer (Horiba, Les Ulis, France). 
The reported values were expressed as means ± SEM of the three biological replicates.  
5.3.2. Results and discussion 
Overall, we observed that the release of enzymes was numerically but not statistically higher in 
the treated samples (DON 10 µM) than the control samples. Release of enzymes was gradually 
increased from 2 h up to 8 h. Medium was renewed at 8 h. Thus, similar result was obtained at 
8 h and 20 h, whereas the release of AST and LDH was lower at 20 h compared to 8 h. Overall, 
no significant difference between the control and treated samples was observed whatever the 
duration of incubation (Table 21). 
Table 21: PCLS damage markers (ALP, AST, ALT, total protein, LDH) level in the incubation medium 
 Controls DON 10 µM 
Markers 2 h 4 h 6 h 8 h 20 h 2 h 4 h 6 h 8 h 20 h 
ALP 
(U/L) 
2.9±0.5 
4.4±1.
8 
4.8±2
.3 
3.9±1
.3 
4.1±2.
5 
4.6±1 
4.7±2.
2 
5.1±1.
8 
4.3±2.
6 
4.5±1.
2 
ALT 
(U/L) 
4.7±0.6 5.0±1 
6.3±1
.5 
6.3±0
.6 
5.3±2.
3 
5.3±0.6 
6.3±0.
6 
6.0±0 
5.3±0.
6 
6.7±0.
6 
AST 
(U/L) 
77±40 
103±2
7 
112±
57 
147±
34 
64±20 98±23.6 
117±1
5 
115±3
8 
152±4
0 
84±38 
LDH 
(U/L) 
43±4.4 73±31 
85±4
3 
97±3
3 
32±5 67±28 87±24 83±44 
117±3
1 
50±17 
Total 
proteins 
(g/L) 
5.2±0.2 
5.2±0.
3 
5.4±0
.4 
5.1±0
.1 
5.3±0.
5 
5.2±0.2 
5.2±0.
2 
5.3±0.
4 
5.0±0.
2 
5.7±0.
3 
Samples were treated to DON 10 µM over 20 h. Treated samples were compared to corresponding 
control at eac incubation time. 
The level of ALP, AST, ALT, total protein, LDH was not significantly impacted by time or 
DON treatment. PCLS could be damaged during preparation or incubation. This potentially 
causes the release in the incubation medium of some enzymes ALP, ALT, AST, LDH as well 
total proteins (Pratt and Kaplan 2000; Limdi 2003). These markers are sensitive indicators of 
hepatocellular injury (Pratt and Kaplan 2000). ALP originates mainly from two sources, liver 
and bone. The physiological role of these enzymes is not entirely clear but their production 
increases in tissues undergoing metabolic stimulation (Limdi 2003). LDH is a cytosolic 
enzyme mainly present in periportal hepatocytes and released when the cells are lysed by 
hepatotoxins. The amount of released enzyme is proportional to the extent of damage caused 
to the cell (Naik et al. 2004). ALT, a cytosolic enzyme is found in its highest concentrations 
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in the liver and is a more specific indicator to liver injury. AST is found, in decreasing order 
of concentration, in liver, cardiac muscle, skeletal muscle, kidneys, brain, pancreas, lungs, 
leukocytes, and erythrocytes (Pratt and Kaplan 2000). 
AST, ALT, ALP, LDH, and total protein are used to evaluate patients with known or suspected 
liver disease (Dufour et al. 2000; Starokozhko et al. 2015). These markers are also used to 
evaluate the liver slices. After 5 days of incubation, the protein content and the hepatic markers 
AST and ALT were modestly decreased (17–22%) relatively to their initial levels at day 0. In 
contrast, the levels of the ALP increased substantially (3-fold) and LDH also increased up to 
25–28% (Behrsing et al. 2003). In another study, human liver slices were incubated and LDH 
release into the medium after 120 h of incubation was assessed in two different incubation 
medium, WME and RegeneMed®. LDH release was about 9–11% after 24 h. Thereafter it 
remained relatively stable (4–6% per day). The elevated LDH release during the first hours of 
incubation can be explained by the damage of the outer cell layers during the slicing and 
handling procedures. No difference was observed between slices incubated in WME and 
RegeneMed® (Starokozhko et al. 2015). When we assessed the LDH release at different 
incubation time (2 h – 20 h), we observed a maximum release at 8 h, whereas after 8 h release 
of LDH remained stable. 
5.4. Analysis of total Proteins and ATP content in PCLS 
The main goal of this experiment was to assess effect of DON on total proteins and ATP 
contents in PCLS during short (2 h) and longer (20 h) exposure period. 
5.4.1. Methods 
Tubes with ceramic beads (Bertin Technologies, St. Quentin en Yvelines, France) containing 
PCLS were taken out from the freezer -80 ⁰C. Then, 1 mL of ice-cold CelLytic™ MT buffer 
(Sigma) was added. All the tubes were transferred into FastPrep-24™ 5G Classic Homogenizer 
(MP Biomedicals). Tissues were immediately homogenized without thawing for 40 seconds 
(speed 6.0 m/s). Homogenates were placed on ice and centrifuged at 10000 g (gravitational 
acceleration) at 4 °C for 10 min to remove cellular debris. In total 0.85-0.9 ml of supernatant 
was transferred into a clean microtube. Proteins contents were measured directly by 
spectrophotometer using Nanodrop ND1000 (Labtech International) directly at 280 nm. The 
concentrations were determined by using a bovine serum albumin (BSA) standard curve (0.1 – 
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1.2 mg/mL), and the proteins content was expressed as mg/mL per slice. Data was obtained as 
mean ± SEM of three biological replicates. 
ATP contents were also assessed in the same lysis extraction buffer from a single slice using 
96-white well flat-bottom cell culture plates (Costar, Cambridge MA, USA). Serial ratios of 
lysed samples and CellTiter-Glo® (CTG) Luminescent (Promega, Charbonnières-les-Bains, 
France) were prepared for the measurement of ATP. Ratio 1 was 1/1 (100 µL CTG + 100 µL 
lysis sample). Ratio 2 was, 1.66/1 (125 µL CTG + 75 µL lysed solution), ratio 3 was 3/1 (150 
µL CTG + 50 µL lysed solution) and ratio 4 was 7/1(175 µL CTG + 25 µL lysed solution) 
respectively. The aim of testing serial dilutions was to verify whether the amount of CTG in the 
mixture was limiting confirm that test work correctly and respect to their dilution factor, the 
final value of diluted or not diluted samples was almost similar. ATP was measured by 
luminescence using spectrophotometer (Tecan Infinite M200 ProTM equipped with the Tecan 
iControl TM software). Blank was subtracted from all the wells. Luminescence of treated slices 
was compared with untreated one. 
5.4.2. Results and discussion 
We first investigated the effect of DON and incubation time on total proteins. As shown in 
Figure 6, incubation time did not affect the total protein content. By contrast, 20 hours of 
exposure to DON 10 µM decreased by 50% the total proteins content, whereas 2 hours exposure 
had no effect. 
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Figure 6: Total protein in PCLS. Samples were treated by DON 10 µM during 2 h and 20 h of incubation 
treatments. Data are mean ± SEM of three biological replicates. Bonferroni multiple comparison test. 
Significant difference between control and treated groups * P<0.05 
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This result demonstrated that incubation had no effect on the total protein contents of PCLS, 
whereas DON 10 µM in longer incubation (20 h) significantly decreased total protein contents. 
Mainly, at the cellular and subcellular level, DON binds to the ribosome, inhibits protein and 
nucleic acid synthesis and triggers ribotoxic stress, leading to the activation of mitogen-
activated protein kinases (MAPKs) and their downstream signaling pathways (Pierron et al. 
2016b). Thus, decrease of proteins in PCLS confirms that DON inhibits synthesis of proteins, 
and inhibition was clearly observed at longer incubation. 
We then analyzed the effect of DON and incubation on ATP content. Results demonstrated that 
a short DON exposure (2h) did not have any effect on ATP content. By contrast a long 
incubation time (20h) with or without DON decreased ATP contents by more than 70% (Figure 
7). 
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Figure 7: Total ATP content in a PCLS. Samples were treated by DON 10 µM during 2 h 
and 20 h of incubation treatments. Data are mean ± SEM of three biological replicates. 
Bonferroni multiple comparison test. Significant difference between control and treated 
groups * P < 0 
Overall, total protein contents of PCLS was reduced just due to the treatment, whereas 
unlikely to protein, ATP was highly reduced due to the incubation (20 h). 
The viability of PCLS is usually assessed via ATP and proteins content. Some studies have 
demonstrated that in longer incubation, a decrease of weight, thickness, total proteins and ATP 
was observed. In rat PCLS incubated for 24 h the wet weight significantly decreased from 17.6 
mg per slice to 9.0 mg (~51%), thickness was reduced from 218 μm (fresh slices) to 184 μm 
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(~84%) and total proteins content was reduced significantly from 1.58 mg per slice to 1.03 
mg(~66%). However, ATP was slightly decreased (17%) compared to the one of control 
(Granitzny et al. 2017). In addition to the treatments, incubation medium also play a role in the 
degradation of ATP. When human liver slices were incubated in two different mediums, WME 
and RegeneMed® after 120 h, the amount of ATP was dissimilar. Slices incubated in 
RegeneMed® had a consistently lower ATP level over time compared to WME. However, the 
incubation time had no effect on ATP levels. These lower ATP levels in slices incubated in 
RegeneMed® medium may be explained by the formation of the large necrotic regions in the 
inner part of the slices (Starokozhko et al. 2015). Furthermore, ATP level was measured in rat 
and mouse PCLS incubated in WME and DMEM medium for 72 h. Both mouse and rat slices 
lost more than 60% ATP level within 72 h in WME medium, however in DMEM with growth 
factors and hormones ATP level instead increased within 72 h (Koch et al. 2014). 
Our results on the total proteins and ATP contents are not in accordance with already published 
results. We incubated slices up 20 h, but we did not see any effect of incubation on total protein 
contents, whereas we observed the significant effect of incubation on the ATP. Previous stated 
results are from human, rats and mouse, whereas we assessed the behavior of pig liver slice. 
These variations might be dependent to the animal species. 
5.5. Assessment of the time and dose dependent effects of DON on the 
expression of selected genes  
The main objectives were (i) to assess the effect of DON 10 µM on the expression of genes of 
PCLS at different time of exposure (2 h, 4 h, 6 h, 8 h and 20 h) and (ii) to assess the doses effect 
of dose (DON 3 µM and 10 µM) at 20 h. Treated samples were compared to corresponding 
controls at each incubation time. 
5.5.1. Methods 
5.5.1.1.  Extraction 
A single PCLS was lysed in 1 mL Extract-all reagent (Eurobio) in a microtube with ceramic 
beads (Bertin Technologies, St. Quentin en Yvelines, France) using FastPrep-24™ 5G Classic 
Homogenizer (MP Biomedicals). Rapidly, the lysate was transferred into a new microtube. 
Then, 200 µL of chloroform (Sigma) were added into lysate, shacked vigorously several times 
and incubated for 5 minutes at room temperature. Afterward, microtubes were centrifuged for 
15 min in 13,000 g. The solution was separated into aqueous and organic phases. RNA 
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remaining in the aqueous phase was collected and recovered by precipitation with isopropyl 
alcohol and washed with ethanol 75% (Sigma) before dilution in RNase-free water. RNA 
concentration and purity with A260/A280 and A260/A230 ratios >1.95 were determined using 
spectrophotometer Nanodrop ND1000. In addition, quality of PCLS RNA was assessed via 
RNA integrity number (RIN) using Agilent 2100 Bioanalyzer (Agilent Santa Clara, CA USA). 
An aliquot of total RNA (1 μL) was analyzed using RNA Nano LabChips (Agilent). RIN value 
is determined by an algorithm for assigning integrity values to RNA measurements using the 
28S-to-18S-Ribosomic RNA ratio. 
5.5.1.2. Reverse transcription and PCR 
Reverse transcription (RT) was performed with the Kit High Capacity cDNA-RT (Fisher 
Scientific, Illkirch, France). Each reaction contained 10 µL RNA (2 µg RNA) and 10 µL of the 
mixture (2 µL of 10X RT buffer; 0.8 µL of 25X dNTP MIX 100 µM; 2 µL of 10X RT random 
primer; 1 µL of RNase inhibitor, 1 µL of multiSribe reverse Transcriptase and 3.2 µL Nuclease-
free H2O) (Thermo Fisher, Life Sciences). The conditions of RT reaction were 25℃ for 10 min, 
37℃ for 2 h, 85℃ for 5 min, maintain at 4℃. Ultimately, 5 µL of cDNA were diluted in 95 µL 
of sterile water. Diluted cDNA (5 ng/µL) was stored at -20 ⁰C for the next steps of qPCR 
(quantitative polymerize chain reaction). 
Quantitative real time polymerize chain reaction (qRT-PCR) was performed to assess the 
relative mRNA expression levels. Each sample was tested in duplicate and the potential 
genomic DNA contamination was verified through a non-template control (NTC). For one 
reaction, 2.5 µL of SyberGreen Power® SYBR Green qPCR master MIX (Sigma-Aldrich) and 
1.5 µL of Primers (reverse and forward) and 1 µL of cDNA (5 ng/ µL) was prepared. The 
specificity of qPCR products was assessed at the end of the reactions by analyzing the 
dissociation curves using QuantStudio-TM (Realtime PCR Software v.1.1, 2014). Data were 
exported into an Excel file. LinRegPCR v2014.3 program was used for qPCR data analysis to 
calculate N0 (the initial RNA concentration) and amplification efficiency (Ruijter et al. 2014) 
and then the data were exported back as an Excel file. For quantification and statistical analysis, 
target genes mRNA expression was normalized with the housekeeping genes (HKG) using N0 
(=10intercept) with LinRegPCR. Three HKG, ribosomal protein L32 (RPL32), Beta-2-
Microglobulin (B2-microglobulin) and TATA-Box Binding Protein (TBP) were used for data 
normalization. The best housekeeping genes were determined using Normfinder program which 
calculates a stability value based on the combined estimate of both intra- and intergroup values 
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(Andersen et al. 2004). In brief, NormFinder and LinRegPCR are the best approaches for 
reference gene selection and efficiency determination, respectively. 
5.5.2. Results and discussion  
5.5.2.1.  Quality of the RNA 
The assessment of RNA integrity is a critical first step before the following steps of RT and 
qPCR. RNA-Integrity (RIN) was obtained from each control slice. Analysis of the Bioanalyzer 
profile of total RNA indicated that the 28S and 18S rRNA bands were visible for each individual 
in each incubation time except for one sample at 20 h (Figure 8). The RIN for an RNA sample 
ranges from 1 to 10. A RIN of 10 is fully intact and a RIN of 1 is completely degraded (Fleige 
and Pfaffl 2006). Average RIN of 3 liver slices (biological replicates) were calculated. Initial 
RIN (sample without incubation) was 7.5 whereas; the final RIN (20 h incubation) was obtained 
6.2. This moderate decrease demonstrates that the quality of PLCS were maintained stable after 
different time of incubation (Figure 9). Thus, the RIN we obtained allowed us to go further and 
perform the qPCR and perform assessment of gene expression. 
 
Figure 8: RIN obtained from an individual control PCLS in different time of incubation: Each letter (D, E, F) 
represent a biological replicate (animal). 
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Figure 9: RIN curve of three controls animals over 20 h of incubation. Data are mean ± SEM of three biological 
replicates. 
Quality of RNA were evaluated in different species (human, rat and mouse). Initial RIN for 
human, rat and mouse PCLS were 8.9, 8.3 and 8.2, whereas after 3 days of incubation the final 
RIN were 7.8, 6.8 and 7.3 respectively (Niehof et al. 2017). RIN is usually higher in cell lines 
rather than PCLS. For example, RIN were always ≥ 8.1 for tissue and ≥ 9.5 for cells during 4 h 
incubation (Delgado-Ortega et al. 2014). 
It should be kept into account, the RIN number is not a tell-all with regard to downstream 
applications. For example, depending upon primer design, RT-PCR can be performed 
successfully when starting with partially degraded RNA when the amplicon is short. Similarly, 
RIN numbers are not particularly useful for nucleic acids that have been purified from archived 
pathology specimens. RNA recovered from formalin-fixed paraffin-embedded tissues and 
tissue sections also exhibit some degree of degradation (Farrel. Jr 2017). 
5.5.2.2. Assessment of gene expression 
Next, we selected several genes involved in different cellular function and processes (Table 22) 
including 3 HKG.  Selection of the genes was based on the literature (Nielsen et al. 2009; Sahu 
et al. 2010; Kouadio et al. 2013; Osselaere et al. 2013; Wu et al. 2014b; Liu et al. 2016; Luo et 
al. 2017). The goal of the first experiment was to determine the quality of the PCLS over the 
incubation time. Therefore, we selected genes already investigated in previous studies to 
confirm those results and hence to evaluate the relevance of the model of PCLS. 
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Table 222: List of selected genes assessed in PCLS in response of DON 10 µM 
Inflammatory 
cytokines 
Lipids 
Metabolism 
Oxidative 
Stress 
Junctional 
Proteins 
Transcriptional 
Factor 
Protease 
Inhibitors 
Housekeeping 
Genes 
CCL20 SCD1 SOD1 E-Cadherin JUN Serpin RPL32 
IL-6 SCARB-2 CAT OCLN FOS 
 B2-
microglobulin 
IL-1b CYP7A1 CCS CLDN-3   TBP 
IL-10 LDLR DUOX     
IL-22 LXR NFKB     
IL-8 ABCG-8      
TNF-alpha NR1H3      
First, we analyzed the effects of DON 10 µM on the gene expression at different incubation 
time (2, 4, 6, 8 and 20 h) (Figures 10-13). Genes were modulated after 4 h when PCLS were 
treated with DON 10 µM at different exposure time. Hereby, inflammatory cytokines were 
upregulated time dependently until 8 h. Most of the genes were upregulated time dependently 
compared to the controls one. CCL-20, IL-1b, IL-8 and IL-10 were significantly upregulated 
until 8 h of exposure, but at 20 h, their expression was decreased. TNF-alpha was upregulated 
only at 6 h of exposure. None of the tested inflammatory cytokines was expressed at 2 h (Figure 
10). Obtained results were consistent to the previous results. DON at 2.5 mg/kg BW markedly 
upregulated TNF-a, IL-1b, IL-6, CXCL-2, CCL-2 and CCL-7 after 2 and 6 h in spleen (Wu et 
al. 2014b). DON at 24 µM also induced inflammatory cytokines IL-1b, IL-1a, IL-8, and TNF-
a when jejunal explants were treated for 4 h (Luo et al. 2017). Altogether, DON induces 
inflammation in liver as in other organs. 
Among the tested genes involved in cellular function of lipid metabolism (ABCG8 and 
SREBP2) were significantly upregulated and LXR was significantly downregulated time 
dependently (Figure 11). Our obtained results were in accordance with previous results. DON 
significantly affected lipids metabolism in HepG2 cells when treated with DON at 10 µM for 4 
h -12 h periods. (Liu et al. 2016). Likewise, DON revealed disorders in lipid metabolism, when 
Swiss mice were orally administered with low doses of DON (45 μg/kg bw/day) during 7 days 
(Kouadio et al. 2013). In liver, disorders of lipid metabolism, may result in deposit of lipids in 
the walls of blood vessels, which can lead to atherosclerosis (a disease characterized by 
abnormal thickening and hardening of the walls of the arteries). In the consequence of gene 
                                                 
2 Definition of abbreviations:  
CCl-20 (C-C Motif Chemokine Ligand), IL (Interlukin), TNF-a (Tumor Necrossis Factor Alpha), SCD1 (Stearoyl-
CoA Desaturase), SCARB-2 (Scavenger Receptor Class B), CYP7A1 (Cytochrome P450 Family), LDLR (Low 
Density Lipoprotein Receptor), LXR (Liver X Receptor), ABCG-8 (ATP Binding Cassette), NR1H3 (Nuclear 
Receptor Subfamily 1), SOD1 (Superoxide Dismutase), CAT (Catalase), CCS (Copper Chaperone), DUOX (Dual 
Oxidase), NFKB (Nuclear Factor kappa-light-chain-enhancer of activated B cells),  OCLN  (Occludin), CLDN-3 
(Claudin-3) JUN (Jun Proto-Oncogene), FOS (Fos Proto-Oncogene), RPL32 (Ribosomal Protein L32), B2 (Beta-
2)-Microglobulin, TBP (TATA-Box Binding Protein) 
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modulation that are involved in cellular function of lipid metabolism may cause an autosomal 
dominant disease. Mainly, this disease in liver is associated due to the deficiency of the low 
density lipoprotein. 
Genes involved in the cellular function of oxidative stress were also modulated time 
dependently except SOD1. All three genes NFKB, CAT and CCS were upregulated 
significantly compared to the corresponding control (Figure 12). These results confirm that 
DON induces oxidative stress in liver. Obtained results were in accordance with previous 
results. DON at 10 µM for 4 h-12 h induced oxidative stress in HepG2 cells (Liu et al. 2016). 
Likewise, similar cells were exposed to DON at 25 µM for 6h-24 h, and was associated with 
oxidative stress (Sahu et al. 2010). Oxidative stress is traditionally defined as an imbalance 
between pro-oxidant compounds and antioxidant defenses (Kunsch Charles and Medford 
Russell M. 1999). Oxidative stress is thought to play a role in the genesis of hepatic 
encephalopathy found in patients who have liver failure (Webb and Twedt 2008). 
DON had moderately effect on gene modulation involved junctional protein of PCLS. Only E-
Cadherin was significantly up regulated in longer incubation time (20 h) (Figure 13). Obtained 
results were consistent and confirmed previous results. DON at 7.5 mg/kg feed, fed during 3 
weeks to broiler chickens, up-regulated CLDN-5 in the jejunum, while no effect was seen on 
genes involved in cells junction (Osselaere et al. 2013). It is well known that in eukaryotic cells, 
at the cellular and subcellular level, DON binds to the ribosome, and inhibits protein synthesis 
(Pierron et al. 2016b). Tight junction (TJ) proteins exert their functional role as integral proteins 
in forming barriers in the liver. A causative role of TJ proteins has been established in the 
pathogenesis of colorectal cancer and gastric cancer. Among the best characterized roles of TJ 
proteins in liver disease biology is their function as cell entry receptors for HCV (hepatitis C 
virus)—one of the most common causes of hepatocellular carcinoma (Zeisel et al. 2019). 
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Figure 10: PCLS treated with DON 10 µM. Inflammatory cytokines, gene modulation: Data are mean 
± SEM of three biological replicates. Bonferroni multiple comparison test. Significant difference 
between treated and corresponding control at each time point * P < 0.05, ** P < 0.01, *** P < 0.001 
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Figure 11: PCLS treated with DON 10 µM. Lipids metabolisms, gene modulation. Data are mean ± 
SEM of three biological replicates. Bonferroni multiple comparison test. Significant difference 
between treated and corresponding control at each time point * P < 0.05, ** P < 0.01, *** P < 0.001 
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Figure 12: PCLS treated with DON 10 µM. Oxidative Stress, gene modulation 
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Figure 13: PCLS treated with DON 10 µM. Protein junction, gene modulation. Data are mean ± 
SEM of three biological replicates. Bonferroni multiple comparison test. Significant difference 
between treated and corresponding control at each time point * P < 0.05, ** P < 0.01, *** P < 0.001 
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Then the effect of the doses of DON 3 µM and 10 µM was assessed on gene regulation at one 
incubation time 20 h (Figure 14). Genes were selected involved in different cellular function or 
process such as (inflammatory cytokines, lipids metabolism, oxidative stress, junctional 
proteins, transcriptional factor and protease inhibitor) (Table 22). All the genes were regulated 
dose dependently except CCS and SOD1 genes involved in cellular function of oxidative stress 
and Serpin which is the largest and most broadly distributed superfamily of protease inhibitors. 
Expression of some studied genes was modulated when PCLS were treated with DON 10 µM. 
However, expression of some genes seems to be modulated with DON 3 µM but not 
significantly. Only one gene of inflammatory cytokine (CCL20) was significantly regulated 
when PCLS were treated with DON 3 µM (Figure 14). 
Overall, genes from different pathways were up regulated at 20 h of exposure in response to 
DON 10 µM. Most of the genes were up-regulated in longer exposure time, whereas some of 
the genes were down-regulated. Likewise, most of the genes were regulated dose dependently. 
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 Figure 14: PCLS treated with DON 3 µM and 10 µM at 20 h incubation. Data are mean ± SEM of three 
biological replicates. Bonferroni multiple comparison test. Significant difference treated and 
corresponding control at each time point * P < 0.05, ** P < 0.01, *** P < 0.001 
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However, it is reported that inflammatory cytokines are regulated due to DON in the intestinal 
cells (Stadnyk 2002; Wan et al. 2013), but we found that DON can induce other genes in hepatic 
cells in addition to inflammatory cytokines. Other studies have also shown that in addition to 
inflammatory cytokines, DON can induce genes from other pathways. DON modulated 
significantly inflammatory cytokines IL-1β, IL-1α, IL-8, and TNF-α as well genes associated 
with oxidative stress MT1A, MT2A, when intestinal jejunal explants were treated with DON 
0.75-24 µM for 4 h (Luo et al. 2017). Furthermore, modulation of inflammatory cytokines (IL-
1β, IL-1α, IL-8, TNF-α) were observed following DON exposure in vitro  and in vivo (Chung 
et al. 2003; Islam et al. 2006). 
5.6. Discussion on PCLS 
The model of tissue slices was invented in 1923 to measure cell metabolism and oxygen 
consumption in tumor tissue and then explored to study amino acid metabolism in various 
organs and species including human (Li et al. 2016). PCLS have been used by many researchers 
because they represent an organ mini-model that closely resembles the organ from which it is 
prepared, with all cell types present in their original tissue-matrix configuration (Graaf et al. 
2007). Before, PCLS were used for a dynamic organ culture system as incubation system 
(Dogterom 1993). Whereas now, PCLS have been shown to be a valuable tool to predict 
metabolism of novel drugs, metabolism and toxicity of xenobiotics and as well for many other 
purposes (Graaf 2006; Graaf et al. 2007). This model has been developed long time ago. 
We developed the PCLS model in order to assess toxicity of mycotoxins through several 
biomarkers, such as ATP and total proteins contents, enzyme release such as ALP, AST, ALT 
and LDH, and as well gene expression. Although we used piglet liver, this model it is easily 
transferable to mouse, guinea pig, monkey, dog, and as well to human (Graaf et al. 2010). We 
found that liver slices is a good model for long incubation time under constant presence of 
carbogen. On the opposite, certain organs such as intestine cannot be incubated for longer 
incubation (Graaf et al. 2010). 
Our results of liver damage markers, ALP, AST, ALT, LDH and total protein contents in the 
incubation medium were not affected either by incubation or treatments. We chose a time of 
exposure of 20 h in order to maintain quality of RNA in PCLS and avoid its degradation. The 
RNA molecule is inherently fragile in the natural environment and constantly degrade into 
smaller molecules through hydrolysis, preventing the faithful reproduction (Spurway and 
Wackerhage 2006; Fiore 2019). 
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Then, we assessed effect of DON 3 µM and 10 µM on gene expression of PCLS. Genes were 
selected based on literature involved in different cellular functions or processes. We confirmed 
that the effect of DON on the gene expression was dose and time dependent. In longer 
incubation and in high concentration of DON, regulation was significant compared to their 
corresponding controls. Most of the genes were modulated time dependently compared to the 
controls. Modulation was mainly pronounced after 2 h of incubation. Most of inflammatory 
cytokines, i.e. CCL-20, IL-1b, IL-8 and IL-10, were significantly upregulated until 8 h of 
exposure. Among the tested genes involved in cellular function of lipid metabolism, ABCG8 
and SREBP2 were significantly upregulated and LXR was significantly downregulated time 
dependently. Genes involved in the cellular function of oxidative stress (NFKB, CAT and CCS) 
were also modulated time dependently except SOD1. DON had a moderate effect on gene 
modulation involved in junctional protein of PCLS. Only E-Cadherin was significantly up 
regulated at longer incubation times. 
To our knowledge, this is the first study that assess the effect of DON on the PCLS. However, 
effect of DON have been addressed on hepatic cells in vivo and in vitro (Sahu et al. 2008; 
Grenier et al. 2011; Osselaere et al. 2013; Bracarense et al. 2017). Effect of low dose 
(commonly found in crops) of DON was examined on five weeks old piglets. DON 
contaminated diets induced significant liver lesions when compared to animals fed control diet 
(Grenier et al. 2011). Effects of 1.75 mg/kg or 11.4 mg/kg of DON in contaminated diet was 
assessed in rats exposed for 7, 14 or 30 days, using histological and immunohistochemical 
analyses on liver. Ingestion of contaminated feed induced a significant increase in the lesional 
score in the liver. The main histological findings observed were cytoplasmic vacuolization and 
hepatocellular megalocytosis. A significant increase in hepatocyte proliferation was observed 
in rats that received 1.75 mg/kg of DON. The results of the morphological and 
immunohistochemical analyses suggest that the ingestion of DON can induce functional hepatic 
impairment and immunosuppression in a dose- and time-dependent manner (Bracarense et al. 
2017). 
In conclusion, the liver slices appear as a promising model to study the effects of food 
contaminants on liver tissue. It allows the assessment of different markers into the tissue or 
released in the culture medium. This tool may also prove useful for identification of genes in 
liver-resident cells that support cancer or invasion in liver. Moreover, this tool can partially 
supplant in vivo pig experiments for prescreening liver diseases. 
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5.7.  Discussion on Experimental models 
A model is “a representation of a real or actual subject”. In the field of toxicology, experimental 
scientific models are used to understand toxicological mechanisms. Toxicology is an 
experimental laboratory science that has traditionally utilized various animal models to study 
the effects of chemicals. Historically, toxicology studies relied heavily on various 
histopathological and biochemical endpoints in whole animals to draw conclusions on the 
effects of a chemical on living systems (Choudhuri et al. 2018). However, the general adoption 
of the principles of 3R (Replace, Reduce, Refine) provided the impetus for the development of 
in silico, ex vivo and in vitro models in toxicity testing (Figure 15). Their relative contributions 
to the scientific and animal welfare implications as well the opportunities they offer in the 
research are different. As each of them facilitated research in one way, on the other hand they 
have disadvantages and limitations.  
 
Figure 15: Experimental models 
5.7.1. In silico models 
In silico toxicology methods are computational approaches that analyze, simulate, visualize or 
predict the toxicity of chemical products. These methods are based on the chemical structure of 
the compounds, and are usually used together with other toxicity tests. The purpose of building 
a model for use in in silico prediction of toxicity is to derive a relationship between the 
properties of the compounds and their biological effect (Cronin and Madden 2010). In silico 
toxicity is assessed using a wide variety of tools (i.e., methods, algorithms, software, data, etc) 
to analyze beneficial or adverse effects of a compound (Yap et al. 2019). In silico models are 
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used to solve many problems in predictive toxicology and furthering knowledge and reducing 
the need to resort to animal testing. Predictions are done based on the chemical structure and 
selected properties of a compound. So, modelling and simulation via in silico contribute to 
reduce, refine and replace animal experimentation. Mainly modelling and simulation are based 
on experimental data, quantitative structure activity relationship and scientific data (Cronin and 
Madden 2010). Following are briefly listed pros and cons of this model: 
In Silico model 
Pros Cons 
 Predictions for a large set of compounds 
in a high-throughput mode 
 Simulation based on the structure of a 
compound 
 Performing without animals 
 Less cost 
 Difficult to extrapolate result to in 
vivo/ex vivo 
 Need special software and expert people 
The building of in silico models is an exciting field as it draws on so many areas of science and 
is dynamic and continually evolving. Looking to the future, there are many opportunities for 
further development of this field. This will include the use of more successful computational 
techniques to gain insight into fundamental molecular and chemical processes (Cronin and 
Madden 2010). 
5.7.2. In vitro models 
The term in vitro presents “the technique of performing a given procedure in an artificial 
environment outside the living organism”. The major aims of in vitro systems are to develop, 
simulate and predict biological reactions to materials when placed into or on tissue in the body. 
The in vitro methods not only assist in hazard identification and risk assessment but also in 
understanding dose response relationship and evaluating a new product before its market launch 
or supplying to researchers or pharmacological companies (Dhawan and Kwon 2017). 
Although, the in vitro studies can be criticized for being very different from the natural 
environment, they present several advantages.  
 
113 
In vitro models 
Pros Cons 
 Reduced number of animals 
 Lower costs 
 Optimal dose test 
 Rapid and easy to perform  
 Allow to analyze the mode of action 
 Adapted to assess interaction 
 Effect on a single cells does not represent 
effect on the whole body 
 Difficult to assess pharmacokinetics/ 
absorption/excretion 
 Difficult to extrapolate results to in vivo 
5.7.3. Ex vivo models 
Ex vivo models represent a tissue or slices culture of an organ, where the natural original three-
dimensional architecture and original cell composition and intercellular connections are 
retained. An ex vivo model is ethically advantageous, requires no postsurgical animal care, 
enables more reproducibility, and provides a tightly controlled artificial environment for 
toxicological studies (Dhawan and Kwon 2017). Although, in vitro and ex vivo appear somehow 
similar, as both testing methods involve experiments on biological matter, conducted outside 
of a living organism in an artificial environment. For instance, ex vivo models are much more 
complex than in vitro in terms of cell diversity, and therefore closer to in vivo conditions. 
Despite of many advantages of ex vivo models, they also has some limitations as well.  
Ex vivo models 
Pros Cons 
 Reduce animal number 
 Closest to in vivo 
 Cytoarchitecture retained 
 Numerous explants from a single tissue 
 Cell remain fully differentiated 
 Physiological function maintained 
 Limited incubation time  
 Require fresh explant for each 
experiment 
 Difficult to extrapolate results from 
animal to human 
5.7.4. In vivo models 
In vivo models are defined as “living organisms with an inherited naturally-acquired or induced 
pathological process that closely resembles the same phenomenon in human” (Chow et al. 
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2008). Their application in biomedical research, and pathophysiological and toxicological 
studies, provide the opportunity to determine pharmacokinetics of toxic compounds and to 
observe other clinical symptoms such as feed and water intake. In order to interpret and validate 
the results of other experimental models (in vitro, in silico, ex vivo), it is essential to perform in 
vivo assays. In vivo models are complex and integrated models that includes ingestion, 
absorption, metabolization and excretion processes. Following are briefly pointed out the main 
pros and cons of this model: 
In vivo model 
Pros Cons 
 Presence of all metabolic process of host 
mechanism 
 Study animal behaviour against toxins 
 Assessment of zootechnical parameters 
 Pharmacokinetics assessment 
 Sampling of different organs 
 Authorization of protocol from Ethical 
Committee 
 Expertise required 
 Large number of animals for statistical 
analysis 
 Costly  
The two forms of in vivo experiments are animal studies and clinical trials in toxicological and 
pharmacological studies. Animal models are classical toxicological models used as a mandatory 
element in preclinical (toxicological and pharmacological) studies of new compounds (Parvova 
et al. 2011). Animal models are used as preclinical tools for potential drug screening processes 
and translation into clinical trials. Preclinical testing includes testing of all materials and 
prototypical devices before testing or using in humans. This testing is conducted in order to 
provide an assurance of device safety prior to use in humans in a clinical trial (Belma et al. 
2019).  
The overall effect of the experiment on a living organism can be observed in in vivo models. 
Thus, in vivo experiments are more realistic than in vitro experiments with respect to the 
phenomenon and toxicity which comes out in the consequence of a toxicological experiment. 
Their main advantages are that they allow studying the toxicity of mycotoxins in presence of 
host defense mechanisms and integrated (ingestion, digestion, and excretion) system. In 
addition, in vivo assays provide the opportunity to assess the toxicity of mycotoxins through 
several endpoints simultaneously. For instance, suitable biomarkers for DON and ZEN 
exposure in porcine plasma, urine and feces and for DON, AFB1 and OTA in plasma and 
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excreta of broiler chickens were identified (Lauwers et al. 2019). The effects of DON and FUM 
alone or in combination during 5 weeks diet on hematological and biochemical blood 
parameters as well histopathological effects on the liver, lungs and kidneys were investigated 
(Grenier et al. 2011). A sub-chronic toxicity study of NIV was conducted in male and female 
rodents for 90 days to assess histopathology of the hematopoietic and immune organs, body 
weight gain, white blood cell and red blood cell counts as well the hemoglobin concentration 
(Takahashi et al. 2008). 
So far, numerous experimental models have be introduced. Each model has its justification at 
some points when applying to investigate toxicity (Sande 1999). Thus, a number of animal and 
non-animal models are used in research over the last years. It is established worldwide that in 
vitro testing models are of extreme importance for screening as well as to elaborate the 
mechanism and set of causes of various diseases (Jain et al. 2018). 
Among all the model previously presented, first we chose a cell culture model in order to 
investigate individual and combined toxicity of DON and emerging mycotoxins in porcine 
intestinal cells in vitro. Then, we developed precision-cut liver Slices (PCLS) model “ex vivo” 
in order to assess hepatotoxicity of DON in liver slice, as briefly discussed their implication, 
pros and cons as following ahead. 
5.7.5. Use of intestinal cells to assess the toxicity of emerging mycotoxins 
In our study, first we used an in vitro model of intestinal cells, the first target of ingested 
contaminants, to characterize the potential toxicity of emerging mycotoxins. We used the 
porcine intestinal epithelial cells (IPEC-1) and this in vitro model allowed us to assess serial 
doses-toxic effects of mycotoxins either alone or in mixture. In the following part, we focused 
on the pro and cons of this cell culture model.  
Intestinal Epithelial Cell culture model 
Pros Cons 
 Standard culture condition 
 Low cost 
 Unlimited lifespan (immortalized cell lines) 
 Obtained from different target organs 
 Altered genomic contents 
 Represent the only smallest part of 
an organ 
 Changing characteristics after 
several passages 
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 Physio-chemical environments precisely 
controlled  
 Need validation via in vivo  
In vitro presents a rapid, easy and economic model that is widely used to investigate toxicity of 
mycotoxins. For instance Novak et al. assessed the individual toxicity of emerging and 
regulated mycotoxins in porcine intestinal cells (IPEC-J2) using an in vitro model (Novak et al. 
2019). On the base of iso-dose effect, the combined toxicity of several ENNs (A, A1, B and 
B1) were assessed individually or in combination using Caco-2 cells (Prosperini et al. 2014a). 
Binary ENN+DON (1:1) and quaternary mixture of ENNS (A, A1, B, B1) were tested in ratios 
1:1:1:1 in Caco-2 cells (Prosperini et al. 2014a). Likewise, binary mixture of ENN+BEA, 
DON+BEA and DON+ZEA were tested in Caco-2 cells using in vitro (Ficheux et al. 2012; 
Fernández-Blanco et al. 2016). 
5.7.6. Development of PCLS model to assess toxicity of mycotoxins 
Precision-cut liver slices (PCLS) are viable ex vivo explants of tissue with a reproducible, well 
defined thickness. They represent a mini-model of the organ under study and contain all cells 
of the tissue in their natural environment, leaving intercellular and cell-matrix interactions 
intact, and are therefore highly appropriate for studying multicellular processes (de Graaf et al. 
2010). We used a liver slice model to assess the toxicity of DON. We aimed to develop the 
PCLS model in order to make screening and assess toxicity through several markers such as 
ATP, total protein contents and gene modulation. With an increasing public demand to limit 
the number of animals used in research and to reduce the distress to the experimental animals 
(3R concept), PCLS represent a promising method with numerous advantages for toxicological 
studies.  
PCLS model 
Pros Cons 
 Lobular structure preserved (all enzyme 
equipment preserved) 
 Selective intralobular effects detectable 
 Studies on human liver possible 
 Studies on several compounds at different 
concentrations 
 Viability: 6 h to 2 days 
 No collection of bile possible 
 Not all the cells preserved similarly 
(inter-assay variability) 
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PCLS represent the closest in vitro model of the in vivo situation. The major advantages are that 
the three-dimensional architecture is preserved. PCLS have been applied by many researchers 
(Graaf et al. 2007). One of the great advantages of the PCLS model is that numerous slices can 
be prepared from a single liver. On the other hands, PCLS can be employed for studies of 
xenobiotic metabolism, xenobiotic-induced cytotoxicity and genotoxicity, and to evaluate the 
effects of xenobiotics on hepatic enzyme activities (Price et al. 1998). 
Moreover, slices can be prepared from a range of tissues (including the heart, kidney, lung, 
intestine and spleen) from both experimental animals and human organs depending on the 
purpose of the study. For example, the effects of 4 h exposure of ENN-B1 alone and mixed 
with the most toxic trichothecene the T-2 toxin were assessed on the histopathology of piglets 
intestinal explants (Kolf-Clauw et al. 2013). Intestinal explants mounted in Ussing chambers 
were used to investigate the effect of mycotoxins on paracellular passage of FITC-dextran 
(Pinton et al. 2009). Mouse precision-cut liver slices (mPCLS) were incubated for 24 h to assess 
drug-induced liver injury (Hadi et al. 2012). Furthermore, splenic explants were used to 
characterize the clinical, immunological, and parasitological features of the hamster spleen 
infected with the parasite Leishmania donovani (Osorio et al. 2011).  
We investigated the toxicity of DON in the PCLS model. To the best of our knowledge this is 
the first study, investigating toxicity of mycotoxins using PCLS. Our aim in developing PCLS 
model was to introduce an appropriate alternative to the in vivo model contributing to the 
reduction of animal number and adapted to the simultaneous study of several toxins. 
In conclusion, all above mentioned models are widely used whereas none of them can be 
considered as ideal model. Each model has its own advantages and limitations, but all those 
models give us a wide and global perspectives to use and implement them in the research. The 
purpose of this discussion was to explore the historical evolution of different culture models 
and the reasons why the continues development of different models exists. 
.  
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6. General Conclusion 
Maintaining a safe global food and feed supply is a critical issue facing society. Cereal grains 
and their processed food products are frequently contaminated with mycotoxins. The diverse 
nature of mycotoxigenic fungi contribute to the worldwide occurrence of mycotoxins. Recent 
finding and surveys have shown that 60 – 80% of food, feed and cereal grains are contaminated 
by well-known as well as by emerging mycotoxins (Gruber-Dorninger et al. 2019; Eskola et al. 
2019; Abdallah et al. 2017; Streit et al. 2013).  
We collected more than 500 finished pig feed samples from the worldwide market during five 
years and analyzed them via LC-MS/MS method. We found that more than 95% of the samples 
were contaminated by at least one mycotoxin and 88% of them were naturally co-contaminated 
by DON and other regulated and emerging mycotoxins. The co-occurrence of mycotoxins 
represents the reality of fungal contamination of cereals and cereal-derived food products (Lee 
and Ryu 2017). 
We analyzed the prevalence and concentration of mycotoxins in compound feed which exact 
composition was unknown. The composition of feed might have an influence on the prevalence 
and as well on the concentration of mycotoxins. Although, more than one mycotoxin, produced 
by a single or several fungal species, may occur in various combinations in a given sample or 
food. Thus, compound feed that are made of several and various commodities, could be more 
contaminated rather than the raw materials (Streit et al. 2012). However, some authors have 
claimed that the concentrations of mycotoxins tend to be lower in processed food products; the 
incidences varied depending on the individual mycotoxins, possibly due to the varying stability 
during processing and distribution of mycotoxins (Lee and Ryu 2017). 
DON is one of the most wide distributed regulated mycotoxins across the world (Knutsen et al. 
2017; Gruber-Dorninger et al. 2019; Novak et al. 2019). Among farm animals, pig is one of the 
most sensitive species to mycotoxins (Pinton et al. 2009; Pierron et al. 2016b). When exposed 
to DON, pig performances and immune response are altered. This lead the CONTAM Panel to 
determine the LOAEL of 1.3 mg DON/kg feed for pig using the reduction of feed intake as the 
most sensitive endpoint (Knutsen et al. 2017). 
In addition to regulated mycotoxins, emerging mycotoxins also occur frequently and in high 
concentrations in cereals and cereal-derived products (Springler et al. 2016b; Malachová et al. 
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2014; Vaclavikova et al. 2013). Emerging mycotoxins are usually co-produced with regulated 
mycotoxins (Hussein and Brasel 2001) and the hazard of exposure to mycotoxin mixtures is 
gaining interest. The individual toxicity of mycotoxins is reported in different cell types 
(Ivanova et al. 2006; Alshannaq and Yu 2017; Olleik et al. 2019; Novak et al. 2019), whereas 
at the present very little is known about the health risk of mycotoxins mixture. 
As we confirmed the co-contamination of finished pig feed by emerging mycotoxins and DON, 
we investigated the combined toxicity of DON and the 10 most prevalent and co-occurring with 
DON emerging mycotoxins. We focused on the effects on the intestine as a first barrier against 
food contaminants. When feed contaminated with mycotoxins is ingested, the gastro-intestinal 
tract is the first possible site of interaction (Fraeyman et al. 2018) and intestinal epithelial cells 
can be exposed to high concentrations of toxins. We tested the individual and combined effects 
of emerging based on their realistic concentrations on IPEC-1 cells. Indeed, the potential risk 
of chronic exposure to multiple mycotoxins bringing the same mechanism of action and/or 
targeting the same organs may lead to synergistic or at least additive effects (Speijers and 
Speijers 2004). Their individual effects lead to identify 3 classes of toxicity: Class #1 (non-
toxic) included BRV-F, Cyclo and TRPT, Class #2 (moderately toxic) included AFN, EMO 
and ENN-B1 and Class #3 (highly toxic) included ENN-A1, B, BEA, and API. Despite of the 
high percentage of co-occurrence with DON, there was very low correlation between the 
concentration of emerging mycotoxins and the one of DON. Thus, we tested the toxicity of the 
mixtures based on 3 scenarios representing plausible to situations of exposure for animals. First 
scenario was low concentration of emerging mycotoxins + high concentration of DON 
(P25/P75), second scenario was median concentration of emerging mycotoxins + median of 
DON, whereas the 3rd scenario was the reverse case of scenario #1 (P75/P25). In most of the 
cases, the combined effect was similar to the individual effect of DON, or lesser than DON. 
In addition to intestine, liver is the main site of detoxification for xenobiotics, including 
mycotoxins and represents a target organ for food contaminants. So, we developed an ex vivo 
model to study the effects of mycotoxins on liver, the Precision Cut Liver Slices (PCLs). The 
first steps of developing this tool aimed to verify the maintenance of the quality of the tissue 
during time. We confirmed through analyzing liver damage makers (AST, ALP, AST, LDH) 
and as well via RIN that quality of tissue maintained stable over time of incubation. This tool 
was then used to assess the toxicity of DON (3 and 10 µM) at different incubation times (0 to 
20 h), by studying gene expression, ATP and total proteins content. Exposure to DON for 4 h 
or more led to induce in the expression of certain genes. The total proteins contents were 
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significantly decreased upon exposure to DON 10 µM in longer incubation time in accordance 
with its well-characterized inhibition of protein synthesis. At the cellular and subcellular level, 
DON binds to the ribosome, inhibits protein and nucleic acid synthesis and triggers ribotoxic 
stress, leading to the activation of mitogen-activated protein kinases (MAPKs) and their 
downstream signaling pathways (Pierron et al. 2016b). PCLS are considered as closely reflect 
the in vivo situation and are potentially useful for studying the toxicity of mycotoxins on liver-
resident cells. Application of the PCLS technique in the field of mycotoxicosis analysis 
however, has not yet been well developed. We confirm that PCLS is a promising model to 
assess hepatotoxicity of mycotoxins.  
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7. Perspectives 
Toxic effect of emerging mycotoxins on PCLS 
This study showed that most of the tested emerging mycotoxins were toxic, some of them being 
more toxic than DON. We analyzed the hepatic toxic effects of DON on several endpoints such 
as gene expression, ATP degradation and total proteins contents using PCLS. However, the 
toxic effect of emerging mycotoxins on above-mentioned markers through PCLS is still to be 
performed to obtain a picture of their potential toxicity on the liver. 
Some of emerging mycotoxins such as ENNs and BEA have ionophoric properties and increase 
ions permeability (Na+ K+ and Ca2+) in biological membrane. They increase oxidative stress by 
altering membrane ion permeability and uncoupling oxidative phosphorylation (EFSA 2014). 
BEA can induce genes from different pathways. A toxicogenomic study of the effects of BEA 
on gene expression changes in Jurkat cells and human lymphoblastic T cells showed changes 
in the expression of genes involved in to apoptosis and programmed cell death (Escrivá et al. 
2018). Furthermore, ENN altered the gene expression profile of primary rat hepatocytes 
(Jonsson et al. 2016). This demonstrates the need of analyzing the overall effect of emerging 
mycotoxins on gene expression using whole transcriptome approach. 
Combined toxicity of DON and emerging mycotoxins on PCLS 
Recently, due to the natural co-occurrence of mycotoxins, the hazard of exposure to mycotoxin 
mixtures is increasing day by day. The potential risk of chronic exposure to multiple 
mycotoxins, when the mechanism of action is similar, or if they target the same organs may 
lead to a synergistic or at least an additive effect when combined together (Speijers and Speijers 
2004). However, in our study performed on intestinal cells, we reported that emerging 
mycotoxins did not exacerbated the toxicity of DON in mixture. In order to improve the 
knowledge on the combined toxicity of emerging mycotoxins and DON using the ex vivo model 
of PCLS is the continuation of the present work. 
Slices from other organs 
The Krumdieck tissue slicer, which underwent regular improvements, is currently one of the 
most widely used instruments and can produce hundreds of slices in a semi-automatic procedure 
within 1 hour. Precision-cut tissue slices (PCTS) are widely used by many researchers as an ex 
vivo model of different animals including rat, mouse, hamster, guinea pig, cow, pig, deer, dog, 
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monkey, trout and humans. Slices can be harvested from different tissues (liver, intestine, lung, 
kidney, brain, spleen, heart, thyroid gland, prostate, lymph node and several types of tumours) 
(Groothuis et al. 2014). If the effects of mycotoxins have already been investigated ex vivo 
using intestinal explants (Pinton et al. 2009; Alassane-Kpembi et al. 2017a) their toxicity on 
explants from other organs is poorly investigated. Thus, PCTS of other organs, such as kidney, 
spleen or reproductive tissue could provide original and useful results. 
Investigation of toxic effect of emerging mycotoxins in vivo 
It is important, ultimately to confirm the results obtained with in vitro or ex vivo approaches by 
performing in vivo trials. Contaminants that show certain effects in vitro may therefore have 
different effects in vivo. In contrast to in vitro studies, in vivo studies are needed to evaluate 
how the body as a whole, will respond to a particular substance (Goodwin 2007). The toxic 
effects of DON have been already addressed via several endpoints in vivo, whereas the toxicity 
of emerging mycotoxins in vivo are fragmentary. We reported the occurrence and co-
contamination of emerging and regulated mycotoxins in pig feed. Perform in vivo experiments 
with pigs exposed to feed contaminated at realistic level and, of course, upon regulations and 
ethics in animal studies, is of high interest for obtaining useful data for risk assessment. 
  
123 
8. References 
1. Abass A, Awoyale W, Sulyok M, Alamu E (2017) Occurrence of Regulated Mycotoxins 
and Other Microbial Metabolites in Dried Cassava Products from Nigeria. Toxins 9:207. 
https://doi.org/10.3390/toxins9070207 
2. Abdallah MF, Girgin G, Baydar T, et al (2017) Occurrence of multiple mycotoxins and 
other fungal metabolites in animal feed and maize samples from Egypt using LC-MS/MS: 
Toxic fungal and bacterial metabolites in feed and maize from Egypt. J Sci Food Agric 
97:4419–4428. https://doi.org/10.1002/jsfa.8293 
3. Abdel-Wahhab MA, El-Kady AA, Hassan AM, et al (2015) Effectiveness of activated 
carbon and Egyptian montmorillonite in the protection against deoxynivalenol-induced 
cytotoxicity and genotoxicity in rats. Food Chem Toxicol 83:174–182. 
https://doi.org/10.1016/j.fct.2015.06.015 
4. Ackerman SB, Seed JR (1976) The effects of tryptophol on immune responses and its 
implications toward trypanosome-induced immunosuppression. Experientia 32:645–647. 
https://doi.org/10.1007/BF01990212 
5. Akbari P, Braber S, Gremmels H, et al (2014) Deoxynivalenol: a trigger for intestinal 
integrity breakdown. FASEB J 28:2414–2429. https://doi.org/10.1096/fj.13-238717 
6. Alassane-Kpembi I, Puel O, Oswald IP (2015) Toxicological interactions between the 
mycotoxins deoxynivalenol, nivalenol and their acetylated derivatives in intestinal 
epithelial cells. Arch Toxicol 89:1337–1346. https://doi.org/10.1007/s00204-014-1309-4 
7. Alassane-Kpembi I, Puel O, Pinton P, et al (2017a) Co-exposure to low doses of the food 
contaminants deoxynivalenol and nivalenol has a synergistic inflammatory effect on 
intestinal explants. Arch Toxicol 91:2677–2687. https://doi.org/10.1007/s00204-016-
1902-9 
8. Alassane-Kpembi I, Schatzmayr G, Taranu I, et al (2017b) Mycotoxins co-contamination: 
Methodological aspects and biological relevance of combined toxicity studies. Crit Rev 
Food Sci Nutr 57:3489–3507. https://doi.org/10.1080/10408398.2016.1140632 
9. Alshannaq A, Yu J-H (2017) Occurrence, Toxicity, and Analysis of Major Mycotoxins 
in Food. Int J Environ Res Public Health 14:632. https://doi.org/10.3390/ijerph14060632 
10. Amuzie CJ, Shinozuka J, Pestka JJ (2009) Induction of Suppressors of Cytokine 
Signaling by the Trichothecene Deoxynivalenol in the Mouse. Toxicol Sci 111:277–287. 
https://doi.org/10.1093/toxsci/kfp150 
11. Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of Real-Time Quantitative 
Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to 
Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets. 
Cancer Res 64:5245–5250. https://doi.org/10.1158/0008-5472.CAN-04-0496 
12. Anjorin ST, Fapohunda S, Sulyok M, Krska R (2016) Natural Co-occurrence of Emerging 
and Minor Mycotoxins on Maize Grains from Abuja, Nigeria. Ann Agric Environ Sci 
1:21–29 
124 
13. Awad WA, Aschenbach JR, Zentek J (2012) Cytotoxicity and metabolic stress induced 
by deoxynivalenol in the porcine intestinal IPEC-J2 cell line. J Anim Physiol Anim Nutr 
96:709–716. https://doi.org/10.1111/j.1439-0396.2011.01199.x 
14. Awad WA, Ghareeb K, Böhm J, Zentek J (2010) Decontamination and detoxification 
strategies for the Fusarium mycotoxin deoxynivalenol in animal feed and the 
effectiveness of microbial biodegradation. Food Addit Contam Part A 27:510–520. 
https://doi.org/10.1080/19440040903571747 
15. Azconaolivera JI, Ouyang Y, Murtha J, et al (1995) Induction of Cytokine mRNAs in 
Mice After Oral Exposure to the Trichothecene Vomitoxin (Deoxynivalenol): 
Relationship to Toxin Distribution and Protein Synthesis Inhibition. Toxicol Appl 
Pharmacol 133:109–120. https://doi.org/10.1006/taap.1995.1132 
16. Bauden M, Tassidis H, Ansari D (2015) In vitro cytotoxicity evaluation of HDAC 
inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent 
treatment. Toxicol Lett 236:8–15. https://doi.org/10.1016/j.toxlet.2015.03.017 
17. Behrsing HP, Vickers AEM, Tyson CA (2003) Extended rat liver slice survival and 
stability monitored using clinical biomarkers. Biochem Biophys Res Commun 312:209–
213. https://doi.org/10.1016/j.bbrc.2003.09.216 
18. Belma P, Dina F, Emina A, et al (2019) ANIMAL MODELS IN MODERN 
BIOMEDICAL RESEARCH. EUROPEAN JOURNAL OF PHARMACEUTICAL AND 
MEDICAL RESEARCH 6:35–38 
19. Bennett JW, Klich M (2003) Mycotoxins. Clin Microbiol Rev 16:497–516. 
https://doi.org/10.1128/CMR.16.3.497-516.2003 
20. Bensassi F, El Golli-Bennour E, Abid-Essefi S, et al (2009) Pathway of deoxynivalenol-
induced apoptosis in human colon carcinoma cells. Toxicology 264:104–109. 
https://doi.org/10.1016/j.tox.2009.07.020 
21. Betts JG, Desaix P, Johnson E, et al (2017) Anatomy & Physiology. Rice Univ 6100 Main 
Str MS-375 Houst Tex 77005 1085–1071 
22. Bilgrami KS (1991) Histopathological and cytolosical abnormalities induced by fusarial 
toxins in mice (Mus musculus). Mycotoxin Res 7:12–16. 
https://doi.org/10.1007/BF03192178 
23. Borutova R, Aragon YA, Nährer K, Berthiller F (2012) Co-occurrence and statistical 
correlations between mycotoxins in feedstuffs collected in the Asia–Oceania in 2010. 
Anim Feed Sci Technol 178:190–197. https://doi.org/10.1016/j.anifeedsci.2012.09.015 
24. Bouhet S, Oswald IP (2005) The effects of mycotoxins, fungal food contaminants, on the 
intestinal epithelial cell-derived innate immune response. Vet Immunol Immunopathol 
108:199–209. https://doi.org/10.1016/j.vetimm.2005.08.010 
25. Bracarense APFL, Basso KM, Da Silva EO, et al (2017) Deoxynivalenol in the liver and 
lymphoid organs of rats: effects of dose and duration on immunohistological changes. 
World Mycotoxin J 10:89–96. https://doi.org/10.3920/WMJ2016.2094 
125 
26. Bradlaw JA, Swentzel KC, Alterman E, Hauswirth JW (1985) Evaluation of purified 4-
deoxynivalenol (vomitoxin) for unscheduled DNA synthesis in the primary rat 
hepatocyte-DNA repair assay. Food Chem Toxicol 23:1063–1067. 
https://doi.org/10.1016/0278-6915(85)90053-5 
27. Bretz M, Beyer M, Cramer B, et al (2006) Thermal Degradation of the Fusarium 
Mycotoxin Deoxynivalenol. J Agric Food Chem 54:6445–6451. 
https://doi.org/10.1021/jf061008g 
28. Capon RJ, Stewart M, Ratnayake R, et al (2007) Citromycetins and Bilains A–C: New 
Aromatic Polyketides and Diketopiperazines from Australian Marine-Derived and 
Terrestrial Penicillium spp. J Nat Prod 70:1746–1752. https://doi.org/10.1021/np0702483 
29. Chang M-H, Huang F-J, Chan W-H (2012) Emodin induces embryonic toxicity in mouse 
blastocysts through apoptosis. Toxicology 299:25–32. 
https://doi.org/10.1016/j.tox.2012.05.006 
30. Chaytor AC, See MT, Hansen JA, et al (2011) Effects of chronic exposure of diets with 
reduced concentrations of aflatoxin and deoxynivalenol on growth and immune status of 
pigs. J Anim Sci 89:124–135. https://doi.org/10.2527/jas.2010-3005 
31. Chen F, Ma Y, Xue C, et al (2008) The combination of deoxynivalenol and zearalenone 
at permitted feed concentrations causes serious physiological effects in young pigs. J Vet 
Sci 9:39–44. https://doi.org/10.4142/jvs.2008.9.1.39 
32. Choudhuri S, Patton GW, Chanderbhan RF, et al (2018) From Classical Toxicology to 
Tox21: Some Critical Conceptual and Technological Advances in the Molecular 
Understanding of the Toxic Response Beginning From the Last Quarter of the 20th 
Century. Toxicol Sci 161:5–22. https://doi.org/10.1093/toxsci/kfx186 
33. Chow PKH, Ng RTH, Ogden BE (2008) Using Animal Models in Biomedical Research: 
A Primer for the Investigator, 1st edn. World Scientific 
34. Chung Y-J, Zhou H-R, Pestka JJ (2003) Transcriptional and posttranscriptional roles for 
p38 mitogen-activated protein kinase in upregulation of TNF-α expression by 
deoxynivalenol (vomitoxin). Toxicol Appl Pharmacol 193:188–201. 
https://doi.org/10.1016/S0041-008X(03)00299-0 
35. Collins TFX, Sprando RL, Black TN, et al (2006) Effects of deoxynivalenol (DON, 
vomitoxin) on in utero development in rats. Food Chem Toxicol 44:747–757. 
https://doi.org/10.1016/j.fct.2005.10.007 
36. Council for Agricultural Science and Technology (2003) Mycotoxins: risks in plant, 
animal, and human systems, 17th edn. Council for Agricultural Science and Technology, 
Ames, Iowa 
37. Cronin MTD, Madden JC (2010) In Silico Toxicology: Principles and Applications. 
Royal Society of Chemistry 
38. Dänicke S, Goyarts T, Valenta H, et al (2004) On the effects of deoxynivalenol (DON) 
in pig feed on growth performance, nutrients utilization and DON metabolism. J Anim 
Feed Sci 13:539–556. https://doi.org/10.22358/jafs/67624/2004 
126 
39. Dawson KA (2001) The application of yeast and yeast derivatives in the poultry industry. 
Aust. Poult. Sci. Symp. 
40. de Graaf IAM, Olinga P, de Jager MH, et al (2010) Preparation and incubation of 
precision-cut liver and intestinal slices for application in drug metabolism and toxicity 
studies. Nat Protoc 5:1540–1551. https://doi.org/10.1038/nprot.2010.111 
41. De Walle JV, Sergent T, Piront N, et al (2010) Deoxynivalenol affects in vitro intestinal 
epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl 
Pharmacol 245:291–298. https://doi.org/10.1016/j.taap.2010.03.012 
42. Debevere S, Cools A, De Baere S, et al (2020) In Vitro Rumen Simulations Show a 
Reduced Disappearance of Deoxynivalenol, Nivalenol and Enniatin B at Conditions of 
Rumen Acidosis and Lower Microbial Activity. Toxins 12:101. 
https://doi.org/10.3390/toxins12020101 
43. Delgado-Ortega M, Melo S, Punyadarsaniya D, et al (2014) Innate immune response to a 
H3N2 subtype swine influenza virus in newborn porcine trachea cells, alveolar 
macrophages, and precision-cut lung slices. Vet Res 45:42. https://doi.org/10.1186/1297-
9716-45-42 
44. Devreese M, Broekaert N, De Mil T, et al (2014) Pilot toxicokinetic study and absolute 
oral bioavailability of the Fusarium mycotoxin enniatin B1 in pigs. Food Chem Toxicol 
63:161–165. https://doi.org/10.1016/j.fct.2013.11.005 
45. Devreese M, De Baere S, De Backer P, Croubels S (2013) Quantitative determination of 
the Fusarium mycotoxins beauvericin, enniatin A, A1, B and B1 in pig plasma using high 
performance liquid chromatography–tandem mass spectrometry. Talanta 106:212–219. 
https://doi.org/10.1016/j.talanta.2012.11.068 
46. Dhawan A, Kwon S (Soga) (2017) In Vitro Toxicology, 1st edn. Academic Press, 125 
London Wall, London EC2Y 5AS, United Kingdom 
47. Diesing A-K, Nossol C, Dänicke S, et al (2011a) Vulnerability of Polarised Intestinal 
Porcine Epithelial Cells to Mycotoxin Deoxynivalenol Depends on the Route of 
Application. PLOS ONE 6:e17472. https://doi.org/10.1371/journal.pone.0017472 
48. Diesing A-K, Nossol C, Panther P, et al (2011b) Mycotoxin deoxynivalenol (DON) 
mediates biphasic cellular response in intestinal porcine epithelial cell lines IPEC-1 and 
IPEC-J2. Toxicol Lett 200:8–18. https://doi.org/10.1016/j.toxlet.2010.10.006 
49. Dogterom P (1993) Development of a simple incubation system for metabolism studies 
with precision-cut liver slices. Drug Metab Dispos 21:699–704 
50. Döll S, Dänicke S, Ueberschär KH, et al (2003) Effects of graded levels of Fusarium toxin 
contaminated maize in diets for female weaned piglets. Arch Tierernahr 57:311–334. 
https://doi.org/10.1080/00039420310001607680 
51. Dornetshuber R, Heffeter P, Kamyar M-R, et al (2007) Enniatin Exerts p53-Dependent 
Cytostatic and p53-Independent Cytotoxic Activities against Human Cancer Cells. Chem 
Res Toxicol 20:465–473. https://doi.org/10.1021/tx600259t 
127 
52. Dufour DR, Lott JA, Nolte FS, et al (2000) Diagnosis and Monitoring of Hepatic Injury. 
I. Performance Characteristics of Laboratory Tests. Clin Chem 23 
53. Dvorska J (2014) Aurofusarin, a newly described Fusarium graminearum mycotoxin: 
oxidative stress and protective effect of MycosorbTM. In: Engormix. 
http://en.engormix.com/mycotoxins/articles/aurofusarin-newly-described-fusarium-
t33383.htm. Accessed 20 Mar 2017 
54. Dvorska JE, Surai PF (2004) Protective effect of modified glucomannans against changes 
in antioxidant systems of quail egg and embryo due to aurofusarin consumption. Asian-
Australas J Anim Sci 17:434–440 
55. Dvorska JE, Surai PF, Speake BK, Sparks NHC (2001) Effect of the mycotoxin 
aurofusarin on the antioxidant composition and fatty acid profile of quail eggs. Br Poult 
Sci 42:643–649 
56. Dvorska JE, Surai PF, Speake BK, Sparks NHC (2003) Protective effect of modified 
glucomannans against aurofusarin-induced changes in quail egg and embryo. Comp 
Biochem Physiol Part C Toxicol Pharmacol 135:337–343. 
https://doi.org/10.1016/S1532-0456(03)00122-4 
57. EFSA (2014) Scientific Opinion on the risks to human and animal health related to the 
presence of beauvericin and enniatins in food and feed: Beauvericin and enniatins in food 
and feed. EFSA J 12:3802. https://doi.org/10.2903/j.efsa.2014.3802 
58. EFSA (2018) Risks to human and animal health related to the presence of moniliformin 
in food and feed. EFSA J 6(3):5082 
59. EFSA (2013) Deoxynivalenol in food and feed: occurrence and exposure. EFSA J 
11:3379: 6–56. https://doi.org/10.2903/j.efsa.2013.3379 
60. EFSA (2004) Opinion of the Scientific Panel on Contaminants in the Food Chain on a 
request from the Commission related to Deoxynivalenol (DON) as undesirable substance 
in animal feed. Off. J. Eur. Union 43 
61. Elferink M, Olinga P, Draaisma A, et al (2008) Microarray analysis in rat liver slices 
correctly predicts in vivo hepatotoxicity. Toxicol Appl Pharmacol 229:300–309. 
https://doi.org/10.1016/j.taap.2008.01.037 
62. Eriksen GS, Pettersson H (2004) Toxicological evaluation of trichothecenes in animal 
feed. Anim Feed Sci Technol 114:205–239. 
https://doi.org/10.1016/j.anifeedsci.2003.08.008 
63. Escrivá L, Font G, Manyes L (2015) Quantitation of enniatins in biological samples of 
Wistar rats after oral administration by LC-MS/MS. Toxicol Mech Methods 25:552–558. 
https://doi.org/10.3109/15376516.2015.1061083 
64. Escrivá L, Jennen D, Caiment F, Manyes L (2018) Transcriptomic study of the toxic 
mechanism triggered by beauvericin in Jurkat cells. Toxicol Lett 284:213–221. 
https://doi.org/10.1016/j.toxlet.2017.11.035 
128 
65. Eskola M, Kos G, Elliott CT, et al (2019) Worldwide contamination of food-crops with 
mycotoxins: Validity of the widely cited ‘FAO estimate’ of 25%. Crit Rev Food Sci Nutr 
1–17. https://doi.org/10.1080/10408398.2019.1658570 
66. European-Commission (2016) Commission Recommendation (EU)  2016/  1319  -  of  29  
July  2016  -  amending  Recommendation  2006/  576/  EC  as  regards  deoxynivalenol,  
zearalenone  and  ochratoxin  A in  pet  food. Off J Eur Union L 208/58-L 208/59 
67. European-Commission (2007) Commission Recommendation (EC) No 1126/2007 of 28 
September 2007 amending Regulation (EC) No 1881/2006 setting maximum levels for 
certain contaminants in foodstuffs as regards Fusarium toxins in maize and maize 
products. Off. J. Eur. Union L 255/14-17 
68. European-Commission (2006) Commission Recommendation of 17 August 2006 on the 
presence of deoxynivalenol, zearalenone, ochratoxin A, T-2 and HT-2 and fumonisins in 
products intended for animal feeding. Off. J. Eur. Union 229, 7–9 
69. Fadeel B, Pietroiusti A, Shvedova AA (2012) Adverse Effects of Engineered 
Nanomaterials: Exposure, Toxicology, and Impact on Human Health. Academic Press 
70. FAO (2019) Crop Prospects and Food Situation | GIEWS - Global Information and Early 
Warning System | Food and Agriculture Organization of the United Nations. 
http://www.fao.org/giews/reports/crop-prospects/en/. Accessed 3 Dec 2019 
71. FAO (2004) Worldwide regulations for mycotoxins in food and feed in 2003. 
http://www.fao.org/3/y5499e/y5499e00.htm. Accessed 20 Sep 2019 
72. FAO, Miller JD (1991) FOOD, NUTRITION AND AGRICULTURE. Natl Inst Nutr 
Hyderabad India Plant Res Cent Agric Can Ott Ont 16 
73. Farrel. Jr REF (2017) RNA Methodologies: Laboratory Guide for Isolation and 
Characterization. Academic Press 
74. Fernández-Blanco C, Font G, Ruiz M-J (2016) Interaction effects of enniatin B, 
deoxinivalenol and alternariol in Caco-2 cells. Toxicol Lett 241:38–48. 
https://doi.org/10.1016/j.toxlet.2015.11.005 
75. Ficheux AS, Sibiril Y, Parent-Massin D (2012) Co-exposure of Fusarium mycotoxins: In 
vitro myelotoxicity assessment on human hematopoietic progenitors. Toxicon 60:1171–
1179. https://doi.org/10.1016/j.toxicon.2012.08.001 
76. Fink‐Gremmels J (1999) Mycotoxins: Their implications for human and animal health. 
Vet Q 21:115–120. https://doi.org/10.1080/01652176.1999.9695005 
77. Fiore M (2019) The Origin and Early Evolution of Life: Prebiotic Chemistry of 
Biomolecules, 1st edn. MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland 
78. Fleige S, Pfaffl MW (2006) RNA integrity and the effect on the real-time qRT-PCR 
performance. Mol Aspects Med 27:126–139. https://doi.org/10.1016/j.mam.2005.12.003 
129 
79. Fotso J, Smith JS (2003) Evaluation of Beauvericin Toxicity with the Bacterial 
Bioluminescence Assay and the Ames Mutagenicity Bioassay. Food Chem Toxicol 
68:1938–1945 
80. Fraeyman S, Croubels S, Devreese M, Antonissen G (2017) Emerging Fusarium and 
Alternaria Mycotoxins: Occurrence, Toxicity and Toxicokinetics. Toxins 9:. 
https://doi.org/10.3390/toxins9070228 
81. Fraeyman S, Devreese M, Antonissen G, et al (2016) Comparative Oral Bioavailability, 
Toxicokinetics, and Biotransformation of Enniatin B1 and Enniatin B in Broiler 
Chickens. J Agric Food Chem 64:7259–7264. https://doi.org/10.1021/acs.jafc.6b02913 
82. Fraeyman S, Meyer E, Devreese M, et al (2018) Comparative in vitro cytotoxicity of the 
emerging Fusarium mycotoxins beauvericin and enniatins to porcine intestinal epithelial 
cells. Food Chem Toxicol 121:566–572. https://doi.org/10.1016/j.fct.2018.09.053 
83. Frandsen RJN, Nielsen NJ, Maolanon N, et al (2006) The biosynthetic pathway for 
aurofusarin in Fusarium graminearum reveals a close link between the naphthoquinones 
and naphthopyrones. Mol Microbiol 61:1069–1080. https://doi.org/10.1111/j.1365-
2958.2006.05295.x 
84. Frisvad JC, Rank C, Nielsen KF, Larsen TO (2009) Metabolomics of Aspergillus 
fumigatus. Med Mycol 47:S53–S71. https://doi.org/10.1080/13693780802307720 
85. García CJ, Jarque JB (2014) Emerging mycotoxins: enniatins (A, A1, B and B1) and 
beauvericin. In: Mycotoxins and their Implications in Food Safety. Future Science Ltd, 
pp 68–89 
86. Gerez JR, Pinton P, Callu P, et al (2015) Deoxynivalenol alone or in combination with 
nivalenol and zearalenone induce systemic histological changes in pigs. Exp Toxicol 
Pathol 67:89–98. https://doi.org/10.1016/j.etp.2014.10.001 
87. Ghareeb K, Awad WA, Böhm J, Zebeli Q (2015) Impacts of the feed contaminant 
deoxynivalenol on the intestine of monogastric animals: poultry and swine. J Appl 
Toxicol 35:327–337. https://doi.org/10.1002/jat.3083 
88. Glenn AE, Bacon CW, Price R, Hanlin RT (1996) Molecular phylogeny of Acremonium 
and its taxonomic implications. Mycologia 88:369–383. 
https://doi.org/10.1080/00275514.1996.12026664 
89. Gonçalves CO, Cubero-leon E (2017) Report on the 2016 Proficiency Test of the 
European Union Reference for Mycotoxins 
90. Goodwin AM (2007) In vitro assays of angiogenesis for assessment of angiogenic and 
anti-angiogenic agents. Microvasc Res 74:172–183. 
https://doi.org/10.1016/j.mvr.2007.05.006 
91. Goossens J, Pasmans F, Verbrugghe E, et al (2012) Porcine intestinal epithelial barrier 
disruption by the Fusariummycotoxins deoxynivalenol and T-2 toxin promotes 
transepithelial passage of doxycycline and paromomycin. BMC Vet Res 8:245. 
https://doi.org/10.1186/1746-6148-8-245 
130 
92. Gouze ME, Laffitte J, Rouimi P, et al (2006) Effect of various doses of deoxynivalenol 
on liver xenobiotic metabolizing enzymes in mice. Food Chem Toxicol 44:476–483. 
https://doi.org/10.1016/j.fct.2005.08.020 
93. Goyarts T, Dänicke S (2006) Bioavailability of the Fusarium toxin deoxynivalenol 
(DON) from naturally contaminated wheat for the pig. Toxicol Lett 163:171–182. 
https://doi.org/10.1016/j.toxlet.2005.10.007 
94. Graaf IA de (2006) Empirical validation of a rat in vitro organ slice model as a tool for in 
vivo clearance prediction. Drug Metab Dispos 34:591–599. 
https://doi.org/10.1124/dmd.105.006726 
95. Graaf IA de, Groothuis GM, Olinga P (2007) Precision-cut tissue slices as a tool to predict 
metabolism of novel drugs. Expert Opin Drug Metab Toxicol 3:879–898. 
https://doi.org/10.1517/17425255.3.6.879 
96. Graaf IA de, Olinga P, de Jager MH, et al (2010) Preparation and incubation of precision-
cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat 
Protoc 5:1540–1551. https://doi.org/10.1038/nprot.2010.111 
97. Granitzny A, Knebel J, Schaudien D, et al (2017) Maintenance of high quality rat 
precision cut liver slices during culture to study hepatotoxic responses: Acetaminophen 
as a model compound. Toxicol In Vitro 42:200–213. 
https://doi.org/10.1016/j.tiv.2017.05.001 
98. Greaves P (2011) Histopathology of Preclinical Toxicity Studies: Interpretation and 
Relevance in Drug Safety Evaluation, 4th edn. Academic Press, 32 Jamestwon Road, 
London NW1 7BY, UK 
99. Grenier B, Bracarense A-PFL, Schwartz HE, et al (2012) The low intestinal and hepatic 
toxicity of hydrolyzed fumonisin B₁ correlates with its inability to alter the metabolism 
of sphingolipids. Biochem Pharmacol 83:1465–1473. 
https://doi.org/10.1016/j.bcp.2012.02.007 
100. Grenier B, Loureiro‐Bracarense A-P, Lucioli J, et al (2011) Individual and combined 
effects of subclinical doses of deoxynivalenol and fumonisins in piglets. Mol Nutr Food 
Res 55:761–771. https://doi.org/10.1002/mnfr.201000402 
101. Griessler K, Rodrigues I, Handl J, Hofstetter U (2010) Occurrence of mycotoxins in 
Southern Europe. World Mycotoxin J 3:301–309. 
https://doi.org/10.3920/WMJ2009.1198 
102. Groothuis GMM, Casini A, Meurs H, Olinga P (2014) Chapter 3. Translational Research 
in Pharmacology and Toxicology Using Precision-Cut Tissue Slices. In: Coleman R (ed) 
Drug Discovery. Royal Society of Chemistry, Cambridge, pp 38–65 
103. Groschwitz KR, Hogan SP (2009) Intestinal barrier function: Molecular regulation and 
disease pathogenesis. J Allergy Clin Immunol 124:3–20. 
https://doi.org/10.1016/j.jaci.2009.05.038 
104. Gruber-Dorninger C, Jenkins T, Schatzmayr G (2019) Global Mycotoxin Occurrence in 
Feed: A Ten-Year Survey. Toxins 11:375. https://doi.org/10.3390/toxins11070375 
131 
105. Gruber-Dorninger C, Novak B, Nagl V, Berthiller F (2016) Emerging Mycotoxins: 
Beyond Traditionally Determined Food Contaminants. J Agric Food Chem 7052–7070. 
https://doi.org/10.1021/acs.jafc.6b03413 
106. Gu MJ, Song SK, Park SM, et al (2014) <italic>Bacillus subtilis</italic> Protects Porcine 
Intestinal Barrier from Deoxynivalenol via Improved Zonula Occludens-1 Expression. 
Asian-Australas J Anim Sci 27:580–586. https://doi.org/10.5713/ajas.2013.13744 
107. Hadi M, Chen Y, Starokozhko V, et al (2012) Mouse Precision-Cut Liver Slices as an ex 
Vivo Model To Study Idiosyncratic Drug-Induced Liver Injury. Chem Res Toxicol 
25:1938–1947. https://doi.org/10.1021/tx300248j 
108. Hamill RL, Higgens CE, Boaz HE, Gorman M (1969) The structure op beauvericin, a 
new depsipeptide antibiotic toxic to Artemia salina. Tetrahedron Lett 10:4255–4258 
109. Han J-W, Ahn SH, Park SH, et al (2000) Apicidin, a histone deacetylase inhibitor, inhibits 
proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 
60:6068–6074 
110. Heilos D, Rodríguez-Carrasco Y, Englinger B, et al (2017) The Natural Fungal 
Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study. 
Toxins 9:. https://doi.org/10.3390/toxins9090258 
111. Heinl S, Hartinger D, Thamhesl M, et al (2010) Degradation of fumonisin B1 by the 
consecutive action of two bacterial enzymes. J Biotechnol 145:120–129. 
https://doi.org/10.1016/j.jbiotec.2009.11.004 
112. Heshmati A, Zohrevand T, Khaneghah AM, et al (2017) Co-occurrence of aflatoxins and 
ochratoxin A in dried fruits in Iran: Dietary exposure risk assessment. Food Chem Toxicol 
106:202–208. https://doi.org/10.1016/j.fct.2017.05.046 
113. Hilgenfeld R, Saenger W (1982) Structural chemistry of natural and synthetic inoophores 
and their complexes with cations. In: Vögtle F (ed) Host Guest Complex Chemistry II. 
Springer Berlin Heidelberg, Berlin, Heidelberg, pp 1–82 
114. Holden MTG, Chhabra SR, Nys RD, et al (1999) Quorum-sensing cross talk: isolation 
and chemical characterization of cyclic dipeptides from Pseudomonas aeruginosa and 
other Gram-negative bacteria. Mol Microbiol 33:1254–1266. 
https://doi.org/10.1046/j.1365-2958.1999.01577.x 
115. Hou Y-J, Zhao Y-Y, Xiong B, et al (2013) Mycotoxin-Containing Diet Causes Oxidative 
Stress in the Mouse. PLOS ONE 8:e60374. https://doi.org/10.1371/journal.pone.0060374 
116. Hunder G, Schümann K, Strugala G, et al (1991) Influence of subchronic exposure to low 
dietary deoxynivalenol, a trichothecene mycotoxin, on intestinal absorption of nutrients 
in mice. Food Chem Toxicol 29:809–814. https://doi.org/10.1016/0278-6915(91)90107-
I 
117. Hussein S, Brasel JM (2001) Toxicity, metabolism, and impact of mycotoxins on humans 
and animals. Toxicology 167:101–134 
132 
118. Inagaki S, Morimura S, Tang Y, et al (2007) Tryptophol Induces Death Receptor (DR) 5-
Mediated Apoptosis in U937 Cells. Biosci Biotechnol Biochem 71:2065–2068. 
https://doi.org/10.1271/bbb.70084 
119. Islam Z, Gray JS, Pestka JJ (2006) p38 mitogen-activated protein kinase mediates IL-8 
induction by the ribotoxin deoxynivalenol in human monocytes. Toxicol Appl Pharmacol 
213:235–244. https://doi.org/10.1016/j.taap.2005.11.001 
120. Ismaiel AA, Papenbrock J (2015) Mycotoxins: Producing Fungi and Mechanisms of 
Phytotoxicity. Agriculture 5:492–537. https://doi.org/10.3390/agriculture5030492 
121. Ivanova L, Skjerve E, Eriksen GS, Uhlig S (2006) Cytotoxicity of enniatins A, A1, B, 
B1, B2 and B3 from Fusarium avenaceum. Toxicon 47:868–876. 
https://doi.org/10.1016/j.toxicon.2006.02.012 
122. Izhaki I (2002) Emodin - a secondary metabolite with multiple ecological functions in 
higher plants. New Phytol 155:205–217. https://doi.org/10.1046/j.1469-
8137.2002.00459.x 
123. Jain AK, Singh D, Dubey K, et al (2018) Models and Methods for In Vitro Toxicity. In: 
In Vitro Toxicology. Elsevier, pp 45–65 
124. Jajić I, Dudaš T, Krstović S, et al (2019) Emerging Fusarium Mycotoxins Fusaproliferin, 
Beauvericin, Enniatins, and Moniliformin in Serbian Maize. Toxins 11:. 
https://doi.org/10.3390/toxins11060357 
125. Jarolim K, Wolters K, Woelflingseder L, et al (2018) The secondary Fusarium metabolite 
aurofusarin induces oxidative stress, cytotoxicity and genotoxicity in human colon cells. 
Toxicol Lett 284:170–183. https://doi.org/10.1016/j.toxlet.2017.12.008 
126. Jestoi M (2008) Emerging Fusarium Mycotoxins Fusaproliferin, Beauvericin, Enniatins, 
And Moniliformin—A Review. Crit Rev Food Sci Nutr 48:21–49. 
https://doi.org/10.1080/10408390601062021 
127. Jestoi M, Rokka M, Yli-Mattila T, et al (2004) Presence and concentrations of the 
Fusarium- related mycotoxins beauvericin, enniatins and moniliformin in finnish grain 
samples. Food Addit Contam 21:794–802. 
https://doi.org/10.1080/02652030410001713906 
128. Jin J, Lee S, Lee J, et al (2010) Functional characterization and manipulation of the 
apicidin biosynthetic pathway in Fusarium semitectum. 76:456–466. 
https://doi.org/10.1111/j.1365-2958.2010.07109.x 
129. Jonsson M, Jestoi M, Anthoni M, et al (2016) Fusarium mycotoxin enniatin B: Cytotoxic 
effects and changes in gene expression profile. Toxicol In Vitro 34:309–320. 
https://doi.org/10.1016/j.tiv.2016.04.017 
130. Jouany JP, Yiannikouris A, Bertin G (2009) Risk assessment of mycotoxins in ruminants 
and ruminant products. CIHEAM 205–224. 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.518.4911&rep=rep1&type=p
df 
133 
131. Juan C, Mañes J, Raiola A, Ritieni A (2013) Evaluation of beauvericin and enniatins in 
Italian cereal products and multicereal food by liquid chromatography coupled to triple 
quadrupole mass spectrometry. Food Chem 140:755–762. 
https://doi.org/10.1016/j.foodchem.2012.08.021 
132. Juan C, Manyes L, Font G, Juan-garc A (2014) Toxicon Evaluation of immunologic effect 
of Enniatin A and quantitative determination in feces , urine and serum on treated Wistar 
rats. 87:45–53. https://doi.org/10.1016/j.toxicon.2014.05.005 
133. Juan-García A, Manyes L, Ruiz M-J, Font G (2013) Involvement of enniatins-induced 
cytotoxicity in human HepG2 cells. Toxicol Lett 218:166–173. 
https://doi.org/10.1016/j.toxlet.2013.01.014 
134. Juan-García A, Ruiz M-J, Font G, Manyes L (2015) Enniatin A1, enniatin B1 and 
beauvericin on HepG2: Evaluation of toxic effects. Food Chem Toxicol 84:188–196. 
https://doi.org/10.1016/j.fct.2015.08.030 
135. Kabak B (2009) The fate of mycotoxins during thermal food processing. J Sci Food Agric 
89:549–554. https://doi.org/10.1002/jsfa.3491 
136. Kamyar M, Rawnduzi P, Studenik CR, et al (2004) Investigation of the 
electrophysiological properties of enniatins. Arch Biochem Biophys 429:215–223. 
https://doi.org/10.1016/j.abb.2004.06.013 
137. Karlovsky P (1999) Biological detoxification of fungal toxins and its use in plant 
breeding, feed and food production. Nat Toxins 7:23 
138. Kasuga F, Hara-Kudo Y, Saito N, et al (1998a) in Vitro Effect of Deoxynivalenol on the 
Differentiation of Human Colonic Cell Lines Caco-2 and t84. Mycopathologia 142:161–
167. https://doi.org/10.1023/A:1006923808748 
139. Kasuga F, Hara-Kudo Y, Saito N, et al (1998b) in Vitro Effect of Deoxynivalenol on the 
Differentiation of Human Colonic Cell Lines Caco-2 and t84. Mycopathologia 142:161–
167. https://doi.org/10.1023/A:1006923808748 
140. Kim J-E, Jin J, Kim H, et al (2006) GIP2, a Putative Transcription Factor That Regulates 
the Aurofusarin Biosynthetic Gene Cluster in Gibberella zeae. Appl Environ Microbiol 
72:1645–1652. https://doi.org/10.1128/AEM.72.2.1645-1652.2006 
141. Kim J-E, Kim J-C, Jin J-M, et al (2008) Functional Characterization of Genes Located at 
the Aurofusarin Biosynthesis Gene Cluster in Gibberella zeae. Plant Pathol J 24:8–16. 
https://doi.org/10.5423/PPJ.2008.24.1.008 
142. Kim JM, Lee HW (2013) Anatomy of the pig. In: 8th Int. Single Top. Symp. Korean 
Assoc. HBP Surg. pp 129–132 
143. Knasmüller S, Bresgen N, Kassie F, et al (1997) Genotoxic effects of three Fusarium 
mycotoxins, fumonisin B1, moniliformin and vomitoxin in bacteria and in primary 
cultures of rat hepatocytes. Mutat Res Toxicol Environ Mutagen 391:39–48. 
https://doi.org/10.1016/S0165-1218(97)00030-X 
134 
144. Knutsen HK, Alexander J, Barreg ard L, et al (2017) Risks to human and animal health 
related to the presence of deoxynivalenol and its acetylated and modified forms in food 
and feed. EFSA J 5(9):4718. https://doi.org/10.2903/j.efsa.2017.4718 
145. Koch A, Saran S, Tran DDH, et al (2014) Murine precision-cut liver slices (PCLS): a new 
tool for studying tumor microenvironments and cell signaling ex vivo. 13 
146. Kolf-Clauw M, Castellote J, Joly B, et al (2009) Development of a pig jejunal explant 
culture for studying the gastrointestinal toxicity of the mycotoxin deoxynivalenol: 
Histopathological analysis. Toxicol In Vitro 23:1580–1584. 
https://doi.org/10.1016/j.tiv.2009.07.015 
147. Kolf-Clauw M, Sassahara M, Lucioli J, et al (2013) The emerging mycotoxin, enniatin 
B1, down-modulates the gastrointestinal toxicity of T-2 toxin in vitro on intestinal 
epithelial cells and ex vivo on intestinal explants. Arch Toxicol 87:2233–2241. 
https://doi.org/10.1007/s00204-013-1067-8 
148. Königs M, Schwerdt G, Gekle M, Humpf H-U (2008) Effects of the mycotoxin 
deoxynivalenol on human primary hepatocytes. Mol Nutr Food Res 52:830–839. 
https://doi.org/10.1002/mnfr.200700439 
149. Korosteleva SN, Smith TK, Boermans HJ (2007) Effects of Feedborne Fusarium 
Mycotoxins on the Performance, Metabolism, and Immunity of Dairy Cows. J Dairy Sci 
90:3867–3873. https://doi.org/10.3168/jds.2007-0162 
150. Kosalec I, Ramić S, Jelić D, et al (2011) Assessment of Tryptophol Genotoxicity in Four 
Cell Lines In Vitro: A Pilot Study with Alkaline Comet Assay. Arch Ind Hyg Toxicol 
62:41–49. https://doi.org/10.2478/10004-1254-62-2011-2090 
151. Kosalec I, Šafranić A, Pepeljnjak S, et al (2008) Genotoxicity of Tryptophol in a Battery 
of Short-Term Assays on Human White Blood Cells in vitro. Basic Clin Pharmacol 
Toxicol 102:443–452. https://doi.org/10.1111/j.1742-7843.2007.00204.x 
152. Kouadio J, Moukha S, Brou K, Gnakri D (2013) Lipid metabolism disorders, 
lymphocytes cells death, and renal toxicity induced by very low levels of deoxynivalenol 
and fumonisin B 1 alone or in combination following 7 days oral administration to mice. 
Toxicol Int 20:218. https://doi.org/10.4103/0971-6580.121673 
153. Kovalsky P, Kos G, Nährer K, et al (2016) Co-Occurrence of Regulated, Masked and 
Emerging Mycotoxins and Secondary Metabolites in Finished Feed and Maize—An 
Extensive Survey. Toxins 8:363: 1–29. https://doi.org/10.3390/toxins8120363 
154. Krumdieck Carol, Santos JED, Ho K-J (1980) A New Instrument for the Rapid 
Preparation of Tissue Slices 
155. Kunsch Charles, Medford Russell M. (1999) Oxidative Stress as a Regulator of Gene 
Expression in the Vasculature. Circ Res 85:753–766. 
https://doi.org/10.1161/01.RES.85.8.753 
156. Lautt WW (2010) Hepatic Circulation: Physiology and Pathophysiology. Morgan & 
Claypool Publishers, LSU Health Science Center and Joey Granger, University of 
Mississippi School of Medicine 
135 
157. Lauwers M, Croubels S, Letor B, et al (2019) Biomarkers for Exposure as A Tool for 
Efficacy Testing of A Mycotoxin Detoxifier in Broiler Chickens and Pigs. Toxins 11:187. 
https://doi.org/10.3390/toxins11040187 
158. Lee HJ, Ryu D (2017) Worldwide Occurrence of Mycotoxins in Cereals and Cereal-
Derived Food Products: Public Health Perspectives of Their Co-occurrence. J Agric Food 
Chem 65:7034–7051. https://doi.org/10.1021/acs.jafc.6b04847 
159. Lerda D (2011) Mycotoxins Factsheet-4th edition. Eur. Comm. JRC 66956-Jt. Res. Cent. 
- Insititute Ref. Mater. Meas. 36 pp 
160. Lewczuk B, Przybylska-Gornowicz B, Gajęcka M, et al (2016) Histological structure of 
duodenum in gilts receiving low doses of zearalenone and deoxynivalenol in feed. Exp 
Toxicol Pathol 68:157–166. https://doi.org/10.1016/j.etp.2015.11.008 
161. Li M, de Graaf IAM, Groothuis GMM (2016) Precision-cut intestinal slices: alternative 
model for drug transport, metabolism, and toxicology research. Expert Opin Drug Metab 
Toxicol 12:175–190. https://doi.org/10.1517/17425255.2016.1125882 
162. Liew W-P-P, Mohd-Redzwan S (2018) Mycotoxin: Its Impact on Gut Health and 
Microbiota. Front Cell Infect Microbiol 8:60. https://doi.org/10.3389/fcimb.2018.00060 
163. Limdi JK (2003) Evaluation of abnormal liver function tests. Postgrad Med J 79:307–
312. https://doi.org/10.1136/pmj.79.932.307 
164. Ling K-H, Wan MLY, El-Nezami H, Wang M (2016) Protective Capacity of Resveratrol, 
a Natural Polyphenolic Compound, against Deoxynivalenol-Induced Intestinal Barrier 
Dysfunction and Bacterial Translocation. Chem Res Toxicol 29:823–833. 
https://doi.org/10.1021/acs.chemrestox.6b00001 
165. Liu Y, Ran R, Hu C, et al (2016) The metabolic responses of HepG2 cells to the exposure 
of mycotoxin deoxynivalenol. World Mycotoxin J 9:577–586. 
https://doi.org/10.3920/WMJ2015.1981 
166. Liuzzi V, Mirabelli V, Cimmarusti M, et al (2017) Enniatin and Beauvericin Biosynthesis 
in Fusarium Species: Production Profiles and Structural Determinant Prediction. Toxins 
9:45. https://doi.org/10.3390/toxins9020045 
167. Logrieco A, Moretti A, Castella G, et al (1998) Beauvericin Production by 
FusariumSpecies. Appl Environ Microbiol 64:3084–3088 
168. Logrieco A, Moretti A, Ritieni A, et al (2002a) Beauvericin: Chemistry, Biology and 
Significance. In: Upadhyay RK (ed) Advances in Microbial Toxin Research and Its 
Biotechnological Exploitation. Springer US, Boston, MA, pp 23–30 
169. Logrieco A, Rizzo A, Ferracane R, Ritieni A (2002b) Occurrence of Beauvericin and 
Enniatins in Wheat Affected by Fusarium avenaceum Head Blight. Appl Environ 
Microbiol 68:82–85. https://doi.org/10.1128/AEM.68.1.82-85.2002 
170. Loi M, Fanelli F, Liuzzi V, et al (2017) Mycotoxin Biotransformation by Native and 
Commercial Enzymes: Present and Future Perspectives. Toxins 9:111. 
https://doi.org/10.3390/toxins9040111 
136 
171. Lucioli J, Pinton P, Callu P, et al (2013) The food contaminant deoxynivalenol activates 
the mitogen activated protein kinases in the intestine: Interest of ex vivo models as an 
alternative to in vivo experiments. Toxicon 66:31–36. 
https://doi.org/10.1016/j.toxicon.2013.01.024 
172. Luo S, Puel S, Oswald IP, Pinton P (2017) Specific intestinal toxicity of deoxynivalenol 
and cadmium: analysis on pig jejunal explants. 12 
173. Luz C, Saladino F, Luciano FB, et al (2017) Occurrence, toxicity, bioaccessibility and 
mitigation strategies of beauvericin, a minor Fusarium mycotoxin. Food Chem Toxicol 
107:430–439. https://doi.org/10.1016/j.fct.2017.07.032 
174. Malachová A, Sulyok M, Beltrán E, et al (2014) Optimization and validation of a 
quantitative liquid chromatography–tandem mass spectrometric method covering 295 
bacterial and fungal metabolites including all regulated mycotoxins in four model food 
matrices. J Chromatogr A 1362:145–156. https://doi.org/10.1016/j.chroma.2014.08.037 
175. Mallebrera B, Meca G, Manyes L, et al (2013) Influence of pro- and prebiotics on gastric, 
duodenal and colonic bioaccessibility of the mycotoxin beauvericin. J Food Compos Anal 
32:141–149. https://doi.org/10.1016/j.jfca.2013.09.003 
176. Manda G, Mocanu MA, Marin DE, Taranu I (2015) Dual Effects Exerted in Vitro by 
Micromolar Concentrations of Deoxynivalenol on Undifferentiated Caco-2 Cells. Toxins 
7:593–603. https://doi.org/10.3390/toxins7020593 
177. Manyes L, Escrivá L, Serrano AB, et al (2014) A preliminary study in Wistar rats with 
enniatin A contaminated feed. Toxicol Mech Methods 24:179–190. 
https://doi.org/10.3109/15376516.2013.876135 
178. Maresca M, Mahfoud R, Garmy N, Fantini J (2002) The Mycotoxin Deoxynivalenol 
Affects Nutrient Absorption in Human Intestinal Epithelial Cells. J Nutr 132:2723–2731. 
https://doi.org/10.1093/jn/132.9.2723 
179. Maresca M, Yahi N, Younès-Sakr L, et al (2008) Both direct and indirect effects account 
for the pro-inflammatory activity of enteropathogenic mycotoxins on the human intestinal 
epithelium: Stimulation of interleukin-8 secretion, potentiation of interleukin-1β effect 
and increase in the transepithelial passage of commensal bacteria. Toxicol Appl 
Pharmacol 228:84–92. https://doi.org/10.1016/j.taap.2007.11.013 
180. Meca G, Font G, Ruiz MJ (2011) Comparative cytotoxicity study of enniatins A, A1, A2, 
B, B1, B4 and J3 on Caco-2 cells, Hep-G2 and HT-29. Food Chem Toxicol 49:2464–
2469. https://doi.org/10.1016/j.fct.2011.05.020 
181. Meca G, Zinedine A, Blesa J, et al (2010) Further data on the presence of Fusarium 
emerging mycotoxins enniatins, fusaproliferin and beauvericin in cereals available on the 
Spanish markets. Food Chem Toxicol 48:1412–1416. 
https://doi.org/10.1016/j.fct.2010.03.010 
182. Mikami O, Yamaguchi H, Murata H, et al (2010) Induction of apoptotic lesions in liver 
and lymphoid tissues and modulation of cytokine mRNA expression by acute exposure 
to deoxynivalenol in piglets. J Vet Sci 11:107–113. 
https://doi.org/10.4142/jvs.2010.11.2.107 
137 
183. Milićević DR, Škrinjar M, Baltić T (2010) Real and Perceived Risks for Mycotoxin 
Contamination in Foods and Feeds: Challenges for Food Safety Control. Toxins 2:572–
592. https://doi.org/10.3390/toxins2040572 
184. Mulaikal TA, Emond JC (2018) Liver anesthesiology and critical care medicine, 2nd edn. 
Springer Berlin Heidelberg, New York, NY 
185. Naik RS, Mujumdar AM, Ghaskadbi S (2004) Protection of liver cells from ethanol 
cytotoxicity by curcumin in liver slice culture in vitro. J Ethnopharmacol 95:31–37. 
https://doi.org/10.1016/j.jep.2004.06.032 
186. Nandani D, Verma RN, Batra A (2013) Isolation and identification of quercetin and 
emodin from Cassia tora L. An PHYTOMEDICINE 2:96–104. 
https://www.semanticscholar.org/paper/Isolation-and-identification-of-quercetin-and-
from-Nandani-Verma/ 
187. Niehaus E-M, Janevska S, von Bargen KW, et al (2014) Apicidin F: Characterization and 
Genetic Manipulation of a New Secondary Metabolite Gene Cluster in the Rice Pathogen 
Fusarium fujikuroi. PLOS ONE 9:e103336. 
https://doi.org/10.1371/journal.pone.0103336 
188. Niehof M, Hildebrandt T, Danov O, et al (2017) RNA isolation from precision-cut lung 
slices (PCLS) from different species. BMC Res Notes 10:121. 
https://doi.org/10.1186/s13104-017-2447-6 
189. Nielsen C, Lippke H, Didier A, et al (2009) Potential of deoxynivalenol to induce 
transcription factors in human hepatoma cells. Mol Nutr Food Res 53:479–491. 
https://doi.org/10.1002/mnfr.200800475 
190. Novak B, Rainer V, Sulyok M, et al (2019) Twenty-Eight Fungal Secondary Metabolites 
Detected in Pig Feed Samples: Their Occurrence, Relevance and Cytotoxic Effects In 
Vitro. Toxins 11:537. https://doi.org/10.3390/toxins11090537 
191. Olleik H, Nicoletti C, Lafond M, et al (2019) Comparative Structure–Activity Analysis 
of the Antimicrobial Activity, Cytotoxicity, and Mechanism of Action of the Fungal 
Cyclohexadepsipeptides Enniatins and Beauvericin. Toxins 11:514. 
https://doi.org/10.3390/toxins11090514 
192. Osorio Y, Travi BL, Renslo AR, et al (2011) Identification of Small Molecule Lead 
Compounds for Visceral Leishmaniasis Using a Novel Ex Vivo Splenic Explant Model 
System. PLoS Negl Trop Dis 5:. https://doi.org/10.1371/journal.pntd.0000962 
193. Osselaere A, Santos R, Hautekiet V, et al (2013) Deoxynivalenol Impairs Hepatic and 
Intestinal Gene Expression of Selected Oxidative Stress, Tight Junction and Inflammation 
Proteins in Broiler Chickens, but Addition of an Adsorbing Agent Shifts the Effects to 
the Distal Parts of the Small Intestine. PLOS ONE 8:e69014. 
https://doi.org/10.1371/journal.pone.0069014 
194. Park J-S, Lee K-R, Kim J-C, et al (1999) A hemorrhagic factor (apicidin) produced by 
toxic Fusarium isolates from soybean seeds. Appl Environ Microbiol 65:126–130 
138 
195. Parvova I, Danchev N, Hristov E (2011) Animal models of human diseases and their 
significance for clinical studies of new drugs. J Clin Med 4:19–29 
196. Payros D, Alassane-Kpembi I, Pierron A, et al (2016) Toxicology of deoxynivalenol and 
its acetylated and modified forms. Arch Toxicol 90:2931–2957. 
https://doi.org/10.1007/s00204-016-1826-4 
197. Pearce SC, Coia HG, Karl JP, et al (2018) Intestinal in vitro and ex vivo Models to Study 
Host-Microbiome Interactions and Acute Stressors. Front Physiol 9:. 
https://doi.org/10.3389/fphys.2018.01584 
198. Peraica M, Radić B, Lucić A, Pavlović M (1999) Toxic effects of mycotoxins in humans. 
Bull World Health Organ 77:754–766 
199. Pestka JJ (2010) Deoxynivalenol: mechanisms of action, human exposure, and 
toxicological relevance. Arch Toxicol 84:663–679. https://doi.org/10.1007/s00204-010-
0579-8 
200. Pestka JJ, Islam Z, Amuzie CJ (2008) Immunochemical assessment of deoxynivalenol 
tissue distribution following oral exposure in the mouse. Toxicol Lett 178:83–87. 
https://doi.org/10.1016/j.toxlet.2008.02.005 
201. Pierron A, Alassane-Kpembi I, Oswald IP (2016a) Impact of mycotoxin on immune 
response and consequences for pig health. Anim Nutr 2:63–68. 
https://doi.org/10.1016/j.aninu.2016.03.001 
202. Pierron A, Alassane-Kpembi I, Oswald IP (2016b) Impact of two mycotoxins 
deoxynivalenol and fumonisin on pig intestinal health. Porc Health Manag 2:. 
https://doi.org/10.1186/s40813-016-0041-2 
203. Pierron A, Mimoun S, Murate LS, et al (2016c) Microbial biotransformation of DON: 
molecular basis for reduced toxicity. Sci Rep 6:29105. https://doi.org/10.1038/srep29105 
204. Pinton P, Braicu C, Nougayrede J-P, et al (2010) Deoxynivalenol Impairs Porcine 
Intestinal Barrier Function and Decreases the Protein Expression of Claudin-4 through a 
Mitogen-Activated Protein Kinase-Dependent Mechanism. J Nutr 140:1956–1962. 
https://doi.org/10.3945/jn.110.123919 
205. Pinton P, Nougayrède J-P, Del Rio J-C, et al (2009) The food contaminant 
deoxynivalenol, decreases intestinal barrier permeability and reduces claudin expression. 
Toxicol Appl Pharmacol 237:41–48. https://doi.org/10.1016/j.taap.2009.03.003 
206. Pinton P, Oswald I (2014) Effect of Deoxynivalenol and Other Type B Trichothecenes 
on the Intestine: A Review. Toxins 6:1615–1643. https://doi.org/10.3390/toxins6051615 
207. Pinton P, Tsybulskyy D, Lucioli J, et al (2012) Toxicity of Deoxynivalenol and Its 
Acetylated Derivatives on the Intestine: Differential Effects on Morphology, Barrier 
Function, Tight Junction Proteins, and Mitogen-Activated Protein Kinases. Toxicol Sci 
130:180–190. https://doi.org/10.1093/toxsci/kfs239 
208. Pongratz I, Bergander L (2011) Hormone-Disruptive Chemical Contaminants in Food. 
Royal Society of Chemistry, Combridge CB4 0WF, UK 
139 
209. Pratt DS, Kaplan MM (2000) Evaluation of Abnormal Liver-Enzyme Results in 
Asymptomatic Patients. N Engl J Med 342:1266–1271. 
https://doi.org/10.1056/NEJM200004273421707 
210. Price RJ, Ball SE, Renwick AB, et al (1998) Use of precision-cut rat liver slices for studies 
of xenobiotic metabolism and toxicity: comparison of the Krumdieck and Brendel tissue 
slicers. Xenobiotica 28:361–371. https://doi.org/10.1080/004982598239470 
211. Prosperini A, Font G, Ruiz MJ (2014a) Interaction effects of Fusarium enniatins (A, A1, 
B and B1) combinations on in vitro cytotoxicity of Caco-2 cells. Toxicol In Vitro 28:88–
94. https://doi.org/10.1016/j.tiv.2013.06.021 
212. Prosperini A, Font G, Ruiz MJ (2014b) Interaction effects of Fusarium enniatins (A, A1, 
B and B1) combinations on in vitro cytotoxicity of Caco-2 cells. Toxicol In Vitro 28:88–
94. https://doi.org/10.1016/j.tiv.2013.06.021 
213. Qiang Z, Truong M, Meynen K, et al (2011) Efficacy of a Mycotoxin Binder against 
Dietary Fumonisin, Deoxynivalenol, and Zearalenone in Rats. J Agric Food Chem 
59:7527–7533. https://doi.org/10.1021/jf202042z 
214. Racanelli V, Rehermann B (2006) The liver as an immunological organ. Hepatology 
43:S54–S62. https://doi.org/10.1002/hep.21060 
215. Randazzo G, Fogliano V, Ritieni A, et al (1993) Proliferin, a new sesterterpene from 
Fusarium proliferatum. Tetrahedron 49:10883–10896. https://doi.org/10.1016/S0040-
4020(01)80241-6 
216. Rao JN, Wang J-Y (2010) Intestinal Architecture and Development. Morgan & Claypool 
Life Sciences 
217. RASFF (2018) The Rapid Alert System for Food and Feed 2018 Annual Report. Eur Com 
53 
218. Rayle DL, Purves WK (1967) Isolation and Identification of Indole-3-Ethanol 
(Tryptophol) from Cucumber Seedlings. Plant Physiol 42:520–524. 
https://doi.org/10.1104/pp.42.4.520 
219. Ritieni A, Moretti A, Logrieco A, et al (1997) Occurrence of Fusaproliferin, Fumonisin 
B1, and Beauvericin in Maize from Italy. J Agric Food Chem 45:4011–4016. 
https://doi.org/10.1021/jf9702151 
220. Rodríguez-carrasco Y, Heilos D, Richter L, et al (2016) Mouse tissue distribution and 
persistence of the food-born fusariotoxins Enniatin B and Beauvericin. 247:35–44. 
https://doi.org/10.1016/j.toxlet.2016.02.008 
221. Rodríguez-Carrasco Y, Heilos D, Richter L, et al (2016) Mouse tissue distribution and 
persistence of the food-born fusariotoxins Enniatin B and Beauvericin. Toxicol Lett 
247:35–44. https://doi.org/10.1016/j.toxlet.2016.02.008 
222. Rotter BA (1996) Invited Review: Toxicology of Deoxynivalenol (Vomitoxin). J Toxicol 
Environ Health 48:1–34. https://doi.org/10.1080/009841096161447 
140 
223. Ruijter JM, Ilgun A, Gunst QD (2014) LinRegPCR (2014.X) Analysis of quantitative RT-
PCR data 
224. Ruiz MJ, Franzova P, Juan-García A, Font G (2011) Toxicological interactions between 
the mycotoxins beauvericin, deoxynivalenol and T-2 toxin in CHO-K1 cells in vitro. 
Toxicon 58:315–326. https://doi.org/10.1016/j.toxicon.2011.07.015 
225. Rutqvist L (1978) Ochratoxin A as the Cause of Spontaneous Nephropathy in Fattening 
Pigs. APPL Env MICROBIOL 36:6 
226. Sahu SC, Garthoff LH, Robl MG, et al (2008) Rat liver clone-9 cells in culture as a model 
for screening hepatotoxic potential of food-related products: hepatotoxicity of 
deoxynivalenol. J Appl Toxicol 28:765–772. https://doi.org/10.1002/jat.1337 
227. Sahu SC, O’Donnell MW, Wiesenfeld PL (2010) Comparative hepatotoxicity of 
deoxynivalenol in rat, mouse and human liver cells in culture. J Appl Toxicol 30:566–
573. https://doi.org/10.1002/jat.1527 
228. Sande MA (1999) Handbook of Animal Models of Infection: Experimental Models in 
Antimicrobial Chemotherapy. Academic Press 
229. Schatzmayr G, Streit E (2013) Global occurrence of mycotoxins in the food and feed 
chain: facts and figures. World Mycotoxin J 6:213–222. 
https://doi.org/10.3920/WMJ2013.1572 
230. Serrano AB, Font G, Ruiz MJ, Ferrer E (2012) Co-occurrence and risk assessment of 
mycotoxins in food and diet from Mediterranean area. Food Chem 135:423–429. 
https://doi.org/10.1016/j.foodchem.2012.03.064 
231. Shen M, Shi H (2015) Sex Hormones and Their Receptors Regulate Liver Energy 
Homeostasis. Int J Endocrinol 2015:1–12. https://doi.org/10.1155/2015/294278 
232. Sheth K, Bankey P (2001) The liver as an immune organ. Univ Rochester Med Cent 601 
Elmw Ave Rochester NY 14642 USA 7:99–104 
233. Sifou A, Meca G, Serrano AB, et al (2011) First report on the presence of emerging 
Fusarium mycotoxins enniatins (A, A1, B, B1), beauvericin and fusaproliferin in rice on 
the Moroccan retail markets. Food Control 22:1826–1830. 
https://doi.org/10.1016/j.foodcont.2011.04.019 
234. Singh S, Banerjee S, Chattopadhyay P, et al (2015) Deoxynivalenol induces cytotoxicity 
and genotoxicity in animal primary cell culture. Toxicol Mech Methods 25:184–191. 
https://doi.org/10.3109/15376516.2015.1006743 
235. Singh SB, Zink DL, Polishook JD, et al (1996) Apicidins: Novel Cyclic Tetrapeptides as 
Coccidiostats and  Antimalarial Agents from Fusarium  paUidoroseum. Pergamon Press 
L S0040-4039(96)01844–8:8077–880 
236. Skóra J, Matusiak K, Wojewódzki P, et al (2016) Evaluation of Microbiological and 
Chemical Contaminants in Poultry Farms. Int J Environ Res Public Health 13:192. 
https://doi.org/10.3390/ijerph13020192 
141 
237. Slobodchikova I, Sivakumar R, Rahman MS, Vuckovic D (2019) Characterization of 
Phase I and Glucuronide Phase II Metabolites of 17 Mycotoxins Using Liquid 
Chromatography—High-Resolution Mass Spectrometry. Toxins 11:433. 
https://doi.org/10.3390/toxins11080433 
238. Sobrova P, Adam V, Vasatkova A, et al (2010) Deoxynivalenol and its toxicity. 
Interdiscip Toxicol 3:. https://doi.org/10.2478/v10102-010-0019-x 
239. Speijers GJA, Speijers MHM (2004) Combined toxic effects of mycotoxins. Toxicol Lett 
153:91–98. https://doi.org/10.1016/j.toxlet.2004.04.046 
240. Sprando RL, Collins TFX, Black TN, et al (2005) Characterization of the effect of 
deoxynivalenol on selected male reproductive endpoints. Food Chem Toxicol 43:623–
635. https://doi.org/10.1016/j.fct.2004.12.017 
241. Springler A, Hessenberger S, Schatzmayr G, Mayer E (2016a) Early Activation of MAPK 
p44/42 Is Partially Involved in DON-Induced Disruption of the Intestinal Barrier 
Function and Tight Junction Network. Toxins 8:. https://doi.org/10.3390/toxins8090264 
242. Springler A, Vrubel G-J, Mayer E, et al (2016b) Effect of Fusarium-Derived Metabolites 
on the Barrier Integrity of Differentiated Intestinal Porcine Epithelial Cells (IPEC-J2). 
Toxins 8:345: 1–20. https://doi.org/10.3390/toxins8110345 
243. Spurway N, Wackerhage H (2006) Genetics and Molecular Biology of Muscle 
Adaptation. Elsevier Health Sciences 
244. Stadnyk AW (2002) Intestinal Epithelial Cells as a Source of Inflammatory Cytokines 
and Chemokines. In: Can. J. Gastroenterol. Hepatol. 
https://www.hindawi.com/journals/cjgh/2002/941087/abs/. Accessed 5 Nov 2019 
245. Starokozhko V, Abza GB, Maessen HC, et al (2015) Viability, function and 
morphological integrity of precision-cut liver slices during prolonged incubation: Effects 
of culture medium. Toxicol In Vitro 30:288–299. 
https://doi.org/10.1016/j.tiv.2015.10.008 
246. Steffen N, Graham R (2017) MYCOTOXINS – THE HIDDEN DANGER IN FOOD 
AND FEED. 74 
247. Stierle AC, Cardellina JH, Strobel GA (1988) Maculosin, a host-specific phytotoxin for 
spotted knapweed from Alternaria alternata. Proc Natl Acad Sci 85:8008–8011. 
https://doi.org/10.1073/pnas.85.21.8008 
248. Streit E, Schatzmayr G, Tassis P, et al (2012) Current Situation of Mycotoxin 
Contamination and Co-occurrence in Animal Feed—Focus on Europe. Toxins 4:788–
809. https://doi.org/10.3390/toxins4100788 
249. Streit E, Schwab C, Sulyok M, et al (2013) Multi-Mycotoxin Screening Reveals the 
Occurrence of 139 Different Secondary Metabolites in Feed and Feed Ingredients. Toxins 
5:504–523. https://doi.org/10.3390/toxins5030504 
250. Sun L-H, Lei M, Zhang N-Y, et al (2014) Hepatotoxic effects of mycotoxin combinations 
in mice. Food Chem Toxicol 74:289–293. https://doi.org/10.1016/j.fct.2014.10.020 
142 
251. Svingen T, Lund Hansen N, Taxvig C, et al (2017) Enniatin B and beauvericin are 
common in Danish cereals and show high hepatotoxicity on a high-content imaging 
platform: OCCURRENCE AND TOXICITY ASSESSMENT MYCOTOXINS IN 
DANISH GRAINS. Environ Toxicol 32:1658–1664. https://doi.org/10.1002/tox.22367 
252. Swamy HVLN, Smith TK, MacDonald EJ, et al (2002) Effects of feeding a blend of 
grains naturally contaminated with Fusarium mycotoxins on swine performance, brain 
regional neurochemistry, and serum chemistry and the efficacy of a polymeric 
glucomannan mycotoxin adsorbent. J Anim Sci 80:3257–3267. 
https://doi.org/10.2527/2002.80123257x 
253. Sy-Cordero AA, Pearce CJ, Oberlies NH (2012) Revisiting the enniatins: a review of their 
isolation, biosynthesis, structure determination and biological activities. J Antibiot 
(Tokyo) 65:541–549. https://doi.org/10.1038/ja.2012.71 
254. Taevernier L (2016) Human skin permeation of emerging mycotoxins (beauvericin and 
enniatins). J Expo Sci Environ Epidemiol 11 
255. Taevernier L, Bracke N, Veryser L, et al (2016) Blood-brain barrier transport kinetics of 
the cyclic depsipeptide mycotoxins beauvericin and enniatins. Toxicol Lett 258:175–184. 
https://doi.org/10.1016/j.toxlet.2016.06.1741 
256. Taevernier L, Detroyer S, Veryser L, Spiegeleer B De (2015) Enniatin-containing 
solutions for oromucosal use : Quality-by-design ex-vivo transmucosal risk assessment 
of composition variability. Int J Pharm 491:144–151. 
https://doi.org/10.1016/j.ijpharm.2015.06.029 
257. Takahashi M, Shibutani M, Sugita-Konishi Y, et al (2008) A 90-day subchronic toxicity 
study of nivalenol, a trichothecene mycotoxin, in F344 rats. Food Chem Toxicol 46:125–
135. https://doi.org/10.1016/j.fct.2007.07.005 
258. Tanaka H, Tamura T (1961) TM& CHEMICAL CONSTITUTION OF 
RlJBROFUSlrRIN. 5. https://doi.org/doi.org/10.1016/S0040-4039(01)99228-7 
259. Tannous J, Snini SP, El Khoury R, et al (2017) Patulin transformation products and last 
intermediates in its biosynthetic pathway, E- and Z-ascladiol, are not toxic to human cells. 
Arch Toxicol 91:2455–2467. https://doi.org/10.1007/s00204-016-1900-y 
260. Tardivel C, Airault C, Djelloul M, et al (2015) The food born mycotoxin deoxynivalenol 
induces low-grade inflammation in mice in the absence of observed-adverse effects. 
Toxicol Lett 232:601–611. https://doi.org/10.1016/j.toxlet.2014.12.017 
261. Thomson A, Shaffer E (1992) First principles of gastroenterology. Basis Dis Approach 
Manag Spons Can Assoc Gastroenterol Mississauga Astra Pharma 
262. Tiemann U, Brüssow K-P, Küchenmeister U, et al (2006) Influence of diets with cereal 
grains contaminated by graded levels of two Fusarium toxins on selected enzymatic and 
histological parameters of liver in gilts. Food Chem Toxicol 44:1228–1235. 
https://doi.org/10.1016/j.fct.2006.01.021 
143 
263. Uhlig S, Torp M, Heier BT (2006) Beauvericin and enniatins A, A1, B and B1 in 
Norwegian grain: a survey. Food Chem 94:193–201. 
https://doi.org/10.1016/j.foodchem.2004.11.004 
264. Vaclavikova M, Malachova A, Veprikova Z, et al (2013) ‘Emerging’ mycotoxins in 
cereals processing chains: Changes of enniatins during beer and bread making. Food 
Chem 136:750–757. https://doi.org/10.1016/j.foodchem.2012.08.031 
265. van Egmond HP (2002) Worldwide regulations for mycotoxins. Springer Boston MA 
504:257–269. https://doi.org/10.1007/978-1-4615-0629-4_27 
266. van Egmond HP, Schothorst RC, Jonker MA (2007) Regulations relating to mycotoxins 
in food: Perspectives in a global and European context. Anal Bioanal Chem 389:147–
157. https://doi.org/10.1007/s00216-007-1317-9 
267. Vandenbroucke V, Croubels S, Martel A, et al (2011) The Mycotoxin Deoxynivalenol 
Potentiates Intestinal Inflammation by Salmonella Typhimurium in Porcine Ileal Loops. 
PLOS ONE 6:e23871. https://doi.org/10.1371/journal.pone.0023871 
268. Varga J, Kocsubé S, Péteri Z, et al (2010) Chemical, Physical and Biological Approaches 
to Prevent Ochratoxin Induced Toxicoses in Humans and Animals. Toxins 2:1718–1750. 
https://doi.org/10.3390/toxins2071718 
269. Vejdovszky K, Warth B, Sulyok M, Marko D (2016) Non-synergistic cytotoxic effects of 
Fusarium and Alternaria toxin combinations in Caco-2 cells. Toxicol Lett 241:1–8. 
https://doi.org/10.1016/j.toxlet.2015.10.024 
270. Vidal A, Claeys L, Mengelers M, et al (2018) Humans significantly metabolize and 
excrete the mycotoxin deoxynivalenol and its modified form deoxynivalenol-3-glucoside 
within 24 hours. Sci Rep 8:5255. https://doi.org/10.1038/s41598-018-23526-9 
271. von Bargen KW, Niehaus E-M, Bergander K, et al (2013) Structure Elucidation and 
Antimalarial Activity of Apicidin F: An Apicidin-like Compound Produced by Fusarium 
fujikuroi. J Nat Prod 76:2136–2140. https://doi.org/10.1021/np4006053 
272. Wan LYM, Turner PC, El-Nezami H (2013) Individual and combined cytotoxic effects 
of Fusarium toxins (deoxynivalenol, nivalenol, zearalenone and fumonisins B1) on swine 
jejunal epithelial cells. Food Chem Toxicol 57:276–283. 
https://doi.org/10.1016/j.fct.2013.03.034 
273. Wang K, Zheng X, Yang Q, et al (2019) S-Adenosylmethionine-Dependent 
Methyltransferase Helps Pichia caribbica Degrade Patulin. J Agric Food Chem 
67:11758–11768. https://doi.org/10.1021/acs.jafc.9b05144 
274. Wauters  i. (2015) Diversity-oriented synthesis based on the brevianamide scaffold for 
the development of physiologically active compounds, “PhD dissertaion.” Ghent Univ 
226 
275. Weaver AC, See MT, Hansen JA, et al (2013) The Use of Feed Additives to Reduce the 
Effects of Aflatoxin and Deoxynivalenol on Pig Growth, Organ Health and Immune 
Status during Chronic Exposure. Toxins 5:1261–1281. 
https://doi.org/10.3390/toxins5071261 
144 
276. Webb C, Twedt D (2008) Oxidative stress and liver disease. Vet Clin North Am Small 
Anim Pract 38:125–135, v. https://doi.org/10.1016/j.cvsm.2007.10.001 
277. Wells JM, Cole RJ, Kirksey JW (1975) Emodin, a Toxic Metabolite of Aspergillus wentii 
Isolated from Weevil-Damaged Chestnuts. 3 
278. Wilson BJ, Yang DTC, Harris TM (1973) Production, Isolation, and Preliminary Toxicity 
Studies of Brevianamide A from Cultures of Penicillium viridicatum. Am Soc Microbiol 
3 
279. Wood GE (1992) Mycotoxins in foods and feeds in the United States. J Anim Sci 
70:3941–3949. https://doi.org/10.2527/1992.70123941x 
280. Wu L, Wang W, Yao K, et al (2013) Effects of Dietary Arginine and Glutamine on 
Alleviating the Impairment Induced by Deoxynivalenol Stress and Immune Relevant 
Cytokines in Growing Pigs. PLOS ONE 8:e69502. 
https://doi.org/10.1371/journal.pone.0069502 
281. Wu M, Xiao H, Ren W, et al (2014a) Therapeutic Effects of Glutamic Acid in Piglets 
Challenged with Deoxynivalenol. PLOS ONE 9:e100591. 
https://doi.org/10.1371/journal.pone.0100591 
282. Wu W, He K, Zhou H-R, et al (2014b) Effects of oral exposure to naturally-occurring and 
synthetic deoxynivalenol congeners on proinflammatory cytokine and chemokine mRNA 
expression in the mouse. Toxicol Appl Pharmacol 278:107–115. 
https://doi.org/10.1016/j.taap.2014.04.016 
283. Xiao H, Wu MM, Tan BE, et al (2013) Effects of composite antimicrobial peptides in 
weanling piglets challenged with deoxynivalenol: I. Growth performance, immune 
function, and antioxidation capacity. J Anim Sci 91:4772–4780. 
https://doi.org/10.2527/jas.2013-6426 
284. Yap BK, Lee C-Y, Choi SB, et al (2019) In Silico Identification of Novel Inhibitors. In: 
Ranganathan S, Gribskov M, Nakai K, Schönbach C (eds) Encyclopedia of 
Bioinformatics and Computational Biology. Academic Press, Oxford, pp 761–779 
285. Younis G, Ibrahim D, Awad A, El Bardisy MM (2016) Determination of Aflatoxin M1 
and Ochratoxin A in Milk and Dairy Products in Supermarkets Located in Mansoura City, 
Egypt. Adv Anim Vet Sci 4:114–121. 
https://doi.org/10.14737/journal.aavs/2016/4.2.114.121 
286. Zain ME (2011) Impact of mycotoxins on humans and animals. J Saudi Chem Soc 
15:129–144. https://doi.org/10.1016/j.jscs.2010.06.006 
287. Zeisel MB, Dhawan P, Baumert TF (2019) Tight junction proteins in gastrointestinal and 
liver disease. Gut 68:547–561. https://doi.org/10.1136/gutjnl-2018-316906 
288. Zhai Y, Zhong L, Gao H, et al (2019) Detoxification of Deoxynivalenol by a Mixed 
Culture of Soil Bacteria With 3-epi-Deoxynivalenol as the Main Intermediate. Front 
Microbiol 10:. https://doi.org/10.3389/fmicb.2019.02172 
145 
289. Zhang J, Lai Z, Huang W, et al (2017) Apicidin Inhibited Proliferation and Invasion and 
Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 
Cells. Anticancer Agents Med Chem 17:. 
https://doi.org/10.2174/1871520617666170419120044 
290. Zhang S (1999) Digestive System. In: Zhang S (ed) An Atlas of Histology. Springer New 
York, New York, NY, pp 187–251 
291. Zielonka Ł, Wiśniewska M, Gajęcka M, et al (2009) Influence of low doses of 
deoxynivalenol on histopathology of selected organs of pigs. Pol J Vet Sci 12:89–95 
292. Zimmermann M, Lampe J, Lange S, et al (2009) Improved reproducibility in preparing 
precision-cut liver tissue slices. Cytotechnology 61:145–152. 
https://doi.org/10.1007/s10616-009-9246-4 
 
  
146 
9. Publications/Communications 
9.1. Publications 
 
 
Article 
Co-occurrence of DON and Emerging Mycotoxins in Worldwide Finished 
Pig Feed and Their Combined Toxicity in Intestinal Cells 
Abdullah Khan Khoshal 1, Barbara Novak 2, Pascal G. P. Martin 1, Timothy Jenkins 2, 
Manon Neves 1, Gerd Schatzmayr 2, Isabelle P. Oswald 1,* and Philippe Pinton 1,*  
Received: 08 November 2019; Accepted: 06 December 2019; Published: 11 December 2019 
9.2. Oral Presentations 
a. Combined Toxicity of Emerging and Regulated Mycotoxins on intestinal 
epithelial cells (IPEC-J2) and intestinal explants 
Abdullah Khan Khoshal 1, Barbara Novak 2, Gerd Schatzmayr 2, Isabelle P. Oswald 1,* and Philippe 
Pinton 1,* 
Graduate School of Science and Technology, AU – Folum , Aarhus University, Denmark 
(August 17, 2017 Summer School Programm) 
b. Toxicity of Emerging and Regulated Mycotoxins on intestinal epithelial 
cells (IPEC-J2) and intestinal explants 
Abdullah Khan Khoshal 1, Barbara Novak 2, Gerd Schatzmayr 2, Isabelle P. Oswald 1,* and Philippe 
Pinton 1,* 
BIOMIN Holding GmbH,  Tulln , Austria (November 17th 2017, Scientific Visit) 
c. Co-occurrence of DON and Emerging Mycotoxins in Worldwide 
Finished Pig Feed and Their Combined Toxicity in Intestinal Cells  
Abdullah Khan Khoshal 1, Barbara Novak 2, Pascal G. P. Martin 1, Timothy Jenkins 2, Manon 
Neves 1, Gerd Schatzmayr 2, Isabelle P. Oswald 1,* and Philippe Pinton 1,* 
8ème édition des Journées Mycotoxines, LUBEM , Brest, France (31 January and 1st February 2020) 
 
